RIFAMYCIN BIOSYNTHESIS GENE CLUSTER

Abstract: The present invention primarily relates to a DNA fragment which is obtainable from the gene cluster responsible for rifamycin biosynthesis within the genome of Amycolatopsis mediterranei, and comprises at least one gene or a part of a gene which codes for a polypeptide which is directly or indirectly involved in the biosynthesis of rifamycin, and to a method for preparing said DNA fragment. The present invention furthermore relates to recombinant DNA molecules which comprise one of the DNA fragments according to the invention, and to the plasmids and vectors derived therefrom. Host organisms transformed with said plasmid or vector DNA are likewise embraced.

Description: lfamycin biosynthesis gene cluster Rifamycins form an important group of macrocyclic antibiotics (Wehrli, Topics in Current Chemistry (1971 ), 72, 21 -49). They consist of a naphthoquinone chromophore which is spanned by a long aliphatic bridge. Rifamycins belong to the class of ansamycin antibiotics which are produced by several Gram-positive soil bacteria of the actinomycetes group and a few plants. Ansamycins are characterized by a flat aromatic nucleus spanned by a long aliphatic bridge joining opposite positions of the nucleus. Two different groups of ansamycins can be distinguished by the structure of the aromatic nucleus. One group has a naphthoquinoid chromophore, with the typical representatives being rifamycin, streptovaricin, tolypomycin and naphthomycin. The second group, which has a benzoquinoid chromophore, is characterized by geldanamycin, maytansines and ansamitocines (Ghisalba et al. , Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281 -327). In contrast to antibiotics of the macrolide type, the ansamycins contain in the aliphatic ring system not a lactone linkage but an amide linkage which forms the connection to the chromophore. The discovery of the rifamycins produced by the microorganism Streptomyces mediterranei (as the organism was called at that time, see below) was described for the first time in 1959 (Sensi et al., Farmaco Ed. Sci. (1959) 14, 146-147). Extraction with ethyl acetate of the acidified cultures of Streptomyces mediterranei resulted in isolation of a mixture of antibiotically active components, the rifamycins A, B, C, D and E. Rifamycin B, the most stable component, was separated from the other components and isolated on the basis of its strongly acidic properties and ease of salt formation. Rifamycin B has the structure of the formula (1) Rifamycin B is the main component of the fermentation when barbiturate is added to the fermentation medium and/or improved producer mutants of Streptomyces mediterranei are used. The rifamycin producer strain was originally classified as Streptomyces mediterranei (Sensi et al., Farmaco Ed. Sci. (1959) 14, 146-147). Analysis of the cell wall of Streptomyces mediterranei by Thiemann et al. later revealed that this strain has a cell wall typical of Nocardia, and the strain was reclassified as Nocardia mediterranei (Thieman et al. Arch. Microbiol. (1969), 67 147-151 ). Nocardia mediterranei has been reclassified again on the basis of more recent accurate morphological and biochemical criteria. Based on the exact composition of the cell wall, the absence of mycolic acid and the insensitivity to Nocardia and Rhodococcus phages, the strain has been assigned to the new genus Amycolatopsis as Amycolatopsis mediterranei (Lechevalier et al., Int. J. Syst. Bacteriol. (1986), 36, 29). Rifamycins have a strong antibiotic activity mainly against Gram-positive bacteria such as mycobacteria, neisserias and staphylococci. The bactericidal effect of rifamycins derives from specific inhibition of the bacterial DNA-dependent RNA polymerase, which interrupts RNA biosynthesis (Wehrli and Staehelin, Bacteriol. Rev. (1971 ), 35, 290-309) . The semisynthetic rifamycin B derivative rifampin (rifampicin) is widely used clinically as antibiotic against the agent causing tuberculosis, Mycobacterium tuberculosis. The naphthoquinoid ansamycins of the streptovaricin and tolypomycin group show, like rifamycin, an antibacterial effect by inhibiting bacterial RNA polymerase. By contrast, naphthomycin has an antibacterial effect without inhibiting bacterial RNA polymerase. The benzoquinoid ansamycins show no inhibition of bacterial RNA polymerase, and they therefore have only relatively weak antibacterial activity, if any. On the other hand, some representatives of this class of substances have an effect on eukaryotic cells. Thus, antifungal, antiprotozoal and antitumour properties have been described for geldanamycin. On the other hand, antimitotic (antitubilin), antileukaemic and antitumour properties are ascribed to the maytansines. Some rifamycins also show antitumour and antiviral activity, but only at high concentrations. This biological effect thus appears to be nonspecific. Despite the great structural variety of the ansamycins, their biosynthesis appears to take place by a metabolic pathway which contains many common elements (Ghisalba et al. Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281 -327). The aromatic nucleus for all ansamycins is probably built up starting from 3-amino-5-hydroxybenzoic acid. Starting from this molecule, which is presumably activated as coenzyme A, the entire aliphatic bridge is synthesized by a multifunctional polyketide synthase. The length of the bridge and the processing of the keto groups, which are initially formed by the condensation steps, are controlled by the polyketide synthase. To build up the complete aliphatic bridge for rifamycins, 10 condensation steps, 2 with acetate and 8 with propionate as building blocks, are necessary. The sequence of these individual condensation steps is likewise determined by the polyketide synthase. Structural comparisons and studies with incorporation of radioactive acetate and propionate have shown that the sequence of acetate and propionate incorporation for the various ansamycins takes place in accordance with a scheme which appears to be identical or very similar in the first condensation steps. Thus, from a common synthesis scheme of the ansamycin polyketide synthases (the rifamycin synthesis scheme), the syntheses of the various ansamycins sooner or later branch off, in accordance with their structural difference from the rifamycin structure, into side branches of the synthesis (Ghisalba et al. , Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281-327). Because of the great structural variety of the rifamycins and their specific and interesting biological effect, there is great interest in understanding the genetic basis of their synthesis in order to create the possibility of specifically influencing it. This is particularly desirable because, as explained above, there is much in common between the synthesis of rifamycins and that of other ansamycins. This similarity in the biosynthesis, which probably derives from a common evolutionary origin of this metabolic pathway, naturally has a genetic basis. The genetic basis of secondary metabolite biosynthesis essentially exists in the genes which code for the individual biosynthetic enzymes, and in the regulatory elements which control the expression of the biosynthesis genes. The secondary metabolite synthesis genes of actinomycetes have hitherto been found as clusters of adjacent genes in all the systems investigated. The size of such antibiotic gene clusters extends from about 10 kilobases (kb) up to more than 100 kb. The clusters often contain specific regulator genes and genes for resistance of the producer organism to its own antibiotic (Chater, Ciba Found. Symp. (1992), 171 , 144-162). The invention described herein has now succeeded, by identifying and cloning genes of rifamycin biosynthesis, in creating the genetic basis for synthesizing by genetic methods rifamycin analogues or novel ansamycins which combine structural elements from rifamycin with other ansamycins. This also creates the basis for preparing novel collections of substances based on the rifamycin biosynthesis gene cluster by combinatorial biosynthesis. It was possible in a first step to identify and clone a DNA fragment from the genome of A mediterranei, which shows homology with known polyketides synthase genes. After obtaining the sequence information from this DNA fragment which confirmed a typical sequence for polyketide synthases it was possible to screen a cosmid library of A mediterranei with specific DNA probes derived from this fragment in a screening program for further DNA fragments which are involved in the rifamycin gene cluster. As a result, the complete rifamycin polyketide synthase gene cluster was identified and subjected to sequence determination (see SEQ ID NO 3). The gene cluster comprises six open reading frames, which are referred to hereinafter as ORF A, B, C, D, E and F and which code for the proteins and polypeptides depicted in SEQ ID NOS 4 to 9. The gene cluster isolated and characterized in this way represents the basis, for example, for targeted optimization of the production of rifamycin, ansamycins or analogues thereof. Examples of techniques and possible areas of application available in this connection are as follows: • Overexpression of individual genes in producer strains with plasmid vectors or by incorporation into the chromosome. • Study of the expression and transcriptional regulation of the gene cluster during fermentation with various producer strains and optimization thereof through physiological parameters and appropriate fermentation conditions. • Identification of regulatory genes and of the DNA binding sites of the corresponding regulatory proteins in the gene cluster. Characterization of the effect of these regulatory elements on the production of rifamycins or ansamycins; and influencing them by specific mutation in these genes or the DNA binding sites. • Duplication of the complete gene cluster or parts thereof in producer strains. Besides these applications of the gene cluster to improve production by fermentation as described above, it can likewise be employed for the biosynthetic preparation of novel rifamycin analogues or novel ansamycins or ansamycin-like compounds in which the aliphatic bridge is connected at only one end to the aromatic nucleus. The following possibilities come into consideration here, for example: • Inactivation of individual steps in the biosynthesis, for example by gene disruption. • Mutation of individual steps in the biosynthesis, for example by gene replacement. • Use of the cluster or fragments thereof as DNA probe in order to isolate other natural microorganisms which produce metabolites similar to rifamycin or ansamycins. • Exchange of individual elements in this gene cluster by those from other gene clusters. • Use of modified polyketide synthases for setting up libraries of various rifamycin analogues or ansamycins, which are then tested for their activity (Jackie & Khosla, Chemistry & Biology, (1995), 2, 355-362). • Construction of mutated actinomycetes strains from which the natural rifamycin or ansamycin biosynthesis gene cluster in the chromosome has been partly or completely deleted, and can thus be used for expressing genetically modified gene clusters. ■ Exchange of individual elements within the gene cluster. Detailed description of the invention The invention relates to a DNA fragment from the genome of Amycolatopsis mediterranei, which comprises a DNA region which is involved directly or indirectly in the gene cluster responsible for rifamycin synthesis; and the adjacent DNA regions; and functional constituents or domains thereof. The DNA fragments according to the invention may moreover comprise regulatory sequences such as promoters, repressor or activator binding sites, repressor or activator genes, terminators; or structural genes. Likewise part of the invention are any combinations of these DNA fragments with one another or with other DNA fragments, for example combinations of promoters, repressor or activator binding sites and/or repressor or activator genes from an ansamycin gene cluster, in particular from the rifamycin gene cluster, with foreign structural genes or combinations of structural genes from the ansamycin gene cluster, especially the rifamycin gene cluster, with foreign promoters; and combinations of structural genes with one another or with gene fragments which code for enzymatically active domains and are from various ansamycin biosynthesis systems. Foreign structural genes, and foreign gene fragments coding for enzymatically active domains, code, for example, for proteins involved in the biosynthesis of other ansamycins. A preferred DNA fragment is one directly or indirectly involved in the gene cluster responsible for rifamycin synthesis. The gene cluster or DNA region described above contains, for example, the genes which code for the individual enzymes involved in the biosynthesis of ansamycins and, in particular, of rifamycin, and the regulatory elements which control the expression of the biosynthesis genes. The size of such antibiotic gene clusters extends from about 10 kilobases (kb) up to over 100 kb. The gene clusters normally comprise specific regulatory genes and genes for resistance of the producer organism to its own antibiotic. Examples of what is meant by enzymes or enzymatically active domains involved in this biosynthesis are those necessary for synthesizing, starting from 3-amino-5-hydroxybenzoic acid , the ansamycins such as rifamycin , for example polyketide synthases , acyltransf erases, dehydratases, ketoreductases, acyl carrier proteins or ketoacyl synthases. Thus, the complete sequence of the gene cluster shown in SEQ ID NO 3, as well as DNA fragments which comprise sequence portions which code for a polyketide synthase or an enzymatically active domain thereof, are particularly preferred. Examples of such preferred DNA fragments are, for example, those which code for one or more of the proteins and polypeptides depicted in SEQ ID ID NOS 4, 5, 6, 7, 8 and 9, or functional derivatives thereof, also including partial sequences thereof which comprise, for example, 15 or more consecutive nucleotides. Other preferred embodiments relate to DNA regions of the gene cluster according to the invention or fragments thereof, like those present in the deposited clones pNE95, pRi44-2 and pNE1 1 2, or derived therefrom. Further preferred DNA fragments are those comprising sequence portions which display homologies with the sequences comprised by the clones pNE95, pRi44-2 and/or pNE1 12 or with SEQ ID ID NOS 1 and/or 3, and therefore can be used as hybridization probe within a genomic gene bank of an ansamycin-, in particular, rifamycin-producing organism for finding constituents of the corresponding gene cluster. The DNA fragment may moreover, for example, comprise exclusively genomic DNA. A particularly preferred DNA fragment is one which comprises the nucleotide sequence depicted in SEQ ID NO 1 or 3, or partial sequences thereof, which, by reason of homologies, can be regarded as structural or functional equivalent to said sequence or partial sequence therefrom, and which therefore are able to hybridize with this sequence. The DNA fragments according to the invention comprise, for example, sequence portions which comprise homologies with the above-described enzymes, enzyme domains or fragments thereof. The term homologies and structural and/or functional equivalents refers primarily to DNA and amino acid sequences with few or minimal differences between the relevant sequences. These differences may have very diverse causes. Thus, for example, this may entail mutations or strain-specific differences which occur naturally or are artificially induced. Or the differences observed from the initial sequence are derived from a targeted modification, which can be introduced, for example, during a chemical synthesis. Functional differences can be regarded as minimal if, for example, the nucleotide sequence coding for a polypeptide. or a protein sequence has essentially the same characteristic properties as the initial sequence, whether in respect of enzymatic activity, immunological reactivity or, in the case of a nucleotide sequence, gene regulation. Structural differences can be regarded as minimal as long as there is a significant overlap or similarity between the various sequences, or they have at least similar physical properties. The latter include, for example, the electrophoretic mobility, chromatographic similarities, sedimentation coefficients, spectrophotometric properties etc. In the case of nucleotide sequences, the agreement should be at least 70%, but preferably 80% and very particularly preferably 90% or more. In the case of the amino acid sequence, the corresponding figures are at least 50%, but preferably 60% and particularly preferably 70%. 90% agreement is very particularly preferred. The invention furthermore relates to a method for identifying, isolating and cloning one of the DNA fragments described above. A preferred method comprises, for example, the following steps: a) setting up of a genomic gene bank, b) screening of this gene bank with the assistance of the DNA sequences according to the invention, and c) isolation of the clones identified as positive. A general method for identifying DNA fragments involved in the biosynthesis of ansamycins comprises, for example, the following steps 1) Cloning of a DNA fragment which shows homology with known polyketide synthase genes. a) The presence of DNA fragments having homology with the polyketide synthase genes according to the invention is detected in the strains of the microorganism to be investigated by a Southern experiment with chromosomal DNA of this strain. The size of such homologous DNA fragments can be determined by digesting the DNA with a suitable restriction enzyme. b) Production of a plasmid gene bank comprising the above digested chromosomal fragments. Normally, individual clones of this gene bank are tested once again for homology with the polyketide synthase genes according to the invention. Clones with recombinant plasmids comprising fragments having homology with the polyketide probe are then normally isolated on the basis of this homology. 2) Analysis of the cloned region a) Restriction analysis of the isolated recombinant plasmids and checking of the identity of these cloned fragments with one another. b) By a chromosomal Southern with DNA of the original microorganism and the isolated DNA fragment as probe it can be demonstrated that the cloned fragment is an original chromosomal DNA fragment from the original microorganism. c) It is possible as an option to demonstrate a significant homology of the cloned DNA fragment with chromosomal DNA from other ansamycin producers (streptovaricin, tolypomycin, geldanamycin, ansamitocin). This would confirm that the cloned DNA is typical of gene clusters of ansamycin biosynthesis and thus also of rifamycin biosynthesis. d) DNA sequencing of an internal restriction fragment and demonstration by comparative sequence analysis that the cloned region is a typical DNA sequence of polyketide synthases, coding for the biosynthesis of polyketide antibiotics from actinomycetes. 3) Isolation and characterization of adjacent DNA regions a) Construction of a cosmid gene bank from the original microorganism and analysis thereof for homology with the isolated fragments. Isolation of cosmids having homology with this fragment. b) Demonstration by restriction analysis that the isolated cosmid clones comprise a DNA region of the original microorganism which overlaps with the original fragment. As described above, the first step in the isolation of the DNA fragments according to the invention is normally the setting up of genomic gene banks from the organism of interest, which synthesize the required ansamycin, especially rifamycin. Genomic DNA can be obtained from a host organism in various ways, for example by extraction from the nuclear fraction and purification of the extracted DNA by known methods. The fragmentation, which is necessary for setting up a representative gene bank, of the genomic DNA to be cloned to a size which is suitable for insertion into a cloning vector can take place either by mechanical shearing or else, preferably, by cutting with suitable restriction enzymes. Suitable cloning vectors, which are already in routine use for producing genomic gene libraries, comprise, for example, cosmid vectors, plasmid vectors or phage vectors. It is then possible in a screening program to obtain suitable clones which comprise the required gene(s) or gene fragment(s) from the gene libraries produced in this way. One possibility for identifying the required DNA region consists in, for example, using the gene bank described above to transform strains which, because of a blocked synthetic pathway, are unable to produce ansamycins, and identifying those clones which are again able after the transformation to produce ansamycin (revertants). The vectors which lead to revertants comprise a DNA fragment which is required in ansamycin synthesis. Another possibility for identifying the required DNA region is based, for example, on using suitable probe molecules (DNA probe) which are obtained for example as described above. Various standard methods are available for identifying suitable clones, such as differential colony hybridization or plaque hybridization. It is possible to use as probe molecule a previously isolated DNA fragment from the same or a structurally related gene or gene cluster which, because of the homologies present, is able to hybridize with the corresponding sequence section within the required gene or gene cluster to be identified. Preferably used as probe molecule for the purpose of the present invention is a DNA fragment obtainable from a gene or a DNA sequence involved in the synthesis of polyketides such as ansamycins or soraphens. If the nucleotide sequence of the gene to be isolated, or at least parts of this sequence, are known, it is possible in an alternative embodiment to use, based on this sequence information, a corresponding synthesized DNA sequence for the hybridizations or PCR amplifications. In order to facilitate detectability of the required gene or else parts of a required gene, one of the DNA probe molecules described above can be labelled with a suitable, easily detectable group. A detectable group for the purpose of this invention means any material which has a particular, easily identifiable, physical or chemical property. Particular mention may be made at this point of enzymatically active groups such as enzymes, enzyme substrates, coenzymes and enzyme inhibitors, furthermore fluorescent and luminescent agents, chromophores and radioisotopes such as 3 H, 35 S, 32 P, 25 l and 1 C. Easy detectability of these markers is based, on the one hand, on their intrinsic physical properties (for example fluorescent markers, chromophores, radioisotopes) or, on the other hand, on their reaction and binding properties (for example enzymes, substrates, coenzymes, inhibitors). Materials of these types are already widely used in particular in immunoassays and, in most cases, can also be used in the present application. General methods relating to DNA hybridization are described, for example, by Maniatis T. et al., Molecular Cloning, Cold Spring Harbor Laboratory Press (1982). Those clones within the previously described gene libraries which are able to hybridize with a probe molecule and which can be identified by one of the abovementioned detection methods can then be further analysed in order to determine the extent and nature of the coding sequence in detail. An alternative method for identifying cloned genes is based on constructing a gene library consisting of plasmid or expression vectors. This entails, in analogy to the methods described previously, the genomic DNA comprising the required gene being initially isolated and then cloned into a suitable plasmid or expression vector. The gene libraries produced in this way can then be screened by suitable procedures, for example by use of complementation studies, and those clones which comprise the required gene or else at least a part of this gene as insert can be selected. It is thus possible with the aid of the methods described above to isolate a gene, several genes or a gene cluster which code for one or more particular gene products. For further characterization, the DNA sequences purified and isolated in the manner described above are subjected to restriction analysis and sequence analysis. For sequence analysis, the previously isolated DNA fragments are first fragmented using suitable restriction enzymes, and then cloned into suitable cloning vectors. In order to avoid mistakes in the sequencing, it is advantageous to sequence both DNA strands completely. Various alternatives are available for analysing the cloned DNA fragment in respect of its function within ansamycin biosynthesis. Thus, for example, it is possible in complementation experiments with defective mutants not only to establish involvement in principle of a gene or gene fragment in secondary metabolite biosynthesis, but also to verify specifically the synthetic step in which said DNA fragment is involved. In an alternative type of analysis, evidence is obtained in exactly the opposite way. Transfer of plasmids which comprise DNA sections which have homologies with appropriate sections on the genome results in integration of said homologous DNA sections via homologous recombination. If, as in the present case, the homologous DNA section is a region within an open reading frame of the gene cluster, plasmid integration results in inactivation of this gene by so-called gene disruption and, consequently, in an interruption in secondary metabolite production. It is assumed according to current knowledge that a homologous region which comprises at least 100 bp, but preferably more than 1000 bp, is sufficient to bring about the required recombination event. However, a homologous region which extends over a range of from 0.3 to 4 kb, but in particular over a range of from 1 to 3 kb, is preferred. To prepare suitable plasmids which have sufficient homology for integration via homologous recombination there is preferably provision of a subcloning step in which the previously isolated DNA is digested, and fragments of suitable size are isolated and subsequently cloned into a suitable plasmid. Examples of suitable plasmids are the plasmids generally used for genetic manipulations in streptomycetes or E. coli. It is possible in principle to use for the preparation and multiplication of the previously described constructs all conventional cloning vectors such as plasmid or bacteriophage vectors as long as they have replication and control sequences derived from species compatible with the host cell. The cloning vector usually has an origin of replication plus specific genes which result in phenotypical selection features in the transformed host cell, in particular resistances to antibiotics. The transformed vectors can be selected on the basis of these phenotypical markers after transformation in a host cell. Selectable phenotypical markers which can be used for the purpose of this invention comprise, for example, without this representing a limitation of the subject-matter of the invention, resistances to thiostrepton, ampicillin, tetracycline, chloramphenicoi, hygromycin, G41 8, kanamycin, neomycin and bleomycin. Another selectable marker can be, for example, prototrophy for particular amino acids. Mainly preferred for the purpose of the present invention are streptomycetes and E. coli plasmids, for example the plasmids used for the purpose of the present invention. Host cells primarily suitable for the previously described cloning for the purpose of this invention are prokaryotes, including bacterial hosts such as streptomycetes, actinomycetes, E. coli or pseudomonads. E. coli hosts are particularly preferred, for example the E. coli strain HB101 or X-1 blue MR*(Stratagene) or streptomyces such as the plasmid-free strains of Streptomyces lividans TK23 and TK24. Competent cells of the E. coli strain HB101 are produced by the methods normally used for transforming E. coli. The transformation method of Hopwood et al. (Genetic manipulation of streptomyces a laboratory manual. The John Innes Foundation, Norwich (1985)) is normally used for streptomyces. After transformation and subsequent incubation on a suitable medium, the resulting colonies are subjected to a differential screening by plating out on selective media. It is then possible to isolate the appropriate plasmid DNA from those colonies which comprise plasmids with DNA fragments cloned in. The DNA fragment according to the invention, which comprises a DNA region which is involved directly or indirectly in the biosynthesis of ansamycin and can be obtained in the previously described manner from the ansamycin biosynthesis gene cluster, can also be used as starter clone for identifying and isolating other adjacent DNA regions overlapping therewith from said gene cluster. This can be achieved, for example, by carrying out a so-called chromosome walking within a gene library consisting of DNA fragments with mutually overlapping DNA regions, using the previously isolated DNA fragment or else, in particular, the sequences located at its 5' and 3' margins. The procedures for chromosome walking are known to the person skilled in this art. Details can be found, for example, in the publications by Smith et al. (Methods Enzymol (1987), 151 , 461 -489) and Wahl et al. (Proc Natl. Acad. Sci, USA (1987), 84, 2160-2164). The prerequisite for chromosome walking is the presence of clones having coherent DNA fragments which are as long as possible and mutually overlap within a gene library, and a suitable starter clone which comprises a fragment which is located in the vicinity or else, preferably, within the region to be analysed. If the exact location of the starter clone is unknown, the walking is preferably carried out in both directions. The actual walking step starts by using the identified and isolated starter clone as probe in one of the previously described hybridization reactions in order to detect adjacent clones which have regions overlapping with the starter clone. It is possible by hybridization analysis to establish which fragment projects furthest over the overlapping region. This is then used as starting clone for the 2nd walking step, in which case there is establishment of the fragment which overlaps with said 2nd clone in the same direction. Continuous progression in this manner on the chromosome results in a collection of overlapping DNA clones which cover a large DNA region. These can then, where appropriate after one or more subcloning steps, be ligated together by known methods to give a fragment which comprises parts or else, preferably all of the constituents essential for ansamycin biosynthesis. The hybridization reaction to establish clones with overlapping marginal regions preferably makes use not of the very large and unwieldy complete fragment but, in its place, a partial fragment from the left or right marginal region, which can be obtained by a subcloning step. Because of the smaller size of said partial fragment, the hybridization reaction results in fewer positive hybridization signals, so that the analytical effort is distinctly less than on use of the complete fragment. It is furthermore advisable to characterize the partial fragment in detail in order to preclude its comprising larger amounts of repetitive sequences, which may be distributed over the entire genome and thus would greatly impede a targeted sequence of walking steps. Since the gene cluster responsible for ansamycin biosynthesis covers a relatively large region of the genome, it may also be advantageous to carry out a so-called large-step walking or cosmid walking. It is possible in these cases, by using cosmid vectors which permit the cloning of very large DNA fragments, to cover a very large DNA region, which may comprise up to 42 kb, in a single walking step. In one possible embodiment of the present invention, for example, to construct a cosmid gene bank from streptomycetes or actinomycetes, complete DNA is isolated with the size of the DNA fragments being of the order of about 100 kb, and is subsequently partially digested with suitable restriction endonucleases. The digested DNA is then extracted in a conventional way in order to remove endonuclease which is still present, and is precipitated and finally concentrated. The resulting fragment concentrate is then fractionated, for example by density gradient centrifugation, in accordance with the size of the individual fragments. After the fractions obtainable in this way have been dialysed they can be analysed on an agarose gel. The fractions which contain fragments of suitable size are pooled and concentrated for further processing. Fragments to be regarded as particularly suitable for the purpose of this invention have a size of the order of 30 kb to 42 kb, but preferably of 35 kb to 40 kb. In parallel with the fragmentation described above, or later, for example a suitable cosmid vector pWE15* (Stratagene) is completely digested with a suitable restriction enzyme, for example BamHI, for the subsequent ligase reaction. Ligation of the cosmid DNA to the streptomyces or actinomycetes fragments which have been fractionated according to their size can be carried out using a T4 DNA ligase. The ligation mixture obtainable in this way is, after a sufficient incubation time, packaged into λ phages by generally known methods. The resulting phage particles are then used to infect a suitable host strain. A recA " E. coli strain is preferred, such as E. co// HB101 or X-1 Blue* (Stratagene). Selection of transfected clones and isolation of the plasmid DNA can be carried out by generally known methods. The screening of the gene bank for DNA fragments which are involved in ansamycin biosynthesis is carried out, for example, using a specific hybridization probe which is assumed (fo r exam ple on the basis of DNA seq uence or DN A homology or complementation tests or gene disruption or the function thereof in other organisms) to comprise DNA regions from the 'ansamycin gene cluster'. A plasmid which comprises an additional fragment of the required size or has been identified on the basis of hybridizations can then be isolated from the gel in the previously described manner. The identity of this additional fragment with the required fragment of the previously selected cosmid can then be confirmed by Southern transfer and hybridization. Function analysis of the DNA fragments isolated in this way can be carried out in a gene disruption experiment as described above. Another possible use of the DNA fragments according to the invention is to modify or inactivate enzymes or domains involved in ansamycin and, in particular, rifamycin biosynthesis, or to synthesize oligonucleotides which are then in turn used for finding homologous sequences in PCR amplification. Besides the DNA fragments according to the invention as such, also claimed are their use firstly for producing rifamycin, rifamycin analogues or precursors thereof, and for the biosynthetic production of novel ansamycins or of precursors thereof. Included in this connection are those molecules in which the aliphatic bridge is connected only at one end to the aromatic nucleus. The DNA fragments according to the invention permit, for example, by combination with DNA fragments from other biosynthetic pathways or by inactivation or modification thereof, the biosynthesis of novel hybrid compounds, in particular of novel ansamycins or rifamycin analogues. The steps necessary for this are generally known and are described, for example, in Hopwood, Current Opinion in Biotechnol. (1993), 4, 531 -537. The invention furthermore relates to the use of the DNA fragments according to the invention for carrying out the novel technology of combinatorial biosynthesis for the biosynthetic production of libraries of polyketide synthases based on the rifamycin and ansamycin biosynthesis genes. If, for example, several sets of modifications are produced, It is possible in this way to produce, by means of biosyntheses, a library of polyketides, for example ansamycins or rifamycin analogues, which then needs to be tested only for the activity of the compounds produced in this way. The steps necessary for this are generally known and are described, for example, in Tsoi and Khosla, Chemistry & Biology (1995), 2, 355-362 and WO-9508548. Besides the DNA fragment as such, also claimed is its use for the genetic construction of mutated actinomycetes strains from which the natural rifamycin or ansamycin biosynthesis gene cluster in the chromosome has been partly or completely deleted, and which can thus be used for expressing genetically modified ansamycin or rifamycin biosynthesis gene clusters. The invention furthermore relates to a hybrid vector which comprises at least one DNA fragment according to the invention, for example a promoter, a repressor or activator binding site, a repressor or activator gene, a structural gene, a terminator or a functional part thereof. The hybrid vector comprises, for example, an expression cassette which comprises a DNA fragment according to the invention which is able to express one or more proteins involved in ansamycin biosynthesis and, in particular in rifamycin biosynthesis, or a functional fragment thereof. The invention likewise relates to a host organism which comprises the hybrid vector described above. Suitable vectors representing the starting point of the hybrid vectors according to the invention, and suitable host organisms such as bacteria or yeast cells are generally known. The host organism can be transformed by generally customary methods such as by means of protoplasts, Ca 2τ , Cs + , polyethylene giycol, electroporation, viruses, lipid vesicles or a particle gun. The DNA fragments according to the invention may then be present both as extrachromosomal constituents in the host organism and integrated via suitable sequence sections into the chromosome of the host organism. The invention likewise relates to polyketide synthases which comprise the DNA fragments according to the invention, in particular those from Amycolatopsis mediterranei which are involved directly or indirectly in rifamycin synthesis, and functional constituents thereof, for example enzymatically active domains. The invention furthermore relates to a hybridization probe comprising a DNA fragment according to the invention, and to the use thereof, in particular for identifying DNA fragments involved in the biosynthesis of ansamycins. In order to obtain unambiguous signals in the hybridization, DNA bound to the filter (for example made of nylon or nitrocellulose) is normally washed at 55-65 c C in 0.2 x SSC (1 x SSC = 0.15 M sodium chloride, 15 mM sodium citrate). Examples General General molecular genetic techniques such as DNA isolation and purification, restriction digestion of DNA, agarose gel electrophoresis of DNA, ligation of restriction fragments, cultivation and transformation of E. coli, plasmid isolation from E. coli, are carried out as described in Maniatis et al., Molecular Cloning: A laboratory manual, 1 st Edit. Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1982). Culture conditions and molecular genetic techniques with A. mediterranei and other actinomycetes are as described by Hopwood et al. (Genetic manipulation of streptomyces a laboratory manual, The John Innes Foundation, Norwich, 1985). All liquid cultures of A. mediterranei and other actinomycetes are carried out in Erlenmeyer flasks at 28°C on a shaker at 250 rpm. Nutrient media used: LB Maniatis et al., Molecular Cloning: A laboratory manual, 1 st Edit. Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1982) NL148 Schupp + Divers FEMS Microbiology Lett. 36, 159-162 (1986) (NL148 = NL148G without glycine) R2YE Hopwood et al. (Genetic manipulation of streptomyces a laboratory manual. The John Innes Foundation, Norwich, 1985) TB : 12 g/l Bacto tryptone 24 g/l Bacto yeast extract 4 ml/l glycerol Example 1 : Detection of chromosomal DNA fragments from A. mediterranei having homology with polyketide synthase genes of other bacteria To obtain genomic DNA from A. mediterranei, cells of the strain A. mediterranei wt3136 (= LBGA 3136, ETH collection of strains) are cultivated in NL148 medium for 48 hours. 1 ml of this culture is then transferred into 50 ml of NL148 medium (+ 2.5 g/l glycine) in a 200 ml Erlenmeyer flask, and the culture is incubated for 48 h. The cells are removed from the medium by centrifugation at 3000 g for 10 min. and are resuspended in 5 ml of SET (75 mM NaCI, 25 mM EDTA, 20 mM Tris, pH 7.5). High molecular weight DNA is extracted by the method of Pospiech and Neumann (Trends in Genetics (1995), 11 , 217-218). In order to detect, by a Southern blot, individual fragments from the isolated A. mediterranei DNA which have homology with polyketide synthase genes, a radioactive DNA probe is prepared from a known polyketide synthase gene cluster. To do this, the Pvul fragment 3.8 kb in size is isolated from the recombinant plasmid p98/1 (Schupp et al. J. of Bacteriol. (1995), 177, 3673-3679), which comprises a DNA region, about 32 kb in size, from the polyketide synthase for the antibiotic soraphen A. About 0.5 μg of the isolated 3.8 kb Pvul DNA fragment is radiolabelled with 32 P-d-CTP by the nick translation system from Gibco/BRL (Basle) in accordance with the manufacturer's instructions. For the Southern blot, about 2 μg of the genomic DNA isolated above from A. mediterranei are completely digested with the restriction enzyme Bglll (Bόhringer, Mannheim), and the resulting fragments are fractionated on a 0.8% agarose gel. A Southern blot with this agarose gel and the DNA probe isolated above (3.8 kb Pvul fragment) detects a DNA Bglll- cut fragment which is about 13 kb in size from the genomic DNA of A. mediterranei, and which has homology with the DNA probe used. It can be concluded on the basis of this homology that the detected DNA fragment from A. mediterranei is a genetic region which codes for a polyketide synthase and thus is involved in the synthesis of a polyketide antibiotic. Example 2: Production of a specific recombinant plasmid collection comprising Ball I- digested chromosomal fragments from A. mediterranei 12-16 kb in size The E. coli positive selection vector plJ4642 (derivative of plJ666, Kieser & Melton, Gene (1988), 65, 83-91 ) developed at the John Innes Centre (Norwich, UK) is used to produce the plasmid gene bank. This plasmid is first cut with BamHI, and the two resulting fragments are fractionated on an agarose gel. The smaller of the two fragments is the filler fragment of the vector and the larger is the vector portion which, on self-ligation after deletion of the filler fragment, forms, owing to the flanking fd termination sequences, a perfect palindrome, which means that the plasmid cannot be obtained as such in E. coli. This vector portion 3.8 kb in size is isolated from the agarose gel by electroelution as described on page 164- 165 of Maniatis et al., Molecular Cloning: A laboratory manual, 1 st Edit. Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1982). To prepare the Bglll-cut DNA fragments from A. mediterranei, the high molecular weight genomic DNA prepared in Example 1 is used. About 10 μg of this DNA are completely digested with the restriction enzyme Bglll and subsequently fractionated on a 0.8% agarose gel. DNA fragments with a size of about 12 - 16 kb are cut out of the gel and detached from the gel block by electroelution (see above). About 1 μg of the Bglll fragments isolated in this way is ligated to about 0.1 μg of the BamHI portion, isolated above, of the vector plJ4642. The ligation mixture obtained in this way is then transformed into the E. coli strain HB101 (Stratagene). About 150 transformed colonies are selected from the transformation mixture on LB agar with 30 μg per ml chlorampheπicol. These colonies contain recombinant plasmids with Bglll-cut genomic DNA fragments from A. mediterranei the size range 12 - 16 kb. Example 3: Cloning and characterization of chromosomal A mediterranei DNA fragments having homology with bacterial polyketide synthase genes 150 of the plasmid clones prepared in Example 2 are analysed by colony hybridization using a nitrocellulose filter (Schleicher & Schuell) as described on pages 318-319 of Maniatis et al., Molecular Cloning: A laboratory manual, 1 st Edit. Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1982). The DNA probe used is the 3.8 kb Pvul fragment, radiolabelled with 32 P-d-CTP and isolated in Example 1 , of the plasmid p98/1. The plasmids are isolated from 5 plasmid clones which show a hybridization signal, and are characterized by two restriction digestions with the enzymes Hindlll or Kpnl. Hindlll cuts twice in the vector portion of the clones, 0.3 kb to the right and left of the BamHI cleavage site into which the A. mediterranei DNA has been integrated. Kpnl does not cut in the plJ 4642 vector portion. This restriction analysis shows that the investigated clones comprise both identical Hindlll fragments of about 14 and 3.1 kb and identical Kpnl fragments approximately 11.4 kb and 5.7 kb in size. This shows that these clones comprise the same genomic Bglll fragment of A. mediterranei, and that the latter has a size of about 13 kb. It can additionally be concluded from this restriction analysis that this cloned Bglll fragment has no internal Hindlll cleavage site, but has 2 Kpnl cleavage sites which afford an internal Kpnl fragment 5.7 kb in size. The plasmid DNA of the above 5 clones with identical restriction fragments is further characterized by a Southern blot. For this purpose, the plasmids are cut with Hindlll and Kpnl, and the DNA probe used is the 32 P-radiolabelled 3.8 kb Pvul fragment of the plasmid p98/1 used above. This experiment confirms that the 5 plasmids contain identical A mediterranei DNA fragments and that these have significant homology with the DNA probe which is characteristic of bacterial polyketide synthase genes. In addition, the Southern blot shows that the internal Kpnl fragment 5.7 kb in size likewise has significant homology with the DNA probe used. The plasmid called pRi7-3 is selected from the 5 plasmids for further processing. To demonstrate that the cloned Bglll fragment about 13 kb in size from A mediterranei is an original chromosomal DNA fragment, another Southern blot is carried out. Chromosomal DNA from A mediterranei which has been cut with Bglll, Kpnl or BamHI is employed in this blot. Two BamHI fragments which are about 1.8 and 1.9 kb in size and are present in the 5.7 kb Kpnl fragment of pRi7-3 are used as radiolabelled DNA probe. This experiment confirms that the Bglll DNA fragment about 13 kb in size cloned in the recombinant plasmid pRi7-3 is an authentic genomic DNA fragment from A mediterranei. In addition, this experiment confirms that the cloned fragment comprises an internal Kpnl fragment 5.7 kb in size and two BamHI fragments about 1.8 and 1.9 kb in size, and that these DNA fragments are likewise authentic genomic DNA fragments from A mediterranei. Example 4: Demonstration of a significant homology of the cloned genomic 13 kb Bglll fragment from A. mediterranei with chromosomal D NA from other actinomycetes which produce ansamycins Demonstration of a significant homology between the cloned chromosomal DNA region of A mediterranei and chromosomal DNA from other ansamycin-producing actinomycetes takes place by a Southern blot experiment. The following ansamycin-producing strains are employed for this purpose (the ansamycins produced by the strains are in parentheses): Streptomyces spectabilis (streptovaricins), Streptomyces tolypophorus (tolypomycins), Streptomyces hygroscopicus (g e l d a na myc i ns) , Nocardia species ATCC31 281 (ansamitocins). Genomic DNA from these strains is isolated as described for A mediterranei in Example 1 and digested with the restriction enzyme Kpnl, and the restriction fragments obtained in this way are fractionated on an agarose gel for the Southern blot. Two BamHI fragments about 1.8 and 1.9 kb in size from A mediterranei, which are used in Example 3 and are isolated from the plasmid pRi7-3, are used as radioactive probe. This experiment shows that these ansamycin-producing strains have a significant DNA homology with the DNA probe used and thus with the cloned chromosomal region of A mediterranei. It is to be observed in this connection that the homology in the case of producers of ansamycins with a naphthoquinoid ring system (streptovaricin, tolypomycin) is greater than in the case of those with a benzoquinoid ring system (geldanamycin, ansamitocin). This result suggests that the cloned chromosomal DNA region from A. mediterranei is typical of ansamycin biosynthesis gene clusters and, especially, of gene clusters for ansamycins with naphthoquinoid ring systems, corresponding to the ring system in rifamycins. Example 5: DNA sequence determination of the Kpnl fragment 5.7 kb in size located within the cloned 13 kb Bglll fragment For the sequencing, the 5.7 kb Kpnl fragment is isolated from the plasmid pRi7-3 (DSM 111 14) (Maniatis et. al. 1992) and subcloned into the Kpnl cleavage site of the vector pBRKanf4, which is suitable for the DNA sequencing, affording the plasmids pTS004 and pTSOOδ. The vector pBRKanf4 (derived from pBRKanfl ; Bhat, Gene (1993) 134, 83-87) is suitable for introducing sequential deletions of Sau3A fragments in the cloned insert fragment, because this vector does not itself have a GATC nucleotide sequence. In addition, the BamHI fragments 1 .9 and 1 .8 kb in size present in the 5.7 kb Kpnl fragment are subcloned into the BamHI cleavage site of pBRKanf4, resulting the plasmids pTS006 and pTS007, and pTS008 and pTS009, respectively. To prepare subclones sequentially truncated by Sau3A fragments for the DNA sequencing, the plasmids pTS004 to pTS009 are partially digested with Sau3A and completely digested with Xbal or Hindlll (a cleavage site in the multiple cloning region of the vector). The DNA obtained in this way (consisting of the linearized vector with inserted DNA fragments truncated by Sau3A fragments) is filled in at the ends using Klenow polymerase (fragment of polymerase I, see Maniatis et al. pages 1 13-1 14), self-ligated with T4 DNA ligase and transformed into E. coli DH5α. The plasmid DNA which corresponds to the pTS004 to pTS009 plasmids, but has DNA regions, which are truncated from one side by Sau3A fragments, from the original integrated fragments of A. mediterranei, is isolated from individual transformed clones obtained in this way. The DNA sequencing is carried out with the plasmids obtained in this way and with pTS004 to pTS009 using the reaction kit from Perkin-Elmer/Applied Biosystems with dye-labelled terminator reagents (Kit N° 402122) and a universal primer or a T7 primer. A standard cycle sequencing protocol with a thermocycler (MJ Research DNA Engine Thermocycler, Model 225) is used, and the sequencing reactions are analysed by the Applied Biosystems automatic DNA sequencer (Modell 373 or 377) in accordance with the manufacturer's instructions. To analyse the results, the following computer programs (software) are employed: Applied Biosystems DNA analysis software, Unix Solaris CDE software, DNA assembly and analysis package GAP licensed from R. Staden (Nucleic Acid Research (1995)23, 1406-1410) and Blast (NCBI). The methods described above can be used to sequence completely both DNA strands of the 5.7 kb Kpnl fragment from A mediterranei strain wt3136. The DNA sequence of the 5.7 kb fragment v/ith a length of 5676 base pairs is depicted in SEQ ID NO 1. Example 6: Analysis of the protein-encoding region (genes) on the 5.7 kb Kpnl fragment from A. mediterranei The nucleotide sequence of the 5.7 kb Kpnl fragment is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that this fragment is over its whole length a protein-encoding region and thus forms part of a larger open reading frame (ORF). The codons used in this ORF are typical of streptomycetes and actinomycetes genes. The amino acid sequence derived from the DNA sequence from this ORF is depicted in SEQ ID NO 2. Polyketide synthases for macrolide antibiotics (such as erythromycin, rapamycin) are very large multifunctional proteins which comprise several enzymatically active domains which are now well characterized (Hopwood und Khosla, Ciba Foundation Symposium (1992), 171 , 88- 1 12; Donadio and Katz, Gene (1992), 111 , 51 -60; Schwecke et al., Proc. Natl. Acad. Sci. U.S.A. (1995) 92 (17), 7839-7843). Comparison of the amino acid sequence depicted in SEQ ID NO 2 with that of the very well-characterized erythromycin polyketide synthase, eryA ORF1 (Donadio, Science, (1991 ) 252, 675-679, DNA sequence gene/EMBL accession NO M63676) gives the following results: Region from SEQ ID NO 2: amino acids 2 - 325: is 40% identical to the acyltransferase domain of module 2 of the eryA locus of Saccharopolyspora erythraea. Region from SEQ ID NO 2: amino acids 325 - 470: is 43% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea. Region from SEQ ID NO 2: amino acids 762 - 940: is 48% identical to the ketoreductase domain of module 2 of the eryA locus of Saccharopolyspora erythraea. Region from SEQ ID NO 2: amino acids 1024- 1 109: is 57% identical to the acyl carrier protein domain of module 2 of the eryA locus of Saccharopolyspora erythraea. Region from SEQ ID NO 2: amino acids 1 126 - 1584: is 59% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. The very large similarities found in the amino acid sequence and in the size and arrangement of the enzymatic domains suggest that the cloned Kpnl region 5.7 kb in size from A mediterranei codes for part of a polyketide synthase which is typical of polyketides of the macrolide type. Example 7: Construction of a cosmid gene bank from A mediterranei The cosmid vector employed is the plasmid pWE15 which can be purchased (Stratagene, La Jolla, CA, USA). pWE15 is completely cut with the enzyme BamHI (Maniatis et al. 1989) and precipitated with ethanol. For ligation to the cosmid DNA, chromosomal DNA from A mediterranei is isolated as described in Example 1 and partially digested with the restriction enzyme Sau3A (Bόhringer, Mannheim) to form DNA fragments most of which have a size of 20 - 40 kb. The DNA pretreated in this way is fractionated by fragment size by centrifugation (83,000 g, 20°C) on a 10% to 40% sucrose density gradient for 18 h. The gradient is fractionated in 0.5 ml aliquots and dialysed, and samples of 10 μl are analysed on a 0.3% agarose gel with DNA size standard. Fractions with chromosomal DNA 25 - 40 kb in size are combined, precipitated with ethanol and resuspended in a small volume of water. Ligation of the cosmid DNA to the A. mediterranei Sau3A fragments isolated according to their size (see above) takes place with the aid of a T4-DNA ligase. About 3 μg of each of the two DNA starting materials are employed in a reaction volume of 20 μl, and the ligation is carried out at 12°C for 15 h. 4 ml of this ligation mixture are packaged into lambda phages using the in vitro packaging kit which can be purchased from Stratagene (La Jolla, CA, USA) (in accordance with the manufacturer's instructions). The resulting phages are ® introduced by infection into the E. coli strain X-1 BlueMR (Stratagene). Titration of the phage material reveals about 20,000 phage particles per ml, analysis of 12 cosmid clones shows that all the clones contain plasmid DNA inserts 25 - 40 kb in size. Example 8: Identification, cloning and characterization of the chromosomal A mediterranei ONA region which is adjacent to the cloned 5.7 kb Kpnl fragment To identify and clone the chromosomal A mediterranei DNA region which is adjacent to the 5.7 kb Kpnl fragment described above in Examples 3 and 5, firstly a radioactive DNA probe is prepared from this 5.7 kb Kpn! fragment. This is done by radiolabelling approximately 0.5 μg of the isolated DNA fragment with 32 P-d-CTP by the nick translation system of Gibco/BRL (Basle) in accordance with the manufacturer's instructions. Infection of E. co/Z X- Blue MR (Stratagene) with an aliquot of the lambda phages packaged in vitro (see Example 7) results in more than 2000 clones on several LB + ampicillin (50 μg/ml) plates. These clones are tested by colony hybridization on nitrocellulose filters (see Example 3 for method). The DNA probe used is the 5.7 kb Kpnl DNA fragment from A. mediterranei which is radiolabelled with "P-d-CTP and was prepared above. 5 cosmid clones showing a significant signal with the DNA probe are found. The plasmid DNA of these cosmids is isolated (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), digested with Kpnl and analysed in an agarose gel. Analysis reveals that all 5 plasmids have integrated chromosomal A. mediterranei DNA with a size of the order of about 25-35 kb, and all contain the 5.7 kb Kpnl fragment. To characterize the chromosomal A. mediterranei DNA region which is adjacent to the cloned Kpnl fragment, the plasmid DNA of one of the 5 cosmid clones is subjected to restriction analysis. The selected plasmid of the cosmid clone has the number pNE1 12 and likewise comprises the 13 kb Bglll fragment described in Example 3. Digestion of the plasmid pNE1 12 with the restriction enzymes BamHI, Bglll, Hindlll (singularly and in combination) allows a restriction map of the cloned region of A. mediterranei to be prepared, and this permits this region about 26 kb in size in the chromosome of A mediterranei to be characterized. This region is characterized by the following restriction cleavage sites with the stated distance in kb from one end: BamHI in position 3.2 kb, Hindlll in position 6.6 kb, Bglll in position 1 1 .5 kb, BamHI in position 16.6 kb, BamHI in position 17.3 kb, BamHI in position 21 kb and Bglll in position 24 kb. Example 9: Determination of the sequence of the chromosomal A. mediterranei DNA region present in the plasmid pNE1 12 and overlapping with the cloned 5.7 kb Kpnl fragment The plasmid pNE1 12 DNA is split up into fragments directly using an Aero-Mist nebulizer (CIS-US Inc., Bedford, MA, USA) under a nitrogen pressure of 8-12 pounds per square inch. These random DNA fragments are treated with T4 DNA polymerase, T4 DNA kinase and E. coli DNA polymerase in the presence of the 4 dNTPs in order to generate blunt ends on the double-stranded DNA fragments (Sambrook et al., Molecular Cloning: A Laboratory ■Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). The fragments are then fractionated in 0.8% low melting agarose (FMC SeaPlaque Agarose, Catalogue N° 501 13), and fragments 1.5-2 kb in size are extracted by hot phenol extraction (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). The DNA fragments obtained in this way are then ligated with the aid of T4 DNA ligase to the plasmid vector pBRKanf4 (see Example 5) or pBlueScript KS+ (Stratagene, La Jolla, CA, USA), each of which is cut once with square ends by appropriate restriction digestion (Smal for pBRKanf4 and EcoRV for pBlueScript KS+), and is dephosphorylated on the ends by a treatment with alkaline phosphatase (Bόhringer, Mannheim). The ligation mixture is then transformed into E. coli DH5α, and the cells are incubated overnight on LB agar with the appropriate antibiotic (kanamycin 40 μg/ml for pBRKanf4, ampicillin 100 μg/ml for pBlueScript KS+). Grown colonies are transferred singly into 1 .25 ml of liquid TB medium with antibiotic in 96-well plates with welis of a volume of 2 ml, and incubated at 37 C C overnight. Template DNA for the sequencing is prepared directly from these cultures by alkaline lysis (Birnboim, Methods in Enzymology (1983) 100, 243-255). The DNA sequencing takes place using the Perkin Elmer/Appied Biosystems reaction kit with dye-labelled terminator reagents (Kit N° 402122) and universal M13 mp18/19 primers or T3, T7 primers, or with primers prepared by us which bind to internal sequences. A standard cycle sequencing protocol with 20 cycles is used with a thermocycler (MJ Research DNA Engine Thermocycler, Model 225). The sequencing reactions are precipitated with ethanol, resuspended in formamide loading buffer and fractionated and analysed by electrophoresis using the Applied Biosystems automatic DNA sequencer (Model 377) in accordance with the manufacturer's instructions. Sequence files are produced with the aid of the Applied Biosystems DNA Analysis Software computer program and transferred to a SUN UltraSpark computer for further analysis. The following computer programs (software) are employed for analysing the results: DNA assembly and analysis package GAP (Genetics Computer Group, University of Wisconsin, R. Staden, Cambridge University UK) and the four programs: Phred, Cross-match, Phrad and Consed (P. Green, University of Washington, B. Ewing and D. Gordon, Washington University in Saint Louis). After the original sequences have been connected together to give longer coherent sequences (contigs), missing DNA sections are specifically sequenced with the aid of new primers (binding to sequenced sections), or by longer sequencing or sequencing the other strand. It is possible with the method described above to sequence the entire chromosomal DNA region 26 kb in size from A. mediterranei which is cloned in pNE112. The DNA sequence is depicted in SEQ ID NO 3 in the base pair 27801 - 53789 section. The DNA sequence of the 5.7 kb Kpnl fragment described in Example 5 is present in pNE1 12, and is depicted in SEQ ID NO 3 in the base pair 43093 - 48768 region. Example 10: Identification and characterization of cosmid clones with chromosomal DNA fragments from A. mediterranei which overlap with one end of the 26 kb A. mediterranei region of pNE1 12 To identify cosmid clones which comprise chro mosomal DNA fragm ents from A. mediterranei located directly in front of the 26 kb region of pNE112, the plasmid pNE112 is cut with the restriction enzyme BamHI, and the resulting BamHI fragment 3.2 kb in size is separated from the other BamHI fragments in an agarose gel and isolated from the gel. This BamHI fragment is located at one end of the incorporated A. mediterranei DNA in pNE112 (see Example 8) and can thus be used as DNA probe for finding the required cosmid clones. Approximately 0.5 μg of the isolated 3.2 kb BamHI DNA fragment is radiolabelled with 32 P-dCTP by the nick translation system from Gibco/BRL (Basel) in accordance with the manufacturer's instructions. The cosmid gene bank from A. mediterranei described in Example 7 is then analysed by colony hybridization (Method of Example 3) using this 3.2 kb DNA probe for clones with overlaps. Two cosmid clones with a strong hybridization signal can be identified in this way and are given the numbers pNE95 and pRi44-2. It is possible by restriction analysis and Southern blot to confirm that the plasmids pNE95 and pRi44-2 comprise chromosomal DNA fragments from A mediterranei which overlap with the 3.2 kb BamHI fragment from pNE112 and together cover a 35 kb chromosomal region of A mediterranei which is directiy adjacent to the 26 kb A mediterranei fragment of pNE112 cloned in pNE1 12. Example 11 : Restriction analysis of the chromosomal A mediterranei ONA region cloned with the cosmid clones pNE112. pNE95 and pRi44-2 The chromosomal A. mediterranei DNA region cloned with the cosmid clones pNE1 12, pNE95 and pRi44-2 is characterized by carrying out a restriction analysis. Digestion of the plasmid DNA of the three cosmids with the restriction enzymes EcoRI, Bglll and Hindlll (singly and in combination) produces a rough restriction map of the cloned region of A mediterranei. Overlapping fragments of the three plasmids are in this case established and confirmed by Southern blot. This chromosomal region of A. mediterranei has a size of about 61 kb and is characterized by the following restriction cleavage sites with the stated distance in kb from one end: EcoRI in position 7.2 kb, Hindlll in position 21 kb, Bglll in position 31 kb, Hindlll in position 42 kb, Bglll in position 47 kb and Bglll in position 59 kb. In this region in the A. mediterranei chromosome, the plasmid pRi 44-2 covers a region from position 1 to approximately 37 kb, plasmid pNE95 covers a region of approximate position 9 kb - 51 kb and plasmid pNE 112 covers a region of approximate position 35 kb - 61 kb. Example 12: Determination of the sequence of the chromosomal A. mediterranei DNA region described in Example 11 from the EcoRI cleavage site in the 7.2 kb position up to the 61 kb end Determination of the DNA sequence of the chromosomal region described in Example 1 1 from A. mediterranei (EcoRI cleavage site in the 7.2 kb position to 51 kb) is carried out with the plasmids pRi 44-2 and pNE95, using exactly the same method as described in Example 9. Analysis of the DNA sequence obtained in this way confirms the rough restriction map described in Example 1 1 and the overlaps of the cloned A. mediterranei fragments in the plasmids pNE112, pNE95 and pRi44-2. The DNA sequence of the chromosomal A. mediterranei DNA region described in Example 11 from the EcoRI cleavage site in the 7.2 kb position up to the end at 61 kb is depicted in SEQ ID NO 3 (length 53789 base pairs). Example 13: Analysis of a first protein-encoding region (ORF A) of the cloned A mediterranei chromosomal region depicted in SEQ ID NO 3 The nucleotide sequence shown in SEQ ID NO 3 is analysed with the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that a very large open reading frame (ORF A) which codes for a protein is present in the first third of the sequence (position 1825 - 15543 including stop codon in SEQ ID NO 3). The codons used in ORF A are typical of actinomycetes genes with a high G+C content. Comparison of the amino acid sequence of ORF A (SEQ ID NO 4, size 4572 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase of Saccharopolyspora erythraea (Donadio, Science, (1991 ) 252, 675-679, DNA sequence gene/EMBL accession N° M63676) gives the following results: Region from ORF A. SEQ ID NO 4: amino acids 370 - 451 : is 50% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A. SEQ ID NO 4: amino acids 469 - 889: is 65% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A. SEQ ID NO 4: amino acids 982 - 1292: is 54% identical to the acyl- transferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A. SEQ ID NO 4: amino acids 1324 - 1442: is 42% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A. SEQ ID NO 4: amino acids 1664 - 1840: is 56% identical to the keto- reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A. SEQ ID NO 4: amino acids 1929 - 2000: is 53% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A. SEQ ID NO 4: amino acids 2032 - 2453: is 64% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A. SEQ ID NO 4: amino acids 2554 - 2865: is 37% identical to the acyl- transferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A. SEQ ID NO 4: amino acids 2918 - 2991 : is 54% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A. SEQ ID NO 4: amino acids 3009 - 3431 : is 65% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 3532 - 3847: is 53% identical to the acyl- transferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF A. SEQ ID NO 4: amino acids 4142 - 4307: is 43% identical to the keto- reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF A. SEQ ID NO 4: amino acids 4405 - 4490: is 50% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. I n addition to these significant homologies with the eryA polyketide synthase of S. erythraea, the region of ORF A. SEQ ID NO 4: amino acids 1 - 356 is 53% identical to the postulated starter unit activation domain of the rapamycin polyketide synthase from Streptomyces hygroscopicus (Aparicio et al. GENE (1996) 169, 9-16) The great similarities found in the amino acid sequence of the enzymatic domains suggest unambiguously that the protein-encoding region (ORF A) of the A. mediterranai chromosomal region depicted in SEQ ID NO 3 codes for a typical modular (type 1 ) polyketide synthase. This very large A. mediterranei polyketide synthase encoded by ORF A comprises three complete bioactive modules which are each responsible for condensation of a C2 unit in the macrolide ring of the molecule and correct modification of the initially formed β-keto groups. Because of the homology with activating domains of the rapamycin polyketide synthase, the first module described above very probably comprises an enzymatic domain for activating the aromatic starter unit of rifamycin biosynthesis, 3- amino-5-hydroxybenzoic acid (Ghisalba et al., Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281 -327). Example 14: Analysis of a second protein encoding region (ORF B) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3 The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that another large open reading frame (ORF B) which codes for a protein is present in the middle region of the sequence (position 15550 - 30759 including stop codon in SEQ ID NO 3). The codons used in ORF B are typical of actinomycetes genes with a high G+C content. Comparison of the amino acid sequence of ORF B (SEQ ID NO 5, length 5069 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase of Saccharopolyspora erythraea (Donadio, Science, (1991 ) 252, 675-679, DNA sequence gene/EMBL accession N° M63676) gives the following results: Reoion of ORF B. SEQ ID NO 5: amino acids 44 - 468: is 62% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B. SEQ ID NO 5: amino acids 571 - 889: is 56% identical to the acyl- transferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B. SEQ I D NO 5: amino acids 921 - 1 055: is 47% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B. SEQ ID NO 5: amino acids 1353 - 1525: is 49% identical to the keto- reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B. SEQ ID NO 5: amino acids 1621 - 1706: is 53% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B. SEQ ID NO 5: amino acids 1726 - 2148: is 62% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B. SEQ ID NO 5: amino acids 2251 - 2560: is 55% identical to the acyl- transferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B. SEQ ID NO 5: amino acids 2961 - 3132: is 49% identical to the keto- reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B. SEQ ID NO 5: amino acids 3228 - 3313: is 52% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B. SEQ ID NO 5: amino acids 3332 - 3755: is 63% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B. SEQ ID NO 5: amino acids 3857 - 4173: is 52% identical to the acyl- transferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B. SEQ ID NO 5: amino acids 4664 - 4799: is 47% identical to the keto- reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B. SEQ ID NO 5: amino acids 4929 - 5014: is 52% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Example 1 5: Analysis of a third protein-encoding region (ORF C) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3 The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that a large open reading frame (ORF C) which codes for a protein is present in the middle region of the sequence (position 30895 - 36060 including stop codon in SEQ ID NO 3). The codons used in ORF C are typical of actinomycetes genes with a high G+C content. Comparison of the amino acid sequence of ORF C (SEQ ID NO 6, length 1721 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase from Saccharopolyspora erythraea (Donadio, Science, (1991) 252, 675-679, DNA sequence gene/EMBL accession N° M63676) gives the following results: Region of ORF C. SEQ ID NO 6: amino acids 1 - 414: is 63% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF C. SEQ ID NO 6: amino acids 514 - 828: is 54% identical to the acyl- transferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF C. SEQ ID NO 6: amino acids 1290 - 1399: is 49% identical to the keto- reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF C. SEQ ID NO 6: amino acids 1563 - 1648: is 55% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Example 16: Analysis of a fourth protein-encoding region (ORF D) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3 The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that a large open reading frame (ORF D) which codes for a protein is present in the middle region of the sequence (position 36259 - 41325 including stop codon in SEQ ID NO 3). The codons used in ORF D are typical of actinomycetes genes with a high G+C content. Comparison of the amino acid sequence of ORF D (SEQ ID NO 7, length 1688 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase from Saccharopolyspora erythraea (Donadio, Science, (1991 ) 252, 675-679, DNA sequence genes/EMBL accession N° M63676) gives the following results: Reoion of ORF D. SEQ ID NO 7: amino acids 1 - 418: is 64% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF D. SEQ ID NO 7: amino acids 524 - 841 : is 54% identical to the acyl- transferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF P. SEQ ID NO 7: amino acids 1260 - 1432: is 51 % identical to the keto- reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF P. SEQ ID NO 7: amino acids 1523 - 1608: is 53% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Example 1 7: Analysis of a fifth protein-encoding region (ORF E of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3 The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that a large open reading frame (ORF E) which codes for a protein is present in the rear region of the sequence (position 41373 - 51614 including stop codon in SEQ ID NO 3). The codons used in ORF E are typical of actinomycetes genes with a high G+C content. Comparison of the amino acid sequence of ORF E (SEQ ID NO 8, length 3413 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase from Saccharopolyspora erythraea (Donadio, Science, (1991 ) 252, 675-679, DNA sequence gene/EMBL accession N° M63676) gives the following results: Region of ORF E. SEQ ID NO 8: amino acids 31 - 451 : is 64% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF E. SEQ ID NO 8: amino acids 555 - 874: is 37% identical to the acyl- transferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF E. SEQ ID NO 8: amino acids 907 - 1036: is 49% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea. Region of ORF E. SEQ ID NO 8: amino acids 1336 - 1500: is 52% identical to the keto- reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF E. SEQ ID NO 8: amino acids 1598 - 1683: is 51 % identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF E, SEQ ID NO 8: amino acids 1702 - 2124: is 62% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Reαion of ORF E. SEQ ID NO 8: amino acids 2229 - 2543: is 53% identical to the acyl- transferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF E. SEQ ID NO 8: amino acids 2573 - 2700: is 47% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea. Region of ORF E. SEQ ID NO 8: amino acids 3054 - 3227: is 52% identical to the keto- reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF E. SEQ ID NO 8: amino acids 3324 - 3405: is 51 % identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Example 1 8: Analysis of a sixth protein-encoding region (ORF F) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3 The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that an open reading frame (ORF F) which codes for a protein is present in the rear region of the sequence (position 51713 - 52393 including stop codon in SEQ ID NO 3). The codons used in ORF F are typical of actinomycetes genes with a high G+C content. Comparison of the amino acid sequence of ORF F (SEQ ID NO 9, length 226 amino acids) with proteins from the EMBL databank (Heidelberg) shows a great similarity with the N- hydroxyarylamine O-acyltransferase from Salmonella typhimurium (29% identity over a region of 134 amino acids) . There is also significant homology with arylamine acyl- transferases from other organisms. It can be concluded from these agreements that the ORF F found in A. mediterranei in SEQ ID No 3 codes for an arylamine acyl transferase, and it can be assumed that this enzyme is responsible for the linkage of the long acyl chain produced by the polyketide synthase to the amino group on the starter molecule, 3-amino-5- hydroxybenzoic acid. This reaction would close the rifamycin ring system correctly after completion of the condensation steps by the polyketide synthase. Example 19: Summarizing assessment of the function of the proteins encoded by ORF A - F in SEQ ID NO 3, and their role in the biosynthesis of rifamycin The five protein-encoding regions (ORF A-E), described in Examples 13 - 17, of SEQ ID NO 3 comprise proteins with very great similarity (in the amino acid sequence and the arrangement of the enzymatic domains) to polyketide synthases for polyketides of the macrolide type. Taken together, these five multifunctional enzymes comprise 10 polyketide synthase modules which are each responsible for a condensation step in the polyketide synthesis. 10 such condensation steps are likewise necessary for rifamycin biosynthesis (Ghisalba et al., Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281 -327). The processing of the particular keto groups required by the enzymatic domains within the modules substantially corresponds to the activity required by the rifamycin molecule, if it is assumed that the polyketide synthesis takes place "colinearly" with the arrangement of the modules in the gene cluster of A. mediterranei (this is so for other macrolide antibiotics such as erythromycin and rapamycin). It may be added here that it is not certain whether transcription of the five ORFs results in five proteins; in particular, ORF C and ORF D might possibly be translated to a large protein. An enzymatic domain which is very probably responsible for activating the starter molecule, 3-hydroxy-5-aminobenzoic acid, of rifamycin biosynthesis can be found at the N terminus of ORF A, the start of the polyketide synthase. Directly below the described rifamycin polyketide synthase gene cluster there is a gene (ORF F) which very probably determines a protein which brings about ring closure of the rifamycin molecule after completion of the condensation steps by the polyketide synthase. It can be concluded on the basis of these findings that the A. mediterranei chromosomal region described in SEQ ID NO 3 is responsible for the ten condensation steps required for rifamycin polyketide synthesis, including activation of the starter molecule 3-hydroxy-5- aminobenzoic acid, and the concluding ring closure. De p osited microorganisms The following microorganisms and plasmids have been deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Mascheroder Weg 1 b, D- 38124 Braunschweig, in accordance with the requirements of the Budapest Treaty. Microorganism/Plasmid Date of deposit Deposit number E. coli with plasmid pRi7-3 10.08.96 DSM 1 1114 E. coli with plasmid pNE112 14.07.97 DSM 11657 E. coli with plasmid pNE95 14.07.97 DSM 1 1656 E. coli with plasmid pRi44-2 14.07.97 DSM 1 1655 SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Novartis AG (B) STREET: Scwarzwaldallee 215 (C) CITY: Basel (E) COUNTRY: Switzerland (F) POSTAL CODE (ZIP): 4058 (G) TELEPHONE: +41 61 324 1111 (K) TELEFAX: + 41 61 322 75 32 (ii) TITLE OF INVENTION: Rifamycin biosynthesis gene cluster (iii) NUMBER OF SEQUENCES: 9 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO) ( xi ) SEQUENCE DESCRIPTION : SEQ ID NO: 1 : GGTACCCGGT GTTCGCGACG GCGTTCGACG AGGCTTGCGA GCAGCTGGAC GTCTGTCTGG 60 CCGGCCGTGC CGGGCACCGC GTGCGGGACG TCGTGCTCGG CGAAGTGCCC GCCGAAACCG 120 GGCTGCTGAA CCAGACGGTC TTCACCCAAG CCGGGCTGTT CGCGGTGGAG AGCGCGCTGT 180 TCCGGCTCGC CGAATCCTGG GGTGTCCGGC CGGACGTGGT GCTCGGCCAC TCCATCGGGG 240 AGATCACCGC CGCGTATGCC GCGGGCGTCT TCTCGCTGCC GGACGCCGCC CGGATCGTCG 300 CGGCGCGCGG CCGGCTGATG CAGGCGCTGG CGCCGGGCGG GGCGATGGTC GCCGTCGCCG 360 CCTCCGAAGC CGAGGTGGCC GAACTGCTCG GCGACGGCGT GGAACTCGCC GCCGTCAACG 420 GCCCTTCGGC GGTAGTCCTT TCCGGGGACG CGGACGCGGT CGTCGCGGCC GCCGCCCGCA 480 TGCGCGAGCG CGGGCACAAG ACCAAGCAGC TCAAGGTTTC GCACGCGTTC CACTCCGCGC 540 GGATGGCGCC GATGCTGGCG GAGTTCGCCG CCGAGCTGGC CGGCGTGACG TGGCGCGAGC 600 CGGAGATCCC GGTGGTCTCC AACGTGACCG GCCGGTTCGC CGAGCCCGGC GAACTGACCG 660 AGCCGGGCTA CTGGGCCGAG CACGTGCGGC GGCCGGTGCG GTTCGCCGAG GGCGTCGCGG 720 CCGCGACGGA GTCCGGCGGC TCGCTGTTCG TGGAGCTCGG GCCGGGGGCG GCGCTGACCG 780 CCCTCGTCGA GGAGACGGCC GAGGTCACCT GCGTCGCGGC CCTGCGGGAC GACCGCCCGG 840 AGGTCACCGC GCTGATCACC GCGGTCGCCG AGCTGTTCGT CCGCGGGGTT GCGGTCGATT 900 GGCCGGCCCT GCTGCCGCCG GTCACCGGGT TCGTCGACCT GCCGAAGTAC GCCTTCGACC 960 AGCAGCACTA TTGGCTGCAG CCCGCCGCGC AGGCCACGGA CGCGGCCTCG CTCGGGCAGG 1020 TCGCGGCCGA CCACCCGCTG CTGGGCGCGG TGGTCCGGCT GCCGCAGTCG GACGGCCTGG 1080 TCTTCACCTC GCGGCTGTCA TTGAAATCGC ACCCGTGGCT GGCCGACCAC GTCATCGGCG 1140 GGGTGGTGCT CGTCGCGGGC ACCGGGCTCG TCGAGCTGGC CGTCCGGGCC GGGGACGAGG 1200 CCGGCTGCCC GGTCCTCGAA GAACTCGTCA TCGAGGCTCC GCTGGTCGTC CCCGACCACG 1260 GCGGGGTCCG GATCCAGGTC GTCGTGGGGG CACCGGGGGA GACCGGTTCG CGCGCGGTCG 1320 AGGTGTACTC CCTGCGCGAG GACGCCGGTG CCGAAGTGTG GGCCCGGCAC GCCACCGGGT 1380 TCCTGGCTGC GACGCCGTCG CAGCACAAGC CGTTCGACTT CACCGCCTGG CCGCCGCCCG 1440 GCGTCGAGCG CGTCGACGTC GAGGACTTCT ACGACGGCTT CGTCGACCGC GGGTACGCCT 1500 ACGGGCCGTC GTTCCGGGGC CTGCGGGCGG TGTGGCGGCG CGGCGACGAA GTGTTCGCCG 1560 AGGTCGCCCT GGCCGAGGAC GACCGCGCGG ACGCGGCCCG GTTCGGCATC CACCCCGGCC 1620 TGCTGGACGC CGCCCTGCAC GCGGGCATGG CCGGTGCCAC CACCACGGAA GAGCCCGGCC 1680 GGCCGGTGCT GCCGTTCGCC TGGAACGGCC TGGTGCTGCA CGCGGCCGGG GCGTCCGCGC 1740 TGCGGGTCCG GCTCGCCCCG AGCGGTCCGG ACGCCCTGTC GGTCGAGGCC GCGGACGAGG 1800 CCGGCGGTCT CGTTGTGACG GCGGACTCGC TGGTCTCCCG GCCGGTGTCG GCCGAACAGC 1860 TGGGCGCGGC GGCGAACCAC GACGCGTTGT TCCGCGTGGA GTGGACCGAG ATTTCCTCGG 1920 CTGGAGACGT TCCGGCGGAC CACGTCGAAG TGCTCGAAGC CGTCGGCGAG GATCCCCTGG 1980 AACTGACCGG CCGGGTCCTG GAGGCCGTGC AGACCTGGCT CGCCGACGCA GCCGACGACG 2040 CTCGCCTGGT CGTGGTGACC CGCGGCGCCG TCCACGAGGT GACTGACCCG GCCGGTGCCG 2100 CGGTGTGGGG CCTGATCCGG GCCGCGCAGG CGGAAAACCC GGACCGGATC GTGCTGCTGG 2160 ACACCGACGG TGAAGTGCCG CTAGGCCGGG TGCTGGCCAC CGGCGAGCCC CAAACAGCCG 2220 TCCGAGGCGC CACGCTGTTC GCCCCGCGGC TGGCCCGCGC CGAGGCCGCG GAGGCACCGG 2280 CAGTGACCGG CGGGACGGTC CTGATCTCGG GCGCCGGCTC GCTGGGCGCG CTCACCGCCC 2340 GGCACCTGGT CGCCCGGCAC GGAGTCCGGC GGCTGGTGCT CGTCAGCCGC CGTGGCCCCG 2400 ACGCCGACGG CATGGCCGAA CTGACCGCTG AACTCATCGC TCAGGGCGCC GAGGTCGCCG 2460 TAGTCGCTTG CGACCTGGCC GACCGGGACC AGGTCCGGGT ACTGCTGGCC GAGCACCGCC 2520 CGAACGCCGT CGTGCACACG GCCGGTGTTC TCGACGACGG CGTCTTCGAG TCGCTGACGC 2580 GGGAGCGGCT GGCCAAGGTC TTCGCGCCCA AAGTTACTGC TGCCAATCAC CTCGACGAGC 2640 TGACCCGCGA ACTGGATCTT CGCGCGTTCG TCGTGTTCTC CTCCGCCTCC GGGGTCTTCG 2700 GCTCCGCCGG GCAGGGCAAC TACGCCGCTG CCAACGCCTA CCTGGACGCC GTGGTCGCCA 2760 ACCGCCGGGC CGCGGGCCTG CCCGGCACAT CGCTGGCCTG GGGCCTGTGG GAACAGACCG 2820 ACGGGATGAC CGCGCACCTC GGCGACGCCG ACCAGGCGCG GGCGAGTCGC GGCGGGGTCC 2880 TCGCCATCTC ACCCGCCGAA GGCATGGAGC TGTTCGACGC AGCGCCGGAC GGGCTCGTCG 2940 TCCCGGTCAA GCTGGACCTG CGCAAGACCC GCGCCGGCGG GACGGTGCCG CACCTGCTGC 3000 GCGGCCTGGT CCGCCCGGGA CGGCAGCAGG CCCGTCCGGC GTCCACTGTG GACAACGGAC 3060 TGGCCGGGCG ACTCGCCGGG CTCGCGCCGG CGGAGCAGGA GGCGCTGCTG CTCGACGTCG 3120 TCCGCACGCA GGTCGCGCTG GTGCTCGGGC ACGCCGGGCC GGAGGCCGTC CGCGCGGACA 3180 CGGCGTTCAA GGACACCGGC TTCGACTCGC TGACGTCGGT GGAACTGCGC AACCGGCTGC 3240 GCGAGGCGAG CGGGCTGAAG CTGCCCGCGA CGCTCGTCTT CGACTACCCG ACGCCGGTCG 3300 CGCTGGCCCG CTACCTGCGT GACGAATTCG GCGACACGGT GGCAACAACT CCGGTGGCCA 3360 CCGCGGCCGC AGCGGACGCC GGCGAGCCGA TCGCCATCGT CGGCATGGCG TGCCGGCTGC 3420 CGGGCGGGGT CACCGATCCC GAAGGCCTGT GGCGCCTGGT GCGCGACGGC CTCGAAGGGC 3480 TGTCTCCCTT CCCCGAGGAC CGGGGCTGGG ACCTGGAGAA CCTGTTCGAC GACGACCCCG 3540 ACCGCTCCGG CACGACGTAC ACCAGCCGGG GCGGGTTCCT CGACGGCGCC GGCCTGTTCG 3600 ACGCGGGCTT CTTCGGGATT TCGCCGCGCG AGGCGCTGGC CATGGACCCG CAGCAGCGGC 3660 TGCTGCTCGA GGCGGCCTGG GAAGCCCTCG AAGGCACCGG TGTCGACCCG GGCTCGTTGA 3720 AGGGCGCCGA CGTCGGGGTG TTCGCCGGGG TGTCCAACCA GGGCTATGGG ATGGGCGCGG 3780 ATCCGGCCGA ACTGGCGGGG TACGCGAGCA CGGCGGGCGC TTCGAGCGTC GTCTCGGGCC 3840 GAGTCTCGTA CGTCTTCGGG TTCGAAGGAC CGGCGGTCAC GATCGACACG GCTTGCTCGT 3900 CGTCGCTGGT GGCGATGCAC CTGGCCGGGC AGGCGCTGCG GCAGGGCGAG TGCTCGATGG 3960 CCCTGGCCGG TGGCGTCACG GTGATGGGGA CGCCCGGCAC GTTCGTGGAG TTCGCGAAGC 4020 AGCGCGGCCT GGCCGGCGAC GGCCGGTGCA AGGCCTACGC CGAAGGCGCG GACGGCACGG 4080 GCTGGGCCGA GGGCGTCGGG GTCGTCGTGC TGGAGCGGCT GTCGGTGGCG CGCGAGCGCG 4140 GGCACCGGGT GCTGGCCGTG CTGCGCGGCA GCGCGGTCAA CTCCGACGGC GCGTCCAACG 4200 GCCTGACCGC CCCCAACGGG CCGTCGCAGC AACGGGTGAT CCGCCGGGCC CTGGCCGGCG 4260 CCGGCCTCGA ACCGTCCGAT GTGGACATCG TGGAAGGGCA CGGCACCGGG ACGGCGCTGG 4320 GCGACCCGAT CGAGGCGCAG GCCCTGCTGG CCACCTACGG CAAGGACCGC GACCCGGAGA 4380 CGCCGTTGTG GCTGGGGTCG GTGAAGTCGA ACTTCGGCCA CACGCAGTCC GCGGCCGGCG 4440 TGGCCGGGGT GATCAAGATG GTGCAGGCGC TGCGCCACGG CGTCATGCCG CCCACCCTGC 4500 ACGTGGACCG GCCCACCAGC CAGGTCGACT GGTCCGCGGG GGCCGTCGAA GTGCTGACCG 4560 AGGCACGGGA GTGGCCGCGG AACGGCCGTC CGCGCCGGGC CGGGGTGTCC TCGTTCGGGA 4620 TCAGCGGCAC GAACGCCCAC CTGATCATCG AAGAAGCACC GGCCGAGCCA CAGCTTGCCG 4680 GACCACCGCC GGACGGCGGT GTGGTGCCGC TGGTCGTCTC GGCTCGCAGC CCCGGTGCCC 4740 TGGCCGGTCA GGCGCGTCGG CTGGCCACGT TCCTCGGCGA CGGGCCCCTT TCCGACGTCG 4800 CCGGTGCGCT GACGAGCCGC GCCCTGTTCG GCGAGCGCGC GGTCGTCGTG GCGGATTCGG 4860 CCGAGGAAGC CCGCGCCGGT CTGGGCGCAC TGGCCCGCGG CGAAGACGCG CCGGGCCTGG 4920 TCCGCGGCCG GGTGCCCGCG TCCGGCCTGC CGGGCAAGCT CGTGTGGGTG TTCCCCGGGC 4980 AGGGGACGCA GTGGGTGGGC ATGGGCCGCG AACTCCTCGA AGAGTCTCCG GTGTTCGCCG 5040 AGCGGATCGC CGAGTGTGCG GCCGCGCTGG AGCCGTGGAT CGGCTGGTCG CTGTTCGACG 5100 TCCTCCGTGG CGACGGTGAC CTCGATCGGG TCGATGTGCT GCAGCCCGCG TGCTTTGCGG 5160 TGATGGTCGG CTTGGCCGCG GTGTGGTCCT CGGCCGGGGT GGTCCCCGAT GCGGTGCTCG 5220 GCCACTCCCA GGGTGAGATC GCCGCGGCGT GCGTGTCGGG TGCGTTGTCG CTGGAGGATG 5280 CGGCGAAGGT GGTTGCCCTG CGCAGCCAGG CCATCGCCGC GAAGCTCTCC GGCCGCGGCG 5340 GGATGGCTTC GGTCGCCTTG GGCGAAGCCG ATGTGGTGTC GCGGCTGGCG GACGGGGTCG 5400 AGGTGGCTGC CGTCAACGGT CCGGCGTCCG TGGTGATCGC GGGGGATGCC CAGGCCCTCG 5460 ACGAAACGCT GGAAGCGCTG TCCGGTGCGG GAATCCGGGC TCGGCGGGTG GCGGTGGACT 5520 ACGCCTCGCA CACCCGGCAC GTCGAAGACA TCGAAGACAC CCTCGCCGAA GCGCTGGCCG 5580 GGATCGACGC CCGGGCGCCG CTGGTGCCGT TCCTCTCCAC CCTCACCGGC GAGTGGATCC 5640 GGGACGAGGG CGTCGTGGAC GGCGGCTACT GGTACC 5676 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1891 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Tyr Pro Val Phe Ala Thr Ala Phe Asp Glu Ala Cys Glu Gin Leu Asp 1 5 10 15 Val Cys Leu Ala Gly Arg Ala Gly His Arg Val Arg Asp Val Val Leu 20 25 30 Gly Glu Val Pro Ala Glu Thr Gly Leu Leu Asn Gin Thr Val Phe Thr 35 40 45 Gin Ala Gly Leu Phe Ala Val Glu Ser Ala Leu Phe Arg Leu Ala Glu 50 55 60 Ser Trp Gly Val Arg Pro Asp Val Val Leu Gly His Ser lie Gly Glu 65 70 75 80 Ile Thr Ala Ala Tyr Ma Ma Gly Val Phe Ser Leu Pro Asp Ma Ma 85 90 95 Arg He Val Ma Ma Arg Gly Arg Leu Met Gin Ma Leu Ma Pro Gly 100 105 110 Gly Ma Met Val Ma Val Ma Ma Ser Glu Ma Glu Val Ma Glu Leu 115 120 125 Leu Gly Asp Gly Val Glu Leu Ma Ma Val Asn Gly Pro Ser Ma Val 130 135 140 Val Leu Ser Gly Asp Ma Asp Ma Val Val Ma Ma Ma Ma Arg Met 145 150 155 160 Arg Glu Arg Gly His Lys Thr Lys Gin Leu Lys Val Ser His Ma Phe 165 170 175 His Ser Ma Arg Met Ala Pro Met Leu Ma Glu Phe Ma Ma Glu Leu ISO 185 190 Ma Gly Val Thr Trp Arg Glu Pro Glu He Pro Val Val Ser Asn Val 195 200 205 Thr Gly Arg Phe Ma Glu Pro Gly Glu Leu Thr Glu Pro Gly Tyr Trp 210 215 220 Ma Glu His Val Arg Arg Pro Val Arg Phe Ma Glu Gly Val Ma Ma 225 230 235 240 Ma Thr Glu Ser Gly Gly Ser Leu Phe Val Glu Leu Gly Pro Gly Ma 245 250 255 Ma Leu Thr Ma Leu Val Glu Glu Thr Ma Glu Val Thr Cys Val Ma 260 265 270 Ma Leu Arg Asp Asp Arg Pro Glu Val Thr Ma Leu He Thr Ma Val 275 280 285 Ma Glu Leu Phe Val Arg Gly Val Ma Val Asp Trp Pro Ma Leu Leu 290 295 300 Pro Pro Val Thr Gly Phe Val Asp Leu Pro Lys Tyr Ma Phe Asp Gin 305 310 315 320 Gin His Tyr Trp Leu Gin Pro Ma Ma Gin Ma Thr Asp Ma Ma Ser 325 330 335 Leu Gly Gin Val Ma Ma Asp His Pro Leu Leu Gly Ma Val Val Arg 340 345 350 Leu Pro Gin Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Leu Lys 355 360 365 Ser His Pro Trp Leu Ma Asp His Val He Gly Gly Val Val Leu Val 370 375 380 Ma Gly Thr Gly Leu Val Glu Leu Ma Val Arg Ma Gly Asp Glu Ma 335 390 395 400 Gly Cys Pro Val Leu Glu Glu Leu Val He Glu Ma Pro Leu Val Val 405 410 415 Pro Asp His Gly Gly Val Arg He Gin Val Val Val Gly Ma Pro Gly 420 425 430 Glu Thr Gly Ser Arg Ma Val Glu Val Tyr Ser Leu Arg Glu Asp Ma 435 440 445 Gly Ma Glu Val Trp Ma Arg His Ma Thr Gly Phe Leu Ma Ma Thr 450 455 46Q Pro Ser Gin Kis Lys Pro Phe Asp Phe Thr Ma Trp Pro Pro Pro Gly 465 470 475 480 Val Glu Arg Val Asp Val Glu Asp Phe Tyr Asp Gly Phe Val Asp Arg 485 490 495 Gly Tyr Ma Tyr Gly Pro Ser Phe Arg Gly Leu Arg Ma Val Trp Arg 500 505 510 Arg Gly Asp Glu Val Phe Ma Glu Val Ma Leu Ma Glu sp .Asp Arg 515 520 525 Ma Asp Ma Ma Arg Phe Gly He His Pro Gly Leu Leu Asp Ma Ma 530 535 540 Leu His Ma Gly Met Ma Gly Ma Thr Thr Thr Glu Glu Pro Gly Arg 545 550 555 560 Pro Val Leu Pro Phe Ma Trp Asn Gly Leu Val Leu His Ma Ma Gly 565 570 575 Ma Ser Ma Leu Arg Val Arg Leu Ma Pro Ser Gly Pro Asp Ma Leu 580 585 590 Ser Val Glu Ma Ma Asp Glu Ma Gly Gly Leu Val Val Thr Ma Asp 595 600 605 Ser Leu Val Ser Arg Pro Val Ser Ma Glu Gin Leu Gly Ma Ma Ma 610 615 620 Asn His Asp Ma Leu Phe Arg Val Glu Trp Thr Glu He Ser Ser Ma 625 630 635 640 Gly Asp Val Pro Ma Asp His Val Glu Val Leu Glu Ma Val Gly Glu 645 650 655 Asp Pro Leu Glu Leu Thr Gly Arg Val Leu Glu Ma Val Gin Thr Trp 660 665 670 Leu Ma Asp Ma Ma Asp Asp Ma Arg Leu Val Val Val Thr Arg Gly 675 680 685 Ma Val His Glu Val Thr Asp Pro Ma Gly Ma Ma Val Trp Gly Leu 690 695 700 He Arg Ma Ma Gin Ma Glu Asn Pro Asp Arg He Val Leu Leu Asp 705 710 715 720 Thr Asp Gly Glu Val Pro Leu Gly Arg Val Leu Ma Thr Gly Glu Pro 725 730 735 Gin Thr Ala Val Arg Gly Ma Thr Leu Phe Ma Pro Arg Leu Ma Arg 740 745 750 Ma Glu Ma Ma Glu Ma Pro Ma Val Thr Gly Gly Thr Val Leu He 755 760 765 Ser Gly Ma Gly Ser Leu Gly Ma Leu Thr Ma Arg His Leu Val Ma 770 775 780 Arg His Gly Val Arg Arg Leu Val Leu Val Ser Arg Arg Gly Pro Asp 785 790 795 800 Ma Asp Gly Met Ma Glu Leu Thr Ma Glu Leu He Ma Gin Gly Ma 805 810 815 Glu Val Ma Val Val Ma Cys Asp Leu Ma Asp Arg Asp Gin Val Arg 820 825 830 Val Leu Leu Ma Glu His Arg Pro Asn Ma Val Val His Thr Ala Gly 835 840 845 Val Leu Asp Asp Gly Val Phe Glu Ser Leu Thr Arg Glu Arg Leu Ma 850 855 860 Lys Val Phe Ma Pro Lys Val Thr Ma Ma Asn His Leu Asp Glu Leu 865 870 875 880 Thr Arg Glu Leu Asp Leu Arg Ma Phe Val Val Phe Ser Ser Ma Ser 885 890 895 Gly Val Phe Gly Ser Ma Gly Gin Gly Asn Tyr Ma Ma Ma Asn Ma 900 905 910 Tyr Leu Asp Ma Val Val Ala Asn Arg Arg Ma Ma Gly Leu Pro Gly 915 920 925 Thr Ser Leu Ma Trp Gly Leu Trp Glu Gin Thr Asp Gly Met Thr Ma 930 935 940 His Leu Gly Asp Ma Asp Gin Ma Arg Ma Ser Arg Gly Gly Val Leu 945 950 955 960 Ma He Ser Pro Ma Glu Gly Met Glu Leu Phe Asp Ma Ma Pro Asp 965 970 975 Gly Leu Val Val Pro Val Lys Leu Asp Leu Arg Lys Thr Arg Ma Gly 980 985 990 Gly Thr Val Pro His Leu Leu Arg Gly Leu Val Arg Pro Gly Arg Gin 995 1000 1005 Gin Ma Arg Pro Ma Ser Thr Val Asp Asn Gly Leu Ma Gly Arg Leu 1010 1015 1020 Ma Gly Leu Ma Pro Ma Glu Gin Glu a Leu Leu Leu Asp Val Val 1025 1030 1035 1040 Arg Thr Gin Val Ma Leu Val Leu Gly His Ma Gly Pro Glu Ma Val 1045 1050 1055 Arg Ma Asp Thr Ma Phe Lys Asp Thr Gly Phe Asp Ser Leu Thr Ser 1060 1065 1070 Val Glu Leu Arg Asn Arg Leu Arg Glu Ma Ser Gly Leu Lys Leu Pro 1075 1080 1085 Ma Thr Leu Val Phe Asp Tyr Pro Thr Pro Val Ma Leu Ma Arg Tyr 1090 1095 1100 Leu Arg Asp Glu Phe Gly Asp Thr Val Ma Thr Thr Pro Val Ma Thr 1105 1110 1115 1120 Ma Ala Ma Ma Asp Ma Gly Glu Pro He Ma He Val Gly Met Ma 1125 1130 1135 Cys Arg Leu Pro Gly Gly Val Thr Asp Pro Glu Gly Leu Trp Arg Leu 1140 1145 1150 Val Arg Asp Gly Leu Glu Gly l.eu Ser Pro Phe Pro Glu Asp Arg Gly 1155 1160 1165 Trp Asp Leu Glu Asn Leu Phe Asp Asp Asp Pro Asp Arg Ser Gly Thr 1170 1175 1180 Thr Tyr Thr Ser Arg Gly Gly Phe Leu Asp Gly Ma Gly Leu Phe Asp 1185 1190 1195 1200 Ma Gly Phe Phe Gly He Ser Pro Arg Glu Ma Leu Ma Met Asp Pro 1205 1210 1215 Gin Gin Arg Leu Leu Leu Glu Ma Ma Trp Glu Ma Leu Glu Gly Thr 1220 1225 1230 Gly Val Asp Pro Gly Ser Leu Lys Gly Ma Asp Val Gly Val Phe Ma 1235 1240 1245 Gly Val Ser Asn Gin Gly Tyr Gly Met Gly Ma Asp Pro Ma Glu Leu 1250 1255 1260 Ma Gly Tyr Ma Ser Thr Ma Gly Ma Ser Ser Val Val Ser Gly Arg 1265 1270 1275 1280 Val Ser Tyr Val Phe Gly Phe Glu Gly Pro Ma Val Thr He Asp Thr 1285 1290 1295 Ma Cys Ser Ser Ser Leu Val Ma Met His Leu Ma Gly Gin Ma Leu 1300 1305 1310 Arg Gin Gly Glu Cys Ser Met Ma Leu Ma Gly Gly Val Thr Val Met 1315 1320 1325 Gly Thr Pro Gly Thr Phe Val Glu Phe Ma Lys Gin Arg Gly Leu Ma 1330 1335 1340 Gly Asp Gly Arg Cys Lys Ma Tyr Ma Glu Gly Ma Asp Gly Thr Gly 1345 1350 1355 1360 Trp Ma Glu Gly Val Gly Val Val Val Leu Glu Arg Leu Ser Val Ma 1365 1370 1375 Arg Glu Arg Gly His Arg Val Leu Ma Val Leu Arg Gly Ser Ma Val 1380 1385 1390 Asn Ser Asp Gly Ma Ser Asn Gly Leu Thr Ma Pro Asn Gly Pro Ser 1395 1400 1405 Gin Gin Arg Val He Arg Arg Ma Leu Ma Gly Ma Gly Leu Glu Pro 1410 1415 1420 Ser Asp Val Asp He Val Glu Gly His Gly Thr Gly Thr Ma Leu Gly 1425 1430 1435 1440 Asp Pro He Glu Ma Gin Ma Leu Leu Ma Thr Tyr Gly Lys Asp Arg 1445 1450 1455 Asp Pro Glu Thr Pro Leu Trp Leu Gly Ser Val Lys Ser Asn Phe Gly 1460 1465 1470 His Thr Gin Ser Ma Ma Gly Val Ma Gly Val He Lys Met Val Gin 1475 1480 1485 Ma Leu Arg His Gly Val Met Pro Pro Thr Leu His Val Asp Arg Pro 1490 1495 1500 Thr Ser Gin Val Asp Trp Ser Ma Gly Ma Val Glu Val Leu Thr Glu 1505 1510 1515 1520 Ma Arg Glu Trp Pro Arg Asn Gly Arg Pro Arg Arg Ma Gly Val Ser 1525 1530 1535 Ser Phe Gly He Ser Gly Thr Asn Ma His Leu He He Glu Glu Ma 1540 1545 1550 Pro Ma Glu Pro Gin Leu Ma Gly Pro Pro Pro Asp Gly Gly Val Val 1555 1560 1565 Pro Leu Val Val Ser Ma Arg Ser Pro Gly Ma Leu Ma Gly Gin Ma 1570 1575 1580 Arg Arg Leu Ma Thr Phe Leu Gly Asp Gly Pro Leu Ser Asp Val Ma 1585 1590 1595 1600 Gly Ma Leu Thr Ser Arg Ma Leu Phe Gly Glu Arg Ma Val Val Val 1605 1610 1615 Ma Asp Ser Ma Glu Glu Ma Arg Ma Gly Leu Gly Ma Leu Ma Arg 1620 1625 1630 Gly Glu Asp Ma Pro Gly Leu Val Arg Gly Arg Val Pro Ma Ser Gly 1635 1640 1645 Leu Pro Gly Lys Leu Val Trp Val Phe Pro Gly Gin Gly Thr Gin Trp 1650 1655 1660 Val Gly Met Gly Arg Glu Leu Leu Glu Glu Ser Pro Val Phe Ma Glu 1665 1670 1675 1680 Arg He Ala Glu Cys Ma Ma Ma Leu Glu Pro Trp He Gly Trp Ser 1685 1690 1695 Leu Phe Asp Val Leu Arg Gly Asp Gly Asp Leu Asp Arg Val Asp Val 1700 1705 1710 Leu Gin Pro Ma Cys Phe Ma Val Met Val Gly Leu Ma Ma Val Trp 1715 1720 1725 Ser Ser Ma Gly Val Val Pro Asp Ma Val Leu Gly His Ser Gin Gly 1730 1735 1740 Glu He Ma Ma Ma Cys Val Ser Gly Ma Leu Ser Leu Glu Asp Ma 1745 1750 1755 1760 Ma Lys Val Val Ma Leu Arg Ser Gin Ma He Ma Ma Lys Leu Ser 1765 1770 1775 Gly Arg Gly Gly Met Ma Ser Val Ma Leu Gly Glu Ma Asp Val Val 1780 17B5 1790 Ser Arg Leu Ma Asp Gly Val Glu Val Ma Ma Val Asn Gly Pro Ma 1795 18C0 1805 Ser Val Val He Ma Gly Asp Ma Gin Ma Leu Asp Glu Thr Leu Glu 1810 1815 1820 Ma Leu Ser Gly Ma Gly He Arg Ma Arg Arg Val Ma Val Asp Tyr 1325 1830 1835 1840 Ma Ser His Thr Arg His Val Glu Asp He Glu Asp Thr Leu Ma Glu 1845 1850 1855 Ma Leu Ma Gly He Asp Ma Arg Ma Pro Leu Val Pro Phe Leu Ser 1860 1865 1870 Thr Leu Thr Gly Glu Trp He Arg Asp Glu Gly Val Val Asp Gly Gly 1875 1880 1885 Tyr Trp Tyr 1890 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 53789 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: GAATTCCAGG CCGTCGACGG CTGCGACATC GCGGTCTTCC GGTGGTCGCA CCGCACGAAG 60 ATCGCCGAAT AAGAATTTCC GGATCTCCCA CGGGAAAGGT TTCCATGACC GACGCAATAT 120 CCTTCGAGGT GCCGTGGGAC CGGACCGACA AGTTCGACCC GCCCGCGGTG TTCGACTCTC 180 TGCGCGAAGA ACGTCCGCTC GCGAAGATGG TTTACCCGGA TGGGCACGTC GGCTGGATCG 2 0 TTTCCAGCTA CGAGCTGGTC CGCGAGGTCC TCAGCGACCT GCGGTTCAGC CACAGCTGCG 300 AAGTCGGCCA CTTCCCGGTG ACCCACCAGG GCCAGGTCAT CCCGACCCAC CCGCTGATCC 360 CCGGCATGTT CATCCACATG GACCCGCCCG AGCACACGCG CTACCGCAAG CTGCTGACCG 420 GCGAGTTCAC CGTCCGCCGC GCCAGCAGGC TGATCCCGCG GGCCGAGGCC GTGGCCGCCG 480 AGCAGATCGA GGTCATGCGG GCCAAGGGCG CCCCCGCGGA CGTGGTCATG GACTTCGCCA 540 AGCCGCTGGT GCTGCGGATG CTGGGCGAGC TCGTCGGCCT GCCCTACGAG GAACGCGACC 600 GGTACGTGCC CGCGGTGACC CTCCTGCACG ACGCCGAAGC GGACCCGGCC GAGGCCGCGG 660 CCGCCTACGA GGTGGCCGGG AAGTTCTTCG ACGAGGTCAT CGAGCGCCGC CGGCAGCGGC 720 CCCAGGACGA CCTCATCAGC TCGCTCGTCA CCGAGGACCT GACCCAGGAG GAGCTGCGCA 780 ACATCGTCAC CCTGCTGCTG TTCGCCGGGT ACGAGACCAC CGAGGGCGCG CTCGCCACCG 840 GCGTCTTCGC GCTGCTGCAC CACACCGATC AGCTGGCGGC ACTGCGCGCG GAGCCGGAAA 900 AGCTCGACGC CGCGATCGAA GAGCTGCTGC GCTACCTGAC CGTCAACCAG TACCACACCT 960 ACCGCACCGC GCTGGAGGAC GTGAAGCTGG AGGGCGAGCT GATCAAGAAG GGCGACACGG 1020 TGACGGTGTC GCTGCCCGCG GCCAACCGCG ACCCGGCCAA GTTCGGCTGT CCCGCGGAGC 1080 TCGACATCGA GCGGGACACC TCCGGCCACG TCGCGTTCGG CTTCGGCATC CACCAGTGCC 1140 TGGGCCAGAA CCTGGCGCGC ATCGAGCTGC GGGCCGGCTT CACGGCGCTC CTGCGGGCGT 1200 TCCCCGAGCT CCGGCTGGCC GTCCCGGCCG ACGAGGTTCC GCTGCGGCTG AAGGGTTCCG 1260 TCTTCTCGGT GAAGAAGCTG CCCGTCTCCT GGTGAGCGTT CTTCCCCTCG AACACCCGAA 1320 AGGATCTGCG GCACAGTGCG CACCGATCTC ATCAAGCCAC TTCACGTCGC ACTCCTGGAG 1380 AACGCGACCC GCTTCGCCGG CAAGCCGGCC TTCGCCGACG ACCACCGGAC GGTCACCTAC 1440 GGCGACCTCG AGGCGCGGAC GCGCCGGCTG GCCGGGCACC TGGCCGGCCT CGGTGTCCGG 1500 CACGGCGACC GGGTGGCGAT CTGCCTCGGC AACCGGGTGT CCACTGTGGA GAGTTACTTC 1560 GCGATCCTGC GCGCGGGTGC CGTCGGCGTG CCGCTCAACC CCGGTTCGGC GACGGCCGAG 1620 CTCGAGCACC CGCTGACCGA CAGCGGCGCC ACGGTGGTCG TCACCGACGC CGCCCAGGCG 1680 GCCCGGCTCC GGCTCGCGCC GCACGTCGAG CTGCTGGTGA CCGGCGACGA CGTCCCGGAG 1740 GGCGCCCACT CCTACGACGA ACTCGCCCTC AGCGAACCGG CCGAGCCCGC CGCGGACGAC 1800 CTCGAGCTCG ACGAGCCGGC GTGGATGTTC TACACGTCGG GCACGACCGG GCGGCCCAAG 1860 GGCGTCGTGT CCACGCAGCG CAACTGCCTC TGGTCCGTCG CTTCCTGCTA CGTGCCGTTC 1920 CCCGGGTTGT CGGACCAGGA CCGGGTGCTC TGGCCGCTCC CGCTGTTCCA CAGCCTTTCG 1980 CACATCGCCT GCGTCCTGTC CGCCACCGTG GTCGGGGCCA GCGTCCGGAT CGCCGACGGC 2040 AGCTCCGCCG ACGACGTGAT GCGGCTGATC GAGGCGGAGA GCTCGACCTT CCTGGCCGGC 2100 GTGCCGACCA CCTACCACCA CCTGGTGCGG GCCGCCCGGC AGCGCGGTTT CTCCGCGCCG 2160 AGCCTGCGGA TCGGCCTGGC CGGGGGCGCG GTCCTCGGCG CCGGGCTGCG AAGCGAGTTC 2220 GAAGAGACCT TCGGGGTCCC GCTGATCGAC GCCTACGGCA GCACCGAGAC CTGCGGGGCG 2280 ATCACCATGA ACCCGCCGGA CGGCGCCCGC GTCGAGGGCT CGTGCGGCTT GGCCGTGCCG 2340 GGCGTCGACG TGCGGGTCGT CGACCCCGAC ACCGGGCTCG ACGTCCCCGC CGGCGAGGAG 2400 GGCGAGGTCT GGGTCAGCGG GCCGAACGTC ATGCTCGGCT ACCACAACAG CCCGGAGGCG 2460 ACCGCCGCGG CGATGCGGGA CGGCTGGTTC CGGACCGGGG ACCTGGCCCG CCGCGACGAC 2520 GCCGGTTACT TCACCATCTG CGGCCGGATC AAGGAACTCA TCATCCGCGG CGGCGCGAAC 2580 ATCCACCCCG GCGAGGTCGA GGCGGTCCTG CGCACGGTCG ACGGCGTCGC GGACGCGGCG 2640 GTCGGCGGTG TGCCGCACGA CACGCTCGGC GAGGTGCCGG TCGCCTACGT CATCCCCGGA 2700 CCGACCGGTT TCGATCCTGC GGCGTTGATC GAGAAGTGCC GCGAACAGCT GTCCGCCTAC 2760 AAGGTGCCGG ACCGGATCCT CGAGGTCGCC CACATTCCCC GGACCGCGTC GGGCAAGATC 2820 CGGCGCGGGC TGCTGACCGA CGAGGCCGCG CAGCTGCGGT ACGCCGCGAC CGAACACGAG 2880 GAACAGTCCC GGCACGCCGA CGAGTCCGTC GCGGCGGCGC TGCGCGCGCG ACTGTCCGGT 2940 TTGGACGAAC GCGCCCAGTG CGAGCTCCTG GAAGACCTCG TCCGCACCCA GGCGGCCGAC 3000 GTGCTGGGGC AGCCGGTCCC GGACGGGCGT GCGTTCCGCG ACCTCGGCTT CACGTCGCTG 3060 GCCATCGTGG AGCTGCGCAA CCGGCTGACC GAGCACACCG GGCTCTGGCT GCCCGCCAGC 3120 GCCGTCTTCG ACCACCCCAC GCCGGCGGCG CTGGCCGCCC GCGTCCGGGC TGAGCTCCTC 3180 GGGATCACGC AGGCCGTCGC GGAGCCGGTC GTCGCGGCCG ACCCGGGCGA GCCGATCGCG 3240 ATCGTGGGGA TGGCCTGCCG CCTGCCGGGT GGCGTGGCGT CCCCGGAAGA CCTGTGGCGG 3300 CTGGTGGCCG AGCGCGTCGA CGCCGTTTCG GAGTTCCCCG GCGACCGCGG CTGGGACCTG 3360 GACAGCCTGA TCGACCCGGA CCGGGAGCGC GCCGGGACGT CGTACGTCGG CCAGGGCGGA 3420 TTCCTGCACG ACGCCGGCGA GTTCGACGCC GGGTTCTTCG GGATCTCGCC GCGTGAGGCC 3480 GTCGCGATGG ACCCGCAGCA GCGGTTGCTG CTGGAGACGT CGTGGGAGGC CCTCGAAAAC 3540 GCCGGAGTCG ACCCGATCGC GTTGAAGGGC ACCGACACCG GCGTGTTCTC CGGCCTCATG 3600 GGCCAGGGGT ACGGGTCCGG CGCGGTGGCG CCGGAGCTCG AAGGTTTCGT CACCACCGGG 3660 GTCGCGTCGA GCGTGGCCTC GGGCCGGGTG TCGTACGTGC TGGGACTGGA AGGCCCGGCG 3720 GTCACCGTGG ACACCGCGTG TTCGTCGTCG CTGGTCGCGA TGCACCTGGC CGCGCAGGCC 3780 CTGCGGCAGG GCGAATGCTC GATGGCGCTC GCCGGCGGGG TCACGGTGAT GGCCACGCCG 3840 GGCTCGTTCG TCGAGTTCTC CCGCCAGCGG GCCCTGGCGC CCGACGGGCG CTGCAAGGCC 3900 TTCGCGGCGG CGGCCGACGG GACCGGCTGG TCCGAGGGTG TCGGCGTGGT CGTCCTCGAG 3960 CGGCTGTCCG TGGCGCGCGA GCGGGGCCAC CGGATCCTGG CCGTTTTGCG TGGCAGCGCG 4020 GTCAACCAGG ACGGCGCGTC CAACGGGCTC ACCGCGCCGA ACGGCCTCTC GCAGCAGCGG 4080 GTCATCCGCC GCGCGCTGGC CGCGGCCGGG CTGGCACCGT CCGATGTGGA CGTCGTCGAG 4140 GCGCACGGCA CCGGGACCAC GCTGGGTGAC CCGATCGAGG CGCAGGCCCT GCTGGCGACC 4200 TACGGCCAGG AGCGGAAGCA GCCGTTGTGG CTCGGTTCGC TCAAGTCGAA CATCGGCCAC 4260 GCGCAGGCGG CCGCGGGCGT TGCGGGCGTC ATCAAGATGG TGCAGGCGCT GCGGCACGAG 4320 ACCTTGCCGC CGACGCTGCA TGTCGACAAG CCGACTCTTG AGGTGGACTG GTCCGCCGGT 4380 GCC TTGAAC TGCTGACGGA GGCCCGTGCG TGGCCGCGCA ACGGCCGTCC GCGCCGGGCC 4440 GGGGTGTCGT CGTTCGGCGT CAGCGGGACC AACGCGCACC TGATCCTGGA GGAGGCGCCG 4500 GCCGAGGAGC CGGTCGCTGC CCCGGAACTG CCGGTGGTGC CCCTGGTGGT GTCGGCGCGG 4560 AGCACGGAGT CGCTGTCCGG GCAGGCCGAG CGGCTGGCGT CCCTCCTCGA AGGGGACGTC 4620 TCGCTGACCG AGGTGGCCGG GGCGCTGGTG TCCCGCCGGG CGGTGCTGGA CGAGCGGGCC 680 GTCGTCGTGG CCGGTTCGCG CGAGGAAGCC GTGACCGGGC TGCGGGCGCT GAACACGGCC 4740 GGTTCGGGGA CGCCGGGCAA GGTCGTGTGG GTGTTCCCGG GGCAGGGGAC GCAGTGGGCC 4800 GGGATGGGCC GTGAGCTGCT GGCCGAGTCC CCGGTGTTCG CCGAGCGGAT CGCCGAGTGC 4860 GCGGCCGCGT TGGCGCCGTG GATCGACTGG TCGCTCGTCG ACGTCCTGCG CGGCGAGGGC 4920 GACCTGGGTC GGGTCGATGT GCTGCAGCCG GCCTGTTTCG CGGTGATGGT CGGGCTGGCT 4980 GCCGTCTGGG AGTCCGTGGG GGTCCGGCCG GACGCCGTCG TCGGGCACTC GCAGGGTGAG 5040 ATCGCGGCTG CCTGCGTTTC GGGGGCGTTG TCCCTCGAGG ACGCGGCGAA GGTGGTGGCC 5100 CTGCGCAGCC AGGCCATCGC GGCGGAACTG TCCGGCCGCG GCGGGATGGC GTCGGTCGCC 5160 CTGGGCGAGG ACGACGTCGT TTCGCGGCTG GTGGACGGGG TCGAGGTCGC CGCCGTCAAC 5220 GGCCCGTCGT CGGTGGTGAT CGCCGGGGAT GCCCATGCCC TCGACGCGAC CCTGGAAATC 5280 TTGTCCGGGG AAGGCATCCG GGTTCGGCGG GTGGCGGTGG ACTACGCCTC GCACACCCGG 5340 CATGTCGAGG ACATCCGCGA CACTCTTGCC GAAACCTTGG CCGGGATCAG TGCGCAGGCG 5400 CCGGCTGTGC CGTTCTACTC CACCGTCACG AGCGAGTGGG TGCGCGACGC GGGGGTGCTG 5460 GACGGCGGCT ACTGGTACCG GAACCTGCGC AACCAGGTCC GGTTCGGAGC GGCCGCGACG 5520 GCCCTGCTCG AGCAGGGCCA CACGGTGTTC GTCGAGGTCA GTGCGCACCC GGTGACGGTC 5580 CAGCCCTTGA GCGAGCTCAC CGGGGACGCG ATCGGGACAT TGCGGCGTGA AGACGGTGGC 5640 CTGCGGCGGT TGCTGGCTTC GATGGGTGAG CTGTTCGTCC GCGGCATCGA CGTGGACTGG 5700 A.CGGCGATGG TGCCCGCGGC CGGCTGGGTC GACTTGCCGA CCTACGCGTT CGAACACCGG 5760 CACTACTGGC TCGAGCCCGC CGAGCCCGCT TCGGCCGGAG ACCCGCTGCT GGGCACAGTC 5820 GTCAGCACTC CCGGTTCGGA CCGACTCACC GCCGTGGCGC AGTGGTCGCG CCGGGCGCAG 5880 CCCTGGGCGG TGGACGGCCT GGTGCCGAAC GCGGCCCTGG TCGAGGCGGC CATCCGGCTC 5940 GGCGACCTGG CCGGCACCCC CGTCGTCGGC GAACTGGTCG TCGACGCGCC GGTGGTGCTG 6000 CCGCGGCGCG GCAGCCGCGA GGTCCAGCTG ATCGTCGGCG AGCCCGGCGA GCAGCGGCGG 6060 CGTCCGATCG AGGTCTTTTC CCGGGAAGCC GACGAGCCGT GGACGCGGCA CGCGCACGGC 6120 ACACTCGCTC CCGCCGCCGC TGCGGTGCCA GAACCGGCGG CGGCGGGAGA CGCCACCGAC 6180 GTCACCGTGG CCGGCCTGCG CGACGCGGAC CGGTACGGGA TCCACCCCGC GCTGCTGGAC 6240 GCCGCCGTCC GCACGGTCGT CGGCGACGAC CTGCTCCCGT CGGTGTGGAC CGGCGTGTCC 6300 CTGCTGGCCT CCGGGGCCAC GGCCGTGACC GTGACGCCGA CGGCGACCGG CCTGCGGCTG 6360 ACCGACCCGG CCGGGCAGCC CGTCCTGACC GTCGAATCCG TGCGCGGCAC GCCGTTCGTC 6420 GCCGAGCAGG GGACCACCGA CGCGCTCTTC CGCGTCGACT GGCCGGAAAT CCCGCTGCCC 6480 ACCGCCGAAA CCGCGGACTT CCTGCCGTAC GAAGCCACGT CGGCCGAGGC GACCCTCTCC 6540 GCGCTCCAGG CCTGGCTGGC AGACCCCGCG GAAACCCGGC TGGCCGTGGT CACCGGGGAC 6600 TGCACCGAAC CCGGCGCGGC CGCGATCTGG GGCCTGGTGC GCTCGGCGCA GTCCGAACAC 6660 CCCGGCCGGA TCGTGCTGGC CGACCTCGAC GACCCCGCCG TGCTGCCCGC CGTGGTGGCG 6720 AGCGGCGAAC CGCAGGTGCG GGTGCGCAAC GGCGTCGCCT CGGTGCCGCG CTTGACCCGG 6780 GTTACTCCCC GGCAGGACGC GCGGCCGCTC GACCCCGAGG GCACCGTCCT GATCACCGGC 6840 GGCACCGGCA CGCTCGGTGC GCTGACCGCC CGGCACCTCG TCACCGCGCA CGGCGTCCGG 6900 CACCTGGTGC TGGTCAGCCG CCGCGGTGAG GCTCCCGAGC TGCAGGAAGA ACTGACCGCA 6960 CTGGGGGCAT CCGTCGCCAT CGCCGCCTGC GACGTGGCAG ACCGGGCGCA GCTCGAAGCC 7020 GTCTTGCGCG CGATCCCGGC CGAGCACCCG CTCACCGCCG TGATCCACAC CGCGGGGGTC 7080 CTCGACGACG GCGTCGTCAC CGAGCTGACC CCGGACCGGC TCGCCACCGT GCGGCGGCCG 7140 AAGGTCGACG CCGCCCGGCT CCTGGACGAG CTCACCCGGG AGGCCGATCT CGCCGCGTTC 7200 GTGCTGTTCT CCTCGGCGGC GGGTGTGCTG GGCAACCCCG GCCAGGCCGG GTACGCCGCC 7260 GCCAACGCCG AGCTGGATGC GTTGGCGCGC CAGCGGAACA GCCTCGACCT GCCCGCGGTG 7320 TCCATCGCAT GGGGCTACTG GGCGACGGTC AGCGGGATGA CCGAGCACCT GGGCGACGCC 7380 GACCTGCGGC GCAACCAGCG GATCGGCATG TCCGGGCTTC CCGCCGACGA GGGCATGGCG 7440 CTGCTGGACG CCGCCATCGC CACCGGTGGC ACGCTGGTCG CGGCCAAGTT CGACGTCGCC 7500 GCGCTGCGGG CGACGGCGAA GGCCGGCGGC CCGGTGCCGC CGCTGCTGCG TGGCCTGGCC 7560 CCGCTGCCGC GCCGGGCGGC GGCCAAGACC GCGTCGCTGA CCGAACGCCT CGCCGGGCTG 7620 GCCGAGACCG AGCAGGCCGC GGCCCTGCTC GACCTGGTCC GGCGGCACGC CGCCGAGGTG 7680 CTCGGGCACA GCGGCGCCGA ATCCGTCCAT TCAGGACGGA CGTTCAAGGA CGCCGGCTTC 7740 GACTCGCTGA CCGCGGTGGA ACTGCGGAAC CGCCTCGCGG CCGCGACCGG GCTCACCCTG 7800 TCCCCGGCGA TGATCTTCGA CTACCCGAAG CCCCCGGCGC TCGCGGACCA CCTGCGCGCC 7860 AAGCTCTTCG GATCGGCGGC GAACCGGCCG GCCGAGATCG GCACCGCCGC GGCCGAGGAG 7920 CCGATCGCGA TCGTCGCGAT GGCGTGCCGC TTCCCCGGTG GCGTGCACAG CCCCGAGGAC 7980 CTGTGGCGGC TGGTCGCCGA CGGCGCCGAC GCCGTCACCG AGTTCCCCGC CGACCGCGGC 8040 TGGGACACCG ACCGGCTCTA CCACGAAGAC CCCGACCACG AAGGCACGAC GTACGTCCGG 8100 CACGGCGCCT TCCTCGACGA CGCCGCCGGG TTCGACGCCG CCTTCTTCGG CATCTCGCCG 8160 AACGAGGCGC TCGCCATGGA CCCGCAGCAG CGGCTGCTGC TGGAGACGTC CTGGGAGCTG 8220 TTCGAGCGGG CCGCGATCGA CCCGACCACG CTGGCCGGCC AGGACATCGG CGTCTTCGCC 8280 GGCGTCAACA GCCACGACTA CAGCATGCGG A.TGCACCGGG CCGCCGGTGT CGAGGGCTTC 8340 CGGCTCACCG GCGGTTCGGC CAGCGTGCTC TCCGGCCGCG TCGCCTACCA CTTCGGCGTC 8400 GAAGGCCCGG CCGTCACGGT CGACACGGCC TGCTCGTCTT CGCTGGTCGC GCTGCACATG 8460 GCGGTGCAGG CCCTGCAGCG CGGCGAGTGC TCCATGGCGC TCGCGGGCGG CGTGATGGTG 8520 ATGGGCACGG TCGAGACGTT CGTCGAGTTC TCGCGGCAGC GCGGGCTGGC CCCCGACGGC 8580 CGCTGCAAGG CGTTCGCCGA CGGCGCGGAC GGCACCGGCT GGTCCGAGGG CGTCGGGCTG 8640 CTCCTGGTGG AGCGGCTGTC CGAGGCTCAG CGTCGCGGGC ACCAGGTCCT CGCCGTGGTC 8700 CGCGGGTCGG CGGTCAACTC CGACGGCGCG TCGAACGGCT TGACGGCCCC GAACGGCCCG 8760 TCCCAGCAGC GCGTGATCCG CAAGGCACTG GCCGCCGCCG GACTGTCCAC ATCGGACGTC 8820 GACGCGGTGG AGGCGCACGG CACCGGGACG ACCCTGGGCG ACCCGATCGA GGCCGAGGCG 8880 CTGCTGGCCA CCTACGGCCA GAACCGGGAA ACGCCGCTGT GGCTCGGGTC GGTGAAGTCG 8940 AACCTCGGGC ACACGCAGGC GGCTGCGGGT GTCGCAGGCG TGATCAAGAT GGTCATGGCC 9000 ATGCGCCACG GCGTCCTGCC CCGGACGCTG CACGTCGACC GGCCGTCGTC CTATGTGGAC 9060 TGGTCGGCCG GTGCGGTCGA GCTGCTGACC GAGGCACGGG ACTGGGTGAG CAACGGCCAC 9120 CCGCGGCGCG CGGGCGTGTC GTCGTTCGGC ATCGGCGGCA CCAACGCGCA CGTCGTCCTC 9180 GAGAGGTTG CCGCACCGAT CACCACGCCG CAGCCTGAGC CGGCCGAGTT CCTGGTGCCG 9240 GTGCTCGTCT CCGCGCGGAC GGCGGCGGGT CTGCGCGGCC AGGCCGGACG GCTCGCCGCG 9300 TTCCTCGGCG ACCGGACCGA CGTCCGCGTC CCCGATGCCG CCTACGCACT GGCCACCACG 9360 CGCGCCCAGC TCGACCACCG GGCCGTCGTC CTGGCCTCCG ACCGGGCACA GCTCTGCGCG 9420 GACCTTGCCG CGTTCGGCTC CGGCGTCGTG ACCGGAACGC CGGTTGACGG CAAGCTGGCC 9 80 GTGCTCTTCA CCGGCCAGGG CAGCCAGTGG GCCGGGATGG GCCGTGAACT CGCCGAGACG 9540 TTCCCGGTCT TCCGCGACGC CTTCGAGGCC GCGTGCGAGG CCGTGGACAC GCACCTGCGT 9600 GAGCGTCCGC TGCGCGAGGT CGTGTTCGAC GACAGCGCGC TGCTCGACCA GACGATGTAC 9660 ACCCAGGGCG CCCTGTTCGC CGTGGAGACC GCGTTGTTCC GGCTCTTCGA GTCCTGGGGT 9720 GTGCGGCCGG GTCTCCTCGC CGGTCACTCG ATCGGCGAGC TCGCCGCCGC GCACGTGTCC 9780 GGCGTGCTGG ACCTGGCCGA CGCGGGCGAG CTGGTCGCCG CGCGCGGCCG GCTGATGCAG 9840 GCCCTGCCCG CGGGCGGCGC GATGGTCGCC GTCCAGGCGA CCGAGGACGA AGTCGCGCCC 9900 CTGCTCGACG GCACGGTCTG CGTCGCCGCG GTCAACGGTC CGGACTCGGT GGTGCTCTCC 9960 GGCACCGAAG CCGCCGTGCT CGCCGTCGCG GATGAACTGG CTGGTCGCGG CCGTAAGACC 10020 CGACGGCTGG CCGTGAGCCA CGCCTTCCAC TCGCCGCTCA TGGAACCGAT GCTCGACGAC 10080 TTCCGCGCGG TCGCCGAACG CCTGACGTAC CGGGCCGGTT CGCTGCCCGT CGTCTCGACG 10140 CTGACCGGGG AACTCGCGGC GCTCGACAGC CCGGACTACT GGGTCGGCCA GGTGCGCAAC 10200 GCCGTGCGGT TCAGCGACGC CGTCACCGCG CTGGGCGCCC AAGGCGCGTC GACGTTCCTC 10260 GAGCTCGGCC CGGGCGGTGC GCTCGCCGCG ATGGCGCTCG GCACGCTCGG CGGACCCGAG 10320 CAGAGCTGCG TCGCGACCCT GCGCAAGAAC GGCGCCGAGG TGCCCGACGT CCTCACCGCG 10380 CTCGCCGAAC TGCACGTCCG GGGCGTGGGC GTCGACTGGA CGACCGTGCT CGACGAACCG 10440 GCCACGGCGG TCGGGACCGT CCTGCCCACC TACGCGTTCC AGCACCAGCG CTTCTGGGTC 10500 GACGTCGACG AAACAGCGGC CGTCAGCGTC ACCCCGCCGC CGGCGGAGCC GATCGTGGAC 10560 CGGCCGGTGC AGGACGTGCT GGAGCTGGTC CGGGAGAGCG CCGCGGTGGT GCTCGGGCAC 10620 CGGGACGCCG GCAGTTTCGA CCTCGACCGG TCCTTCAAGG ACCACGGCTT CGACTCGCTC 10680 AGCGCGGTCA AGCTGCGCAA CCGTCTGCGC GACTTCACCG GCGTGGAGCT GCCCAGCACC 10740 CTGATCTTCG ACTACCCGAA CCCGGCCGTC CTCGCGGACC ACCTGCGGGC CGAACTGCTC 10800 GGCGAGCGCC CGGCCGCGCC GGCCCCGGTG ACGAGGGACG TCTCCGACGA GCCGATCGCG 10860 ATCGTCGGCA TGAGCACCCG GCTGCCGGGT GGCGCCGACA GCCCCGAAGA GCTGTGGAAG 10920 CTCGTCGCGG AGGGACGGGA CGCCGTGTCC GGCTTCCCCG TCGACCGCGG CTGGGACCTC 10980 GACGGCCTCT ACCACCCGGA CCCCGCCCAC GCCGGGACGA GCTACACGCG TTCGGGCGGC 11040 TTCCTGCACG ACGCGGCCCA GTTCGACGCC GGGCTCTTCG GGATCTCACC GCGTGAGGCC 11100 CTGGCCATGG ACCCGCAGCA GCGGCTGCTG CTGGAGACGT CGTGGGAAGC CTTGGAGCGC 11160 GCGGGGGTCG ACCCGCTGTC CGCCCGCGGC AGCGACGTCG GCGTCTTCAC CGGGATCGTC 11220 CACCACGACT ACGTGACGCG GCTGCGCGAA GTGCCCGAAG ACGTCCAGGG CTACACGATG 11280 ACCGGCACGG CTTCGAGCGT GGCGTCGGGC CGGGTGGCGT ACGTCTTCGG CTTCGAGGGC 11340 CCGGCGGTCA CCGTGGACAC CGCGTGTTCG TCGTCGCTGG TCGCGATGCA CCTGGCGGCG 11400 CAGGCGCTGC GGCAGGGGGA GTGCTCGATG GCCCTGGCCG GCGGCGCGAC CGTGATGGCC 11460 AGCCCGGACG CCTTCCTCGA GTTCTCCCGC CAGCGCGGCC TGTCCGCGGA CGGCCGGTGC 11520 AAGGCGTACG CGGAAGGCGC GGACGGCACG GGCTGGGCCG AGGGCGTCGG TGTCGTCGTC 11580 CTCGAACGGC TTTCGGTGGC ACGCGAACGT GGCCACCGGG TGCTGGCGGT CCTGCGCGGC 11640 AGCGCGGTGA ACCAGGACGG TGCTTCCAAC GGCCTGACCG CCCCGAACGG GCCGTCGCAG 11700 CAGCGGGTGA TCCGCGGCGC GCTGGCGAGC GCCGGGCTGG CACCGTCCGA TGTGGACGTC 11760 GTGGAGGGCC ACGGGACCGG GACCGCGCTG GGTGACCCGA TCGAGGTCCA GGCGCTGCTG 11820 GCCACCTACG GGCAGGAGCG GGAACAGCCG TTGTGGCTCG GCTCGCTGAA GTCGAACCTC 11880 GGGCACACGC AGGCCGCGGC CGGGGTCGTG GGCGTGATCA AGATGATCAT GGCCATGCGC 11940 CACGGCGTCA TGCCGGCCAC GCTGCACGTC GACGAGCGCA CGAGCCAGGT CGACTGGTCG 12000 GCGGGCGCGA TCGAGGTGTT GACCGAGGCC CGGGAGTGGC CGCGCACCGG ACGTCCGCGC 12060 CGGGCCGGGG TGTCCTCCTT CGGCGCCAGC GGCACCAACG CGCACCTGAT CATCGAGGAA 12120 GGTCCCGCCG AAGAGGCCGT GGACGAAGAG GTGGCCTCCG TGGTGCCGCT GGTCGTCTCC 12180 GCCCGCAGCG CCGGTTCGCT GGCCGGGCAG GCCGGGCGCC TGGCCGCGGT CCTCGAGAAC 12240 GAATCGTTGG CCGGGGTGGC CGGTGCCCTG GTTTCCGGCC GCGCGACGCT GAACGAGCGC 12300 GCGGTCGTCA TCGCGGGCTC CCGCGACGAG GCCCAGGACG GCCTGCAGGC ACTGGCCCGC 12360 GGCGAGAACG CGCCCGGCGT CGTGACCGGG ACGGCGGGCA AGCCGGGCAA GGTCGTCTGG 12420 GTCTTCCCCG GCCAGGGCTC GCAGTGGATG GGCATGGGCC GGGACCTCCT GGACTCCTCG 12480 CCGGTGTTCG CCGCGCGGAT CAAGGAATGC GCTGCGGCAC TGGAACAGTG GACCGACTGG 12540 TCGCTGCTGG ACGTGCTGCG CGGCGACGCC GACCTGCTGG ACCGGGTCGA CGTGGTGCAG 12600 CCGGCCAGCT TCGCGATGAT GGTCGGGCTC GCCGCGGTGT GGACCTCGCT GGGGGTGACC 12660 CCGGATGCGG TGCTCGGCCA CTCCCAGGGC GAGATCGCCG CGGCGTGCGT GTCCGGCGCG 12720 CTGTCGCTGG ACGACGCGGC GAAGGTGGTC GCGTTGCGCA GCCAGGCGAT CGCGGGGGAG 12780 CTGGCGGGCC GCGGCGGGAT GGCGTCGGTC GCACTGAGCG AAGAGGACGC AGTCGCGCGG 12840 CTGACGCCGT GGGC AACCG GGTCGAGGTG GCCGCGGTCA ACAGCCCGTC CTCGGTCGTC 12900 ATCGCGGGAG ACGCGCAGGC CCTCGACGAA GCCCTCGAAG CCCTGGCCGG CGACGGTGTC 12960 CGGGTCCGGC GGGTCGCGGT GGACTACGCC TCCCACACCC GGCACGTCGA GGCGATCGCC 13020 GAAACCCTGG CCAAGACCTT GGCCGGGATC GACGCGCGGG TTCCGGCGAT TCCGTTCTAT 13080 TCCACCGTCC TGGGCACGTG GATCGAGCAG GCCGTCGTCG ACGCGGGCTA CTGGTACCGG 13140 AACCTGCGGC AGCAGGTGCG GTTCGGCCCC TCGGTGGCGG ACCTGGCCGG GCTGGGGCAC 13200 ACGGTGTTCG TGGAGATCAG CGCCCACCCG GTGCTGGTCC AGCCGCTGAG CGAGATCAGC 13260 GACGACGCGG TGGTGACCGG GTCGCTGCGG CGGGACGACG GGGGACTGCG GCGCCTGCTG 13320 GCGTCGGCGG CCGAACTGTA CGTCCGGGGC GTGGCCGTGG ACTGGACGGC GGCCGTGCCC 13380 GCGGCCGGCT GGGTGGACCT GCCGACGTAC GCCTTCGACC GCCGCCACTT CTGGCTGCAC 13440 GAAGCCGAGA CCGCCGAAGC CGCCGAGGGC ATGGACGGCG AGTTCTGGAC GGCGATCGAA 13500 CAGTCCGATG TGGACAGCTT GGCCGAGCTG CTCGAGCTGG TGCCGGAGCA GCGCGGGGCG 13560 CTCAGCACCG TCGTGCCCGT GCTGGCGCAG TGGCGGGACC GGCGCCGCGA GCGCTCGACC 13620 GCGGAGAAGC TGCGCTACCA GGTCACCTGG CAGCCCCTGG AGCGCGAAGC CGCCGGCGTG 13680 CCGGGCGGGC GCTGGCTGGC CGTCGTCCCG GCCGGCACCA CCGACGCGCT CCTGAAGGAG 13740 CTGACCGGCC AGGGACTCGA CATCGTCCGG CTGGAGATCG AGGAAGCTTC GCGGGCACAG 13800 CTCGCCGAGC AGCTGCGGAA CGTCCTGGCG GAGCACGACC TCACCGGCGT GCTGTCGCTG 13860 CTCGCTCTCG ACGGCGGCCC CGCGGACGCG GCCGAGATCA CCGCGTCGAC GCTCGCGCTG 13920 GTCCAGGCCC TGGGCGACAC CACCACGTCC GCGCCGCTGT GGTGCCTCAC TTCCGGCGCG 13980 GTGAACATCG GCATCCAGGA CGCCGTGACC GCACCGGCCC AGGCGGCCGT GTGGGGGCTC 14040 GGCCGGGCCG TCGCGCTGGA GCGCCTCGAC CGGTGGGGCG GCCTGGTCGA CTTGCCCGCC 14100 GCGATCGACG CCCGCACGGC TCAGGCCCTG CTCGGCGTCC TGAACGGCGC CGCCGGGGAA 14160 GACCAGCTCG CGGTCCGGCG CTCGGGCGTC TACCGCAGGC GGCTGGTCCG CAAGCCCGTG 14220 CCGGAGTCCG CGACGAGCCG GTGGGAACCC CGCGGCACGG TCCTGGTGAC CGGTGGGGCC 14280 GAAGGACTCG GCCGGCACGC CTCGGTCTGG CTCGCGCAGT CCGGCGCCGA ACGGCTCATC 14340 GTCACCGGCA CCGACGGCGT CGACGAACTG ACGGCCGAGC TGGCCGAGTT CGGCACCACG 14400 GTCGAGTTCT GCGCCGACAC CGACCGGGAC GCGATCGCGC AGCTGGTGGC GGACTCGGAG 14460 GTCACCGCCG TGGTGCACGC CGCGGACATC GCGCAGACCA GCTCCGTCGA CGACACCGGC 14520 GTGGCCGACC TCGACGAGGT GTTCGCCGCG AAGGTGACCA CCGCGGTGTG GCTGGACCAG 1 580 CTGTTCGAGG ACACCCCGCT CGACGCGTTC GTCGTGTTCT CCTCGATCGC CGGCATCTGG 14640 GGCGGTGGCG GGCAGGGCCC GGCGGGTGCG GCGAACGCCG TCCTCGACGC CCTGGTCGAA 14700 TGGCGCCGGG CCCGCGGCCT CAAGGCGACG TCGATCGCCT GGGGCGCGCT CGACCAGATC 14760 GGCATCGGCA TGGACGAGGC CGCCCTCGCC CAGCTGCGCC GCCGCGGTGT CATCCCGATG 14820 GCGCCGCCGC TGGCGGTCAC CGCGATGGTG CAGGCGGTCG CCGGCAACGA GAAGGCCGTG 14880 GCGGTGGCCG ACATGGACTG GGCCGCCTTC ATCCCGGCGT TCACCTCGGT CCGGCCCAGC 14940 CCGCTGTTCG CCGATCTGCC CGAGGCGAAG GCCATCCTCC GGGCGGCGCA GGACGACGGC 15000 GAAGACGGCG ACACCGCGTC GTCGCTCGCG GACTCCCTGC GCGCGGTCCC CGACGCCGAG 15060 CAGAACCGCA TCCTGCTGAA GCTGGTCCGC GGCCACGCTT CGACGGTGCT CGGCCACAGC 15120 GGCGCCGAAG GCATCGGCCC GCGCCAGGCG TTCCAGGAGG TCGGCTTCGA CTCGCTGGCC 15180 GCGGTCAACC TCCGCAACAG CCTGCACGCG GCCACCGGGC TGCGGCTGCC CGCGACGCTG 15240 ATCTTCGACT ACCCCACCCC GGAGGCGCTG GTCGGCTACC TGCGCGTCGA ACTCCTGCGG 15300 GAGGCCGACG ACGGCCTGGA CGGGCGGGAA GACGACCTCC GGCGAGTCCT CGCGGCCGTG 15360 CCGTTCGCCC GGTTCAAGGA GGCGGGCGTG CTGGACACGC TGCTCGGCCT CGCCGACACC 15420 GGCACCGAAC CGGGCACGGA CGCCGAGACC ACCGAAGCGG CCCCGGCCGC CGACGACGCA 15480 GAACTGATCG ACGCACTGGA CATCTCCGGT CTCGTGCAAC GAGCCCTCGG GCAGACGAGC 15540 TGACCGCCGA TGGCGAACCA ATCGTGGAGG AAGAACATGT CCGCGCCGAA CGAGCAGATC 15600 GTTGACGCAC TGCGCGCGTC GCTGAAGGAG AACGTCCGGC TTCAGCAGGA GAACAGCGCG 15660 CTCGCCGCGG CCGCCGCGGA GCCCGTCGCG ATCGTCTCCA TGGCCTGCCG CTACGCGGGC 15720 GGGATCCGCG GCCCGGAGGA CTTCTGGCGG GTGGTGTCGG AAGGCGCCGA CGTCTACACC 15780 GGCTTCCCCG AGGACCGCGG CTGGGACGTC GAAGGCCTCT ACCACCCGGA CCCCGACAAC 15840 CCCGGCACGA CGTACGTGCG GGAGGGCGCC TTCCTGCAGG ACGCGGCCCA GTTCGACGCC 15900 GGGTTCTTCG GCATCTCGCC GCGCGAGGCG CTGGCCATGG ACCCCCAGCA GCGGCAGCTC 15960 CTGGAGGTGT CCTGGGAGAC CTTGGAACGG GCCGGCATCG ACCCGCATTC GGTGCGGGGC 16020 AGCGACATCG GCGTCTACGC CGGGGTCGTG CACCAGGACT ACGCCCCCGA CCTCAGCGGG 16080 TTCGAAGGCT TCATGAGCCT GGAGCGCGCC CTGGGCACCG CGGGCGGTGT CGCCTCCGGC 16140 CGGGTCGCCT ACACGCTCGG GCTCGAAGGC CCCGCCGTCA CCGTCGACAC GATGTGCTCG 16200 TCGTCGCTGG TGGCGATTCA CCTTGCCGCG CAAGCTCTTC GCCGTGGTGA GTGCTCGATG 16260 GCCCTCGCGG GCGGCTCGAC CGTGATGGCG ACCCCGGGCG GGTTCGTCGG CTTCGCGCGT 16320 CAGCGGGCGT TGGCCTTCGA CGGGCGCTGC AAGTCCTACG CCGCGGCCGC CGACGGTTCC 16380 GGCTGGGCCG AGGGCGTCGG CGTGCTGCTG CTGGAGCGGC TGTCGGTGGC GCGCGAGCGC 16440 GGGCACCAGG TGCTGGCCGT CATCCGCGGC AGCGCGGTCA ACCAGGACGG CGCTTCCAAC 16500 GGCCTGACCG CGCCCAACGG CCCGGCGCAG CAGCGGGTCA TCCGCAAGGC ACTGGCGAGC 16560 GCCGGGCTGA CACCGTCCGA TGTGGACACC GTGGAGGGCC ACGGCACCGG CACCGTCCTC 16620 GGCGACCCGA TCGAGGTCCA GGCGCTGCTG GCCACCTACG GCCAGGGCCG CGACCCGCAG 16680 CAACCGCTGT GGCTGGGCTC GGTCAAGTCC GTCGTCGGGC ACACGCAGGC GGCATCCGGT 16740 GTGGCCGGCG TGATCAAGAT GGTCCAGTCG CTGCGGCACG GGCAGCTCCC GGCGACCCAG 16800 CACGTCGACG CGCCCACGCC GCAAGTGGAC TGGTCGGCCG GAGCGATCGA GCTGCTGGCC 16860 GAGGGCCGGG AGTGGCCGCG CAACGGCCAC CCGCGCCGGG GCGGCATCTC GTCGTTCGGG 16920 GCCAGCGGCA CGAACGCGCA CATGATCCTC GAAGAAGCGC CCGAGGACGA GCCGGTGACC 16980 GAAGCGCCGG CGCCCACGGG TGTCGTACCG CTGGTGGTGT CGGCGGCGAC CGCTGCTTCC 17040 CTGGCCGCCC AGGCCGGTCG GCTGGCGGAG GTCGGCGACG TCTCCCTGGC GGATGTCGCC 17100 GGGACGCTGG TGTCCGGCCG CGCGATGCTC AGCGAGCGCG CGGTCGTCGT GGCCGGCTCC 17160 CACGAAGAAG CCGTGACCGG GCTGCGGGCG CTGGCCCGCG GCGAGAGCGC GCCCGGCCTG 17220 CTTTCCGGCC GCGGCTCGGG GGTCCCGGGC AAGGTCGTCT GGGTGTTCCC CGGCCAGGGC 17280 ACGCAGTGGG CCGGCATGGG CCGCGAGCTG CTGGACTCCT CGGAGGTGTT CGCCGCGCGG 17340 ATCGCCGAGT GCGAGACCGC GCTCGGGCGG TGGGTCGACT GGTCGCTGAC CGACGTGCTG 17400 CGCGGCGAGG CCGACCTGCT GGACCGGGTC GACGTGGTGC AACCGGCGAG CTTCGCCGTG 17460 ATGGTCGGGC TTGCCGCCGT CTGGGCCTCC CTCGGCGTCG AGCCCGAGGC CGTGGTGGGC 17520 CACTCGCAGG GCGAGATCGC GGCCGCATGC GTGTCCGGGG CACTGTCCCT GGAGGACGCG 17580 GCGAAGGTGG TGGCGTTGCG CAGCCAGGCG ATCGCCGCCT CGCTGGCCGG CCGGGGCGGC 17640 A.TGGCGTCGG TCGCGTTGAG CGAAGAAGAC GCGACCGCGC GGCTCGAGCC GTGGGCGGGC 17700 CGCGTGGAGG TCGCCGCCGT C .GGGCCG ACGTCCGTGG TGATCGCCGG GGACGCCGAG 17760 GCGCTGGACG AAGCCCTCGA CGCGCTCGAC GACCAAGGCG TCCGGATCCG GCGGGTGGCG 17820 GTGGACTACG CCTCCCACAC CCGGCACGTC GAAGCCGCGC GCGACGCACT GGCCGAGATG 17880 CTGGGCGGGA TCCGCGCGCA GGCGCCGGAA GTGCCGTTCT ACTCGACCGT GACCGGCGGC 17940 TGGGTCGAAG ACGCCGGCGT GCTCGACGGC GGCTACTGGT ACCGGAACCT CCGCCGTCAG 18000 GTGCGGTTCG GCCCGGCGGT GGCCGAGCTG ATCGAGCAGG GCCACCGGGT GTTCGTCGAG 18060 GTCAGCGCGC ATCCCGTGCT GGTTCAGCCG ATCAACGAAC TCGTCGACGA CACCGAAGCC 18120 GTGGTCACCG GGACGCTGCG GCGCGAGGAC GGCGGCCTCC GGCGCCTGCT GGCCTCGGCG 18180 GCCGAGCTCT TCGTCCGCGG CGTGACCGTG GACTGGTCCG GTGTGCTGCC ACCGTCCCGC 18240 CGGGTCGAGC TGCCGACGTA CGCCTTCGAC CACCAGCACT ACTGGCTGCA GATGGGCGGG 18300 TCGGCCACCG ACGCCGTGTC GCTGGGCCTG GCCGGCGCCG ACCACCCGCT GCTGGGCGCG 18360 GTCGTCCCGC TGCCGCAGTC CGACGGGCTC GTCTTCACCT CGCGGCTGTC GCTGAAGTCG 18420 CACCCGTGGC TGGCCGGGCA CGCGATCGGC GGGGTCGTGC TCATTCCGGG CACGGTGTAC 18480 GTCGACCTCG CGCTGCGCGC CGGCGACGAG CTCGGCTTCG GCGTCCTGGA AGAGCTCGTG 18540 ATCGAGGCAC CGCTGGTGCT GGGCGAGCGC GGCGGCGTTC GCGTGCAGGT CGCCGTGAGC 18600 GGGCCGAACG AGACCGGCTC GCGTGCGGTG GACGTCTTCT CCATGCGGGA AGACGGCGAC 18660 GA^TGGACCC GGCACGCGAC CGGTCTCCTC GGGGCGTCGA CGTCCCGGGA ACCGAGCCGC 18720 TTCGACTTCG CCGCCTGGCC GCCGGCCGGG GCGGAGCCGA TCGACGTCGA AAACTTCTAC 18780 ACCGACCTCA CCGAGCGCGG GTACGCCTAC AGCGGCGCCT TCCAGGGCAT GCGGGCGGTC 18840 TGGCGGCGCG GTGACGAGGT CTTCGCCGAG GTCGCGCTGC CTGACGACCA CCGCGAGGAC 18900 GCCGGCAAGT TCGGCCTCCA CCCCGCCCTC CTCGACGCCG CTCTGCACAC GAACGCCTTC 18960 GCGAACCCGG ACGACGACCG CAGTGTGCTG CCGTTCGCGT GGAACGGCCT GGTCCTGCAC 19020 GCCGTGGGCG CGTCGGCGCT GCGGGTGCGG GTGGCGCCGG GCGGTCCGGA CGCGCTGACG 19080 TTCCAGGCCG CCGACGAGAC CGGTGGCCTG GTCGTCACCA TGGATTCGCT GGTGTCCCGC 19140 GAGGTGTCGG CCGCGCAGCT GGAGACGGCG GCGGGCGAAG AGCGCGACTC GCTGTTCCAG 19200 GTGGACTGGA TCGAGGTCCC CGCGACCGAG ACCGCGGCCA CCGAGCACGC CGAGGTGCTC 19260 GAAGCCTTCG GCGAGGCAGC GCCCCTCGAG CTGACCAGCC GGGTGCTGGA GGCCGTGCAG 19320 TCCTGGCTCG CCGACGCGGC CGACGAAGCA CGGTTGGTCG TGGTGACCCG TGGCGCCGTG 19380 CGCGAGGTGA CGGACCCGGC CGGTGCCGCC GTGTGGGGTT TGGTGCGAGC CGCCCAGGCG 19440 GAGAACCCGG GCCGGATCAT CCTCGTCGAC ACCGACGGCG ACGTCCCGCT GGGTGCGGTG 19500 CTGGCCAGTG GTGAGCCGCA GCTCGCCGTG CGCGGCAACG CTTTCTCCGT CCCGCGCCTC 19560 GCCCGGGCCA CCGGCGAGGT GCCGGAGGCC CCCGCGGTGT TCAGTCCGGA AGGGACGGTC 19620 CTGCTCACCG GCGGCACCGG CTCGCTGGGC GGTCTGGTGG CCAAGCACCT GGTTGCCCGG 19680 CACGGCGTCC GGCGGCTGGT GCTCGCCAGC CGCCGAGGCG TGGCCGCGGA AGACCTCGTC 19740 ACCGAGCTGA CCGAGCAGGG CGCGACGGTG TCCGTGGTGG CTTGCGACGT CTCCGACCGC 19800 GACCAGGTGG CCGCGTTGCT GGCCGAACAC CGCCCGACCG GCATCGTGCA CCTGGCCGGC 19860 CTGCTGGACG ACGGCGTCAT CGGAGCCCTG AACCGGGAGC GGCTGGCCGG GGTGTTCGCG 19920 CCCAAGGTCG ATGCCGTCCA GCACCTCGAC GAACTGACCC GCGACCTCGG CCTCGACGCG 19980 TTCGTCGTGT TCTCGTCCGC AGCCGCGCTC ATGGGCTCCG CCGGCCAGGG CAACTACGCG 20040 GCCGCCAACG CCTTCCTCGA CGGCTTGATG GCCGGGCGCC GCGCGGCGGG CCTGCCAGGC 20100 GTGTCCCTGG CGTGGGGCCT GTGGGAGCAG GCGGACGGCC TGACCGCGAA CCTCAGCGCC 20160 ACCGACCAGG CCCGGATGAG CCGCGGCGGC GTGCTGCCGA TGACACCGGC CGAGGCCCTG 20220 GACATCTTCG ACATCGGCCT GGCCGCCGAG CAGGCCCTGC TGGTCCCGAT CAAGCTCGAC 20280 CTGCGGACGC TGCGCGGCCA GGCCACCGCC GGCGGCGAGG TGCCGCACCT GCTGCGCGGC 20340 CTGGTCCGCG CGAGCCGCCG CGTGACCCGC ACGGCTGCCG CGAGTGGCGG CGGTGGCCTG 20400 GTCCACAAGC TCGCCGGGCG GCCAGCCGAA GAGCAGGAAG CCGTGCTGCT GGGCATCGTC 20460 CAGGCGGAGG CGGCCGCGGT GCTCGGCTTC AACGCCCCCG AGCTGGCCCA GGGCACCCGC 20520 GGGTTCAGCG ACCTCGGCTT CGACTCGCTG ACCGCGGTCG AGCTGCGGAA CCGGCTGAGC 20580 GCGGCGACCG GCGTCAAATT GCCCGCCACG CTCGTCTTCG ACTACCCGAC GCCGGTCGCG 20640 CTCGCCCGCC ACCTGCGCGA AGAGCTGGGC GAGACGGTGG CGGGTGCGCC GGCCACGCCG 20700 GTGACGACCG TCGCCGACGC GGGCGAGCCG ATCGCCATCG TCGGCATGGC GTGCCGCCTG 20760 CCGGGCGGCG TGATGAGCCC CGACGACCTC TGGCGGATGG TCGCCGAGGG CCGCGATGGG 20820 ATGTCGCCGT TCCCCGGAGA CCGCGGCTGG GACCTGGACG GCCTGTTCGA CTCGGACCCC 20880 GAGCGCCCGG GCACCGCCTA CATCCGCCAA GGCGGCTTCC TGCACGAGGC CGCGCTGTTC 20940 GACCCGGGCT TCTTCGGGAT CTCGCCGCGC GAAGCCCTGG CCATGGACCC GCAGCAGCGG 21000 CTGCTGCTCG AAGCCTCCTG GGAAGCCCTG GAGCGCGCGG GCATCGACCC GACCAAGGCC 21060 CGCGGTGACG CCGTCGGCGT CTTCTCCGGC GTCTCCATCC ACGACTACCT CGAGTCCCTG 21120 AGCAACATGC CCGCCGAGCT CGAAGGCTTC GTCACCACGG CCACGGCGGG CAGCGTCGCC 21180 TCGGGCCGGG TGTCCTACAC CTTCGGGTTC GAGGGCCCGG CGGTCACGGT GGACACGGCG 21240 TGCTCGTCGT CGCTGGTCGC GATCCACCTG GCCGCACAGG CACTGCGGCA GGGCGAGTGC 21300 ACGATGGCCC TGGCCGGCGG TGTCGCCGTG ATGGGCTCGC CGATCGGTGT CATCGGCATG 21360 TCGCGGCAGC GCGGCATGGC CGAGGACGGC CGGGTCAAGG CGTTCGCCGA CGGCGCGGAC 21420 GGCACCGTCC TGTCCGAAGG CGTCGGCATC GTCGTCCTCG AACGGCTTTC GGTGGCCCGC 21480 GAACGCGGGC ACCGGGTGCT CGCCGTGCTC CGCGGCAGCG CGGTCAACCA GGACGGCGCT 21540 TCGAACGGCC TGACCGCGCC CAACGGGCCG TCGCAGCAGC GGGTGATCCG CAGCGCGCTG 21600 GCCGGGGCCG GACTGCAACC GTCCGAAGTG GACGTCGTCG A^GCGCACGG CACCGGGACC 21660 GCGCTGGGCG ACCGATCGA AGCCCAGGCC CTGCTGGCCA CCTACGGCAA GAGCCGCGAG 21720 ACGCCGTTGT GGCTCGGGTC GCTGAAGTCG A*ICATCGGCC ACACCCAGGC GGCCGCGGGC 21780 GTGGCGGCCG TGATCAAGAT GGTCCAGGCG CTGCGGCAGG ACACCCTGCC GCCGACCCTC 21840 CACGTGCAGG AACCCACCAA GCAGGTGGAC TGGTCCGCGG GTGCGGTCGA GCTGCTGACC 21900 GAAGGCCGGG AGTGGGCCCG CAACGGCCAC CCGCGCCGGG CCGGTGTCTC GTCGTTCGGC 21960 ATCAGCGGCA CCAACGCGCA CCTCATCCTG GAAGAGGCGC CCGCCGACGA CACCGCCGAG 22020 GCGGACGTGC CCGACGCCGT GGTGCCCGTG GTGATCTCCG CGCGCAGCAC CGGATCCCTG 22080 GCGGGCCAGG CCGGACGCCT GGCGGCGTTC CTCGACGGAG ACGTCCCGCT GACCCGCGTG 22140 GCGGGTGCCC TGCTGTCGAC CCGGGCGACG CTGACCGACC GGGCCGTCGT CGTGGCGGGC 22200 TCGGCCGAGG AGGCCCGGGC GGGGCTGACC GCGCTGGCCC GCGGCGAGAG CGCGAGCGGG 222 0 CTTGTGACCG GTACCGCAGG GATGCCGGGC AAGACGGTCT GGGTGTTCCC CGGCCAGGGG 22320 ACGCAGTGGG CGGGCATGGG CCGGGAGCTC CTCGAAGCGT CCCCGGTGTT CGCCGAGCGC 22380 ATTGAGGAAT GCGCGGCCGC GCTGCAGCCG TGGATCGACT GGTCGCTGCT GGACGTCCTC 22440 CGTGGCGAAG GTGAGCTGGA TCGGGTCGAC GTGCTGCAGC CGGCGTGTTT CGCGGTGATG 22500 GTGGGGCTGG CCGCCGTCTG GGCCTCGGTC GGCGTCGTGC CGGACGCGGT CCTGGGCCAC 22560 TCCCAGGGCG AGATTGCCGC CGCCTGCGTG TCGGGTGCAC TGTCCCTCGA GGACGCAGCC 22620 AAGGTCGTCG CGCTGCGCAG CCAGGCGATC GCGGCGGAGC TGTCGGGCCG CGGGGGCATG 22680 GCGTCGATCC AGCTGAGCCA CGACGAGGTG GCTGCCCGGC TCGCGCCGTG GGCGGGCCGC 22740 GTCGAGATCG CCGCCGTCAA CGGTCCGGCC TCGGTCGTGA TCGCCGGTGA CGCCGAAGCG 22800 CTCACCGAGG CCGTCGAAGT CCTCGGCGGT CGGCGGGTGG CGGTGGACTA CGCGTCCCAC 22860 A.CGCGGCACG TCGAGGACAT CCAGGACACC CTCGCCGAGA CTCTGGCCGG GATCGACGCG 22920 CAGGCCCCCG TGGTGCCCTT CTACTCCACG GTCGCCGGCG AGTGGATCAC CGATGCCGGG 22980 GTCGTCGACG GCGGGTACTG GTACCGGAAC CTGCGCAACC AGGTCGGCTT CGGCCCGGCC 23040 GTGGCCGAGC TGATCGAGCA GGGGCACGGG GTGTTCGTCG AGGTCAGTGC GCATCCGGTG 23100 CTGGTGCAGC CGATCAGCGA GCTCACCGAT GCGGTCGTCA CCGGGACGTT GCGGCGCGAC 23160 GACGGTGGGG TGCGGCGGCT GCTGACCTCG ATGGCCGAAC TGTTCGTCCG CGGTGTCCCG 23220 GTCGACTGGG CCACGATGGC GCCGCCCGCG CGCGTCGAGC TGCCGACCTA CGCCTTCGAC 23280 CACCAGGACT TCTGGCTCA.G CCCGCCCGCC GTGGCGGACG CGCCCGCGCT CGGCCTGGCC 23340 GGCGCCGACC ACCCGCTGCT GGGGGCGGTT CTCCCGCTGC CGCAGTCCGA CGGCCTGGTG 23400 TTCACCTCGC GCCTGTCGGT GCGGACGCAT CCGTGGCTGG CCGACGGCGT CCCCGCCGCC 23460 GCCTTGGTGG A.GCTGGCCGT GCGGGCCGGT GACGAAGCCG GTTGCCCGGT CCTCGCCGAC 23520 CTGACCGTCG A^AAGCTGCT GGTGCTGCCG GAGAGCGGTG GCCTGCGCGT CCAGGTGATC 23580 GTGAGCGGCG AGCGCACGGT CGAGGTGTAT TCGCAGCTCG AAGGCGCCGA AGACTGGATC 236 0 CGGAACGCCA CCGGGCACCT GTCCGCCACG GCTCCGGCGC ACGAGGCCTT CGACTTCACC 23700 GCCTGGCCGC CCGCCGGAGC CCAGCAGGTC GACGGCCTCT GGCGGCGCGG CGACGAGATC 23760 TTCGCCGAGG TCGCCCTGCC GGAGGAGCTG GACGCCGGCG CGTTCGGCAT CCACCCCTTC 23820 CTGCTGGACG CGGCCGTGCA GCCGGTCCTC GCGGACGACG AGCAGCCGGC GGAGTGGCGC 23880 AGCCTGGTCC TGCACGCCGC GGGTGCCTCG GCGCTGCGCG TGCGGCTGGT GCCCGGCGGT 23940 GCCCTCCAAG CGGCGGACGA AACCGGCGGG CTGGTCCTCA CGGCGGATTC GGTGGCAGGC 24000 CGGGAACTCT CGGCCGGGAA GACCCGCGCC GGATCGCTGT ACCGGGTCGA CTGGACCGAA 24060 GTGTCCATTG CAGACAGTGC GGTGCCGGCC AACATCGAGG TCGTCGAAGC CTTCGGTGAA 24120 GAGCCCCTGG AACTGACCGG CCGGGTCCTG GAGGCTGTGC AGACCTGGCT CGTCACCGCG 24180 GCCGACGATG CGCGGCTGGT CGTGGTGACC CGCGGCGCCG TGCGCGAGGT GACCGACCCC 24240 GCCGGTGCGG CCGTGTGGGG CCTGGTCCGA GCCGCGCAGG CGGAGAACCC CGGTCGCATC 24300 TTCCTGATCG ACACCGACGG CGAGATCCCG GCCCTGACCG GTGACGAGCC CGAGATCGCG 24360 GTGCGCGGCG GGAAGTTCTT CGTGCCCCGC ATCACTCGCG CGGAGCCGAG CGGGGCCGCC 24420 GTGTTCCGCC CGGACGGGAC AGTGCTGATC TCGGGCGCGG GTGCGCTCGG TGGCCTGGTG 24480 GCCCGGCGTC TCGTCGAACG CCACGGCGTG CGGAAGCTCG TGCTGGCGTC CCGGCGCGGC 24540 CGAGACGCCG ACGGCGTGGC GGACCTGGTC GCCGACCTGG CCGCGGACGT GTCCGTGGTG 24600 GCTTGCGACG TCTCCGATCG CGCCCAGGTG GCGGCCCTGC TCGACGAGCA CCGGCCGACC 24660 GCCGTCGTGC ACACCGCCGG CGTCATCGAC GCGGGCGTGA TCGAGACGCT GGACCGGGAC 24720 CGGCTGGCCA CGGTGTTCGC GCCGAAGGTC GACGCCGTGC GGCACCTCGA CGAGCTGACC 24780 CGCGACCGCG ACCTCGACGC CTTCGTCGTC TACTCCTCGG TCTCGGCCGT GTTCATGGGC 24840 GCGGGCAGCG GCAGTTACGC CGCGGCGAAC GCCTTCCTGG ACGGCCTGAT GGCGAACCGC 24900 CGGGCGGCGG GCCTGCCGGG CCTGTCGCTG GCGTGGGGCC TGTGGGACCA GAGCACCGGT 24960 ATGGCCGCCG GCACCGACGA GGCCACCCGG GCGCGGATGA GCCGCCGCGG TGGCCTGCAG 25020 ATCATGACGC AGGCCGAGGG CATGGACCTG TTCGACGCCG CGCTGTCGTC GGCCGAGTCG 25080 CTGCTGGTGC CCGCCAAGCT CGACCTGCGT GGGGTGCGCG CCGACGCCGC CGCGGGCGGG 25140 GTCGTGCCGC ACATGCTGCG TGGCCTGGTC CGCGCGGGCC GGGCGCAGGC CCGCGCGGCG 25200 TCCACTGTGG ACAACGGGCT GGCCGGACGG CTGGCCGGGC TCGCCCCGGC GGACCAGCTC 25260 ACGCTGCTCC TGGACCTGGT CCGGGCGCAG GTCGCGGCCG TGCTCGGGCA CGCCGACGCG 25320 AGCGCCGTCC GCGTCGACAC GGCCTTCAAG GACGCCGGCT TCGACTCGCT GACCGCGGTC 25380 GAGCTGCGCA ACCGCATGCG GACCGCCACC GGCCTGAAGC TGCCCGCGAC GCTCGTCTTC 25440 GACTACCCGA A.CCCCCAGGC GCTCGCCCGG CACCTGCGCG ACGAACTCGG TGGTGCGGCC 25500 CAGACGCCGG TGACCACAGC GGCCGCGAAG GCCGACCTCG ACGAGCCGAT CGCCATCGTC 25560 GGGATGGCGT GCCGCTTGCC GGGCGGGGTC GCCGGGCCCG AGGACCTCTG GCGGCTGGTC 25620 GCCGAGGGCC GGGACGCGGT GTCGAGCTTC CCGACCGACC GCGGCTGGGA CACCGACAGC 25680 CTGTACGACC CCGATCCGGC CCGCCCGGGC AAGACCTACA CCCGGCACGG CGGCTTCCTG 25740 CACGAAGCCG GGCTCTTCGA CGCGGGCTTC TTCGGGATCT CGCCACGCGA GGCCGTCGCC 25800 ATGGACCCGC AGCAGCGGCT GCTGCTGGAG GCCTCCTGGG AGGCCATGGA AGACGCCGGG 25860 GTCGACCCAC TTTCGCTGAA GGGCAACGAC GTCGGCGTGT TCACCGGCA.T GTTCGGCCAG 25920 GGTTACGTCG CTCCCGGGGA CAGCGTCGTC ACGCCGGAGC TGGAGGGTTT CGCGGGCACG 25980 GGCGGGTCGT CGAGTGTCGC GTCCGGCCGC GTGTCGTACG TGTTCGGGTT CGAAGGCCCG 26040 GCCGTGACGA TCGACTCGGC GTGCTCGTCC TCGCTGGTCG CGATGCACCT CGCCGCGCAG 26100 TCGCTGCGGC AGGGCGAGTG CTCGATGGCC TTGGCCGGCG GCGCGACGGT GATGGCGAAC 26160 CCCGGCGCAT TCGTGGAGTT CTCGCGGCAG CGGGGCCTCG CCGTCGACGG TCGCTGCAAG 26220 GCGTTCGCCG CCGCGGCCGA CGGCACCGGC TGGGCCGAGG GCGTCGGTGT GGTCATCCTC 26280 GAGCGGCTGT CGGTGGCGCG GGAACGCGGC CACCG ATCC TGGCCGTGCT GCGCGGCAGC 26340 GCGGTCAACC AGGACGGCGC CTCGAACGGC CTGACCGCGC CGAACGGGCC GTCGCAGCAG 26400 CGGGTGATCC GCCGGGCGCT GGTGAGCGCC GGGCTGGCAC CGTCCGATGT GGACGTCGTC 26460 GAGGCGCACG GCACCGGGAC CACGCTGGGT GACCCGATCG AGGCGCAAGC TCTGCTGGCT 26520 ACCTACGGCA AGGACCGCGA GTCGCCGCTG TGGCTCGGCT CGCTGAAGTC GAACATCGGC 26580 CACGCGCAGG CCGCCGCGGG GGTCGCCGGC GTCATCAAGA TGGTCCAGGC GCTCCGGCAC 26640 GAAGTCCTGC CGCCGACGCT GCACGTCGAC CGGCCTACCC CCGAGGTCGA CTGGTCGGCC 26700 GGTGCCGTCG AACTGCTGAC GGAAGCCCGC GAGTGGCCGC GCAACGGGCG CCCGCGCCGG 26760 GCCGGGGTCT CCGCGTTCGG CGTCAGCGGC ACGAACGCGC ACCTGATCCT GGAGGAGGCG 26820 CCCGCCGAAG AGCCGGTGCC CACACCCGAG GTTCCCCTGG TGCCGGTCGT GGTCTCCGCG 26880 CGGAGCAGGG CGTCCCTGGC CGGTCAGGCC GGTCGCCTCG CCGGATTCGT GGCGGGTGAC 26940 GCGTCCTTGG CCGGTGTGGC CCGGGCGCTG GTGACGAACC GGGCCGCGCT GACCGAGCGC 27000 GCGGTCATGG TCGTGGGCTC TCGCGAAGAA GCCGTGACGA ACCTGGAAGC GCTGGCCCGC 27060 GGCGAAGACC CGGCCGCGGT GGTCACCGGC CGGGCGGGTT CGCCGGGCAA GCTCGTCTGG 27120 GTCTTCCCCG GCCAGGGCTC GCAGTGGATC GGGATGGGCC GGGAACTCCT GGACTCTTCG 27180 CCGGTCTTCG CCGAGCGGGT CGCCGAATGC GCGGCCGCCC TGGAACCGTG GATCGATTGG 27240 TCACTGCTCG ACGTGCTGCG CGGGGAGTCC GACCTGCTGG ACCGGGTCGA CGTCGTGCAG 27300 CCCGCCAGCT TCGCGATGAT GGTCGGCCTG GCCGCGGTGT GGCAGTCGGT GGGTGTCCGC 27360 CCGGATGCCG TCGTCGGCCA CTCGCAGGGC GAGATCGCCG CCGCCTGCGT CTCGGGCGCG 27420 CTGTCGCTGC AGGACGCCGC GAAGGTGGTT GCCTTGCGCA GCCAGGCGAT CGCCACCCGG 27480 CTGGCCGGGC GCGGCGGCAT GGCTTCCGTG GCGTTGAGCG AAGAAGACGC GACCGCGTGG 27540 CTGGCGCCGT GGGCCGACCG GGTCCAGGTG GCCGCGGTCA ACAGCCCTGC CTCCGTGGTG 27600 ATCGCCGGGG AAGCCCAGGC CCTCGACGAG GTCGTCGACG CGTTGTCCGG TCAGGAAGTC 27660 CGCGTCCGGC GGGTGGCCGT GGACTACGGG TCCCACACCA ACCAGGTCGA AGCCATCGAG 27720 GATCTGCTGG CCGAGACCTT GGCCGGCATC GAGGCGCAGG CCCCGAAGGT GCCCTTCTAC 27780 TCGACCCTGA TCGGTGACTG GATCCGTGAC GCCGGGATCG TCGACGGCGG CTACTGGTAC 27840 CGAACCTGC GCAACCAGGT CGGGTTCGGT CCGGCCGTCG CGGAGCTCGT TCGCCAGGGC 27900 CACGGGGTGT TCGTCGAGGT CAGCGCGCAC CCGGTGCTGG TCCAGCCGCT CAGTGAACTC 27960 AGCGACGACG CGGTGGTGAC CGGGTCGCTG CGGCGCGAAG ACGGTGGCCT GCGCCGCCTG 28020 CTGACGTCGA TGGCCGAGCT GTACGTGCAG GGTGTCCCGC TCGACTGGAC CGCGGTCCTG 28080 CCGCGGACCG GCCGGGTCGA CCTGCCGAAG TACGCCTTCG ACCACCGGCA CTACTGGCTG 28140 CGGCCCGCCG AGTCCGCGAC CGACGCGGCT TCGCTGGGCC AGGCGGCGGC CGACCACCCG 28200 CTGCTGGGCG CGGTCGTCGA GCTGCCGCAG TCCGACGGCC TGGTGTTCAC CTCGCGGCTG 28260 TCCGTGCGGA CGCACCCGTG GCTGGCCGAC CACGCGGTCG GTGGCGTGGT CATCCTCCCC 28320 GGCTCCGGGC TGGCCGAACT GGCCGTCCGG GCCGGCGACG AAGCCGGGTG CACCGCCCTC 28380 GACGAGCTGA TCATCGAAGC TCCGCTGGTC GTGCCCGCCC AAGGCGCGGT CCGCGTCCAG 28440 GTCGCGTTGA GCGGCCCGGA CGAGACCGGC TCGCGCACGG TGGACCTCTA CTCCCAGCGC 28500 GACGGCGGCG CGGGGACGTG GACGCGGCAC GCCACCGGCG TGCTGTCGAC GGCCCCCGCT 28560 CAGGAACCCG AGTTCGACTT CCACGCCTGG CCGCCCGCGG ATGCCGAGCG GATCGACGTC 28620 GAGACCTTCT ACACCGACCT GGCCGAGCGT GGTTACGGCT ACGGGCCGGC GTTCCAGGGG 28680 CTGCAAGCGG TGTGGCGGCG TGACGGCGAC GTCTTCGCCG AGGTCGCCCT GCCCGAGGAC 28740 CTGCGCAAGG ACGCGGGCCG GTTCGGCGTC CACCCGGCGC TGCTCGACGC GGCGCTGCAG 28800 GCCGCCACGG CCGTGGGCGG CGACGAGCCC GGTCAGCCGG TGCTGGCGTT CGCGTGGAAC 28860 GGCCTGGTCC TGCACGCCGC GGGCGCGTCG GCCCTGCGGG TCCGGCTCGC GCCGAGCGGC 28920 CCGGACACGC TGTCCGTGGC AGCCGCCGAC GAAACCGGCG GCTTGGTCCT GACCATGGAA 28980 TCGCTGGTCT CCCGGCCGGT TTCGGCCGAG CAGCTCGGCG CCGCGGCCGA CGCGGGCCAC 29040 GACGCGATGT TCCGCGTCGA CTGGACCGAG CTGCCTGCCG TGCCCCGCGC GGAACTGCCG 29100 CCGTGGGTGC GGATCGACAC CGCCGACGAC GTCGCGGCCT TGGCGGAGAA GGCGGACGCA 29160 CCACCGGTGG TGGTCTGGGA AGCCGCCGGG GGAGACCCGG CCCTGGCCGT GAGTTCCCGG 29220 GTGCTCGAGA TCATGCAGGC CTGGCTGGCC GCGCCCGCGT TCGAGGAGGC CCGGCTGGTC 29280 GTGACGACCC GCGGCGCGGT ACCCGCCGGC GGTGACCACA CACTGACCGA CCCGGCCGCG 29340 GCCGCGGTGT GGGGCCTGGT CCGGTCCGCG CAGGCGGAAC ACCCGGACCG GGTCGTCCTG 29400 CTGGACACCG ACGGCGAAGT TCCGCTGGGC GCGGTGCTGG CCTCCGGTGA GCCGCAGCTC 29460 GCGGTGCGCG GAACGACGTT CTTCGTGCCC CGGCTGGCCC GCGCCACCCG GCTCTCGGAC 29520 GCGCCTCCTG CGTTCGACCC GGACGGGACC GTGCTGGTCT CGGGCGCCGG ATCGCTGGGC 29580 ACCTTGGTGG CCCGGCACCT GGTCACCCGG CACGGCGTGC GCCGGGTGGT GCTGGCCAGC 29640 CGGCAGGGCC GGGACGCCGA GGGCGCCCAG GACCTGATCA CCGAGCTCAC CGGCGAAGGC 29700 GCGGACGTGT CCTTCGTGGC CTGTGACGTC TCCGATCGCG ACCAGGTGGC CGCGCTGCTC 29760 GCGGGCCTCC CGGACCTGAC CGGGGTGGTG CACACCGCCG GCGTCTTCGA GGACGGCGTG 29820 ATCGAGGCGC TGACGCCCGA CCAGCTCGCG AACGTGTACG CGGCCAAGGT CACGGCCGCG 29880 ATGCACCTCG ACGAGCTCAC CCGCGACCGG GATCTCGGCG CGTTCGTCGT GTTCTCCTCC 29940 GTCGCGGGGG TGATGGGTGG TGGCGGTCAA GGCCCGTACG CGGCGGCGAA CGCCTTCCTG 30000 GACGCGGCGA TGGCGAGTCG TCAGGCCGCG GGCCTGCCGG GCCTGTCCCT GGCGTGGGGC 30060 CTCTGGGAAC GCAGCAGCGG CATGGCCGCC CACCTCAGCG AGGTCGACCA CGCGCGGGCG 30120 AGCCGCAACG GTGTCCTGGA ACTGACCCGG GCCGAGGGCC TGGCGCTGTT CGACCTCGGG 30180 CTGCGGATGG CCGAGTCGCT GCTCGTGCCG ATCAAGCTCG ACCTCGCCGC GATGCGGGCG 30240 AGCACGGTCC CGGTCCTGTT CCGCGGCCTG GTCCGGCCGA GCCGGACCCA GGCGCGCACG 30300 GCGTCCACTG TGGACCGGGG GCTGGCCGGG CGGCTCGCCG GGCTGCCGGT GGCCGAGCGG 30360 GCGGCGGTGC TGGTCGACCT GGTGCGCGGG CAGGTCGCGG TCGTGCTCGG CTACGACGGG 30420 CCGGAGGCCG TCCGCCCGGA CACGGCGTTC AAGGACACCG GGTTCGACTC GCTGACGTCG 30480 GTGGAACTGC GCAACCGGCT GCGCGAGGCG ACCGGGCTCA AGCTCCCCGC CACGCTCGTC 30540 ITCGACTACC CGAACCCCTT GGCGGTGGCG CGCTACCTGG GCGCGCGGCT GGTCCCGGAC 30600 GGGACCGCGA ACGGCAACGG GAACGGGAAT GGGCACAGCG AAGACGACCG GCTGCGGCAC 30660 GCGCTGGCGG CCATCGCGGC CGAGGACGCG GGCGAGGAGC GGTCGATCGC CGACCTGGGC 30720 GTCGACGACC TCGTGCAACT GGCTTTCGGC GACGAGTGAT TGGGGCAAGT GGTGAGTGCG 30780 TCGTATGAAA AGGTCGTCGA GGCGCTGCGG AAGTCGCTCG AAGAGGTCGG CACGCTGAAG 308 0 AAGCGGAACC GGCAGCTCGC CGACGCGGCC GGCGAGCCGA TCGCCATCGT CGGCATGGCC 30900 TGCCGGCTGC CCGGTGGCGT CACCGGGCCC GGTGACCTCT GGCGGCTGGT GGCCGAGGGC 30960 GGCGACGCCG TCTCGGGGTT CCCCACCGAC CGCTGCTGGG ACCTGGACAC CCTGTTCGAC 31020 CCGGATCCCG ACCA.CGCGGG GACGTCGTAC ACCGACCAGG GCGGCTTCCT CCACGACGCG 31080 GCCCTGTTCG ACCCGGGCTT CTTCGGGATT TCGCCGCGCG AGGCGCTGGC CATGGACCCG 31140 CAGCAGCGGT TGCTGCTGGA GGCGTCCTGG GAGGCGCTGG AAGGTGTCGG CCTCGACCCG 31200 GCTTCGTTGC AGGGCACCGA CGTCGGCGTG TTCACCGGCG CGGGCGGGTC GGGCTACGGC 31260 GGCGGCCTCA CCGGGCCGGA GATGCAGAGT TTCGCGGGCA CCGGGCTGGC CTCGAGCGTG 31320 GCTTCGGGCC GGGTGTCCTA CGTCTTCGGG TTCGAGGGAC CGGCGGTCAC GATCGACACG 31380 GCGTGCTCGT CGTCGCTGGT GGCGATGCAC CTCGCCGCGC AGGCCCTGCG CCAAGGCGAC 31440 TGCTCGATGG CACTGGCCGG CGGCGCGATG GTGATGTCGG GCCCCGACTC CTTCGTCGTC 31500 TTCTCCCGGC AGCGGGGGCT GGCCACCGAC GGGCGGTGCA AGGCGTTCGC GTCGGGCGCC 31560 GACGGCATGG TGCTCGCCGA GGGCATCAGC GTGGTCGTGC TGGAGCGGCT TTCGGTCGCG 31620 CGGGAACGCG GGCACCGGGT GCTGGCCGTG CTGCGCGGCA GCGCGGTGAA CCAGGATGGC 31680 GCGTCGAACG GCCTGACCGC CCCGAACGGC CCTTCCCAGC AGCGCGTGAT CCGCGCCGCG 31740 C GGCCAACG CCGGAATCGG ACCGTCCGAT GTGGACCTCG TCGAGGCGCA CGGGACCGGG 31800 ACGAGCCTGG GTGATCCCAT CGAGGCGCAG GCCTTGCTGG CGACCTACGG CCAGGACCGG 31860 GAGACGCCGT TGTGGCTCGG CTCGCTGAAG TCGAACATCG GGCACACGCA GGCGGCCGCG 31920 GGCGTGGCGA GCGTGATCAA GGTCGTGCAG GCGCTGCGGC ACGGCGTCAT GCCGCCGACC 31980 CTGCACGTCG ACGAGCCCAG CTCGCAGGTC GACTGGTCCG AAGGCGCGGT GGAACTGCTG 32040 ACCGGGAGCC GGGACTGGCC GCGCGGGGAC CGGCCGCGCC GGGCCGGGGT GTCGTCGTTC 32100 GGCGTCAGCG GGACGAACGT GCACCTGATC ATCGAGGAAG CCCCCGAGGA GCCCGCTGCG 32160 GCCGTGCCGA CGTCCGCGGA CGTCGTGCCG CTGGTGGTTT CCGCACGCAG CACGGGTTCC 32220 CTGGCCGGTC AGGCCGACCG GCTGACCGAG GTGGACGTCC CCCTCGGACA CCTCGCCGGG 32280 GCGCTGGTGG CCGGGCGCGC GGTGCTCGAG GAACGCGCGG TCGTGGTCGC CGGTTCGGCC 32340 GAAGAAGCCC GCGCGGGGCT GGGTGCGCTG GCTCGCGGTG AAGCCGCGCC CGGCGTCGTG 32400 ACCGGGACCG CGGGCAAGCC GGGCAAGGTC GTCTGGGTGT TCCCGGGACA GGGGACGCAG 32460 TGGGTGGGCA TGGGCCGGGA GCTCCTCGAC GCGTCCCCGG TGTTCGCCGA GCGGATCAAG 32520 GAGTGCGCGG CGGCACTGGA CCAGTGGACC GACTGGTCGC TGCTGGACGT CCTGCGTGGT 32580 GACGGTGACC TGGATTCTGT CGAGGTGCTG CAGCCCGCGT GCTTCGCGGT GATGGTGGGG 32640 CTGGCCGCGG TCTGGGAGTC GGCGGGGGTC CGGCCGGACG CCGTCGTCGG CCACTCGCAG 32700 GGCGAGATCG CCGCGGCCTG CGTGTCCGGC GCGCTCACCC TCGACGACGC CGCGAAGGTG 32760 GTGGCCCTGC GCAGCCAGGC GATCGCGGCG CGGCTGTCCG GCCGCGGCGG GATGGCGTCG 32820 GTCGCGTTGA GCGAGGACGA GGCGAACGCA CGGCTGGGTT TGTGGGACGG CCGGATCGAG 32880 GTGGCCGCGG TCAACGGCCC CGCCTCCGTG GTGATCGCGG GGGACGCCCA AGCCCTCGAC 32940 GAGGCTTTGG AGGTGCTGGC CGGGGACGGC GTCCGCGTCC GGCAGGTCGC GGTCGACTAC 33000 GCCTCCCACA CCCGGCACGT CGAGGACATC CGCGACACCC TCGCCGAGAC GCTGGCCGGG 33060 ATCACCGCGC AGGCCCCGGA CGTGCCGTTC CGCTCCACCG TCACCGGCGG CTGGGTGCGG 33120 GACGCCGACG TCCTGGACGG CGGGTACTGG TACCGCAACC TGCGCAACCA GGTCCGGTTC 33180 GGCCCGGCCG TGGCCGAGCT GCTCGAGCAG GGCCACGGGG TGTTCGTCGA GGTCAGCGCC 33240 CACCCCGTGC TGGTGCAGCC GATCAGCGAG CTCACCGACG CGGTCGTCAC CGGGACGCTG 33300 CGGCGCGACG ACGGCGGCCT GCGCCGCCTG CTGACGTCGA TGGCCGAGCT GTTCGTCCGC 33360 GGTGTTCGCG TCGACTGGGC CACGCTGGTG CCGCCCGCGC GCGTGGACCT CCCGACGTAC 33420 GCCTTCGACC ACCAGCACTT CTGGCTCCGG CCGGCCGCGC AGGCGGACGC CGTCTCGCTC 33480 GGCCAGGCCG CGGCGGAGCA CCCGCTGCTC GGCGCGGTCG TCCGGCTGCC GCAGTCGGAC 33540 GGCCTGGTCT TCACCTCGCG GCTGTCGCTG CGGACGCACC CGTGGCTGGC CGACCACACC 33600 ATCGGCGGCG TGGTGCTGTT CCCCGGCACC GGGCTGGTCG AACTGGCCGT GCGGGCCGGC 33660 GACGAGGCCG GGTGCCCGGT CCTGGACGAA CTCGTGACCG AGGCGCCGCT GGTCGTGCCC 33720 GGGCAGGGCG GAGTGAACGT CCAGGTCACG GTGAGCGGCC CGGACCAGAA CGGCTTGCGC 33780 ACGGTGGACA TCCACTCCCA GCGCGACGAC GTGTGGACCC GGCACGCGAC CGGAACGGTC 33840 TCGGCGACCC CGGCGAGCAG CCCCGGCTTC GACTTCACCG CGTGGCCGCC GCCGGACGGG 33900 CAGCGCGTCG AGATCGGCGA CTTCTACGCC GACCTCGCCG AGCGCGGGTA CGCGTACGGG 33960 CCCTTGTTCC AGGGCGTGCG GGCGGTGTGG CAGCGCGGCG AAGACGTGTT CGCCGAGGTC 34020 GCGCTGCCCG AAGACCGGCG GGAGGACGCC GCCCGGTTCG GCCTGCACCC GGCGTTGCTG 34080 GACGCGGCCC TGCAGACCGG GACGATCGCC GCGGCCGCGT CCGGTCAGCC GGGCAAGTCC 34140 GTGATGCCGT TCTCGTGGAA CCGGCTGGCG CTGCACGCCG TCGGGGCCGC GGGCCTCCGG 34200 GTCCGCGTGG CCCCCGGCGG ACCGGACGCG CTGACCGTCG AGGCCGCCGA CGAGACCGGC 34260 GCCCCGGTCC TCACCATGGA CTCGCTGATC CTGCGTGAAG TCGCCCTCGA CCAGCTGGAC 34320 A.CTGCGCGCG CCGGCTCGCT CTACCGGGTG GACTGGACGC CACTGCCCAC TGTGGACAGT 34380 GCGGTGCCCG CTGGTCGGGC CGAGGTGCTG GAAGCTTTCG GCGAGGAGCC CCTGGACCTG 34440 ACCGGCCGGG TGCTGGCCGC CCTGCAGGCG TGGCTTTCCG ACGCGGCGGA GGAAGCCCGC 34500 CTGGTCGTGG TGACCCGGGG TGCGGTGCCC GCCGGAGACG GTGTGGTGAG CGATCCGGCG 34560 GGTGCCGCGG TGTGGGGCCT GGTCCGGGCC GCGCAGGCGG AGAACCCGGA CCGGTTCGTC 34620 CTGCTCGACA CCGACGGCGA GGTGCCGCTG GAAGCGGTGC TGGCGACCGG TGAGCCGCAG 34680 CTCGCGCTGC GCGGCACGAC GTTCTCGGTG CCCCGGCTCG CCCGCGTCAC CGAACCGGCG 34740 GAAGCCCCGC TGACGTTCCG TCCGGACGGG ACGGTCCTGG TCTCCGGCGC CGGGACGCTG 34800 GGTGCGCTCG CCGCCCGCGA CCTCGTCACC CGGCACGGCG TCCGGCGGCT CGTGCTGGCC 34860 AGCCGGCGCG GCCGGGCCGC CGAGGGCATC GACGACCTCG TCGCCGAGCT GACCGGGCAC 34920 GGCGCCGAAG TGACGGTCGC CGCCTGCGAC GTCTCCGACC GCGACCAGGT GGCGGCGCTG 34980 CTCAAGGAAC ACGCGCTGAC CGCGGTGGTG CACACGGCGG GCGTGTTCGA CGCCGGTGTC 35040 ACCGGCGCGC TGACCCGGGA GCGGCTGGCC AAGGTGTTCG CGCCCAAGGT CGACGCGGCC 35100 AACCACCTCG ACGAGCTGAC CCGCGACCTG GACCTCGACG CGTTCATCGT CTACTCGTCC 35160 GCCTCCTCGA TCTTCATGGG CGCGGGCAGC GGCGGGTACG CGGCGGCGAA CGCCTACCTC 35220 GACGGCCTGA TGGCCGCCCG GCGCGCGGCG GGCCTGCCGG GGCTGTCGCT GGCCTGGGGC 35280 CCGTGGGAGC AGCTCACCGG CATGGCCGAC ACCATCGACG ACCTCACCCT GGCCCGGATG 35340 AGCCGGCGCG AAGGCCGCGG CGGCGTCCGC GCGCTCGGCT CCGCCGACGG CATGGAGCTG 35400 TTCGACGCCG CGCTCGCGGC CGGGCAGGCG CTGCTGGTGC CGATCGAGCT CGACCTGCGC 35460 GAGGTGCGGG CCGACGCGGC CGGCGGCGGC ACGGTGCCGC ACCTGCTGCG CGGGCTGGTC 35520 CGCGCGGGCC GGCAGGCGGC GCGGACGGCG GCCACCGAGG ACGGCGGCCT GGAACGCCGG 35580 CTGGCCGGGC TCACCGTGGC CGAACAGGAA GCGCTGCTGC TCGACCTCGT CCGCGGTCAG 35640 GTCGCCGTCG TGCTCGGGCA CGCCGACAGC TCCGGCGTCC GCGCCGACGC GGCGTTCAAG 35700 GACGCCGGGT TCGACTCGCT GACGTCGGTG GAGCTGCGCA ACCGGCTGCG CGAGACGACC 35760 GGCCTGAAAC TGCCCGCGAC GCTGGTCTTC GACCATCCGA ACCCGCTGGC ACTGGCCCGG 35820 CACCTGCGGG CGGAACTCGC CGTCGACGAG GCATCCCCGG CCGATGCGGT GCTGGCCGGG 35880 CTCGCCGGGC TGGAGGCGGC CATCGCGGCC GCCGGCGCCC CGGACGGCGA CCGGATCACC 35940 GCGCGGCTGC GGGAACTGCT CAAGGCCGCC GAGGCGGCCG AGGCCCGGCC GGGCACCTCC 36000 GGCGATCTCG ACACGGCCAG CGACGAGGAA CTGTTCGCCC TCGTCGACGG GCTCGACTGA 36060 AACCGCTGTG ACATCCGGGG CTTCGCCACC CGGGCCCCGA AAAGCAAGCA CACGTGAGAG 36120 TTCTGGGAGT TGAGTTCAGT GGCTGACGAG GGACAACTCC GCGACTACCT CAAGCGGGCC 36180 ATCGCCGACG CCCGCGACGC CCGCACGCGG CTGCGCGAGG TCGAGGAGCA GGCGCGGGAG 36240 CCGATCGCCA TCGTCGCCAT GGCGTGCCGG TACCCGGGCG GGGTGTCCTC GCCCGAGGAC 36300 CTGTGGCGGC TGGTGGCCGA GGGGACCGAC GCCGTCTCCG CGTTCCCCGG CGACCGCGGC 36360 TGGGACGTCG ACGGGCTCGT CGACCCGGAC CCCGACCGCC CGGGCACGAC GTACACGGAC 36420 CAGGGTGGCT TCCTCCACGA GGCCGGCCTC TTCGACGCGG GGTTCTTCGG GATCTCGCCG 36 80 CGGGAGGCCG TCGCGATGGA CCCGCAGCAG CGGCTGCTGC TGGAGACGTC CTGGGAGGCC 36540 ATCGAACGCA CCGGCACCGA CCCGCTTTCG CTGAAGGGCA GCGACATCGG CGTCTTCACC 36600 GGCGTCGCGA GCATGGGTTA CGGCGCCGGT GGCGGCGTGG TCGCGCCGGA GCTGGAGGGT 36660 TTCGTCGGCA CCGGTGCGGC GCCGTGCATC GCGTCCGGCC GGGTGTCGTA CGTCCTCGGC 36720 TTCGAAGGCC CGGCGGTCAC CGTCGACACC GGGTGTTCGT CGTCGCTGGT GGCGATGCAC 36780 CTCGCCGCGC AGGCGCTGCG GCGGGGTGAG TGCTCGATGG CTCTGGCCGG CGGCGCGATG 36840 GTGATGGCCC AGCCGGGTTC GTTCGTGTCC TTCTCGCGGC AACGCGGGCT CGCCCTGGAC 36900 GGGCGCTGCA AGGCGTTTTC GGACAGCGCC GACGGGATGG GACTGGCCGA GGGCGTCGGC 36960 GTCATCGCGC TGGAACGGCT GTCGGTCGCC CGTGAGCGTG GGCACCGGGT GCTGGCCGTG 37020 CTGCGCGGTA TCGCGGTGAA CCAGGATGGC GCGTCGAACG GCTTGACCGC CCCGAACGGC 37080 CCGTCCCAGC AGCGGGTGAT CCGCGCCGCG CTGGCCGAAG CCGGGCTGTC GCCGTCCGAT 37140 GTGGACGCCG TCGAAGGGCA CGGGACGGGC ACGACGCTGG GCGATCCGAT CGAAGCGCAG 37200 GCGTTGCTGG CCACCTACGG CAAGGGCCGG GACCCGGAGA AGCCGCTCTG GCTGGGCTCG 37260 GTGAAGTCGA ACCTCGGGCA CACGCAAGCG GCCGCGGGCG TGGCCAGCGT GATCAAGATG 37320 GTGCAGGCGC TGCGCCACGG CGTGCTGCCC CCGACGCTGC ACGTCGACCG GCCGTCCACC 37380 GAAGTCGACT GGTCGGCCGG TGCGGTCTCG CTGTTGACGG AGGCTCGGGA GTGGCCGCGC 37440 GAAGGGCGGC CGCGCCGGGC CGGGGTGTCC TCGTTCGGGA TCAGCGGGAC CAACGCGCAC 37500 CTCATCCTGG AGGAAGCGCC CGAGGAGGAG CCGCCCGTCG CCGAAGCGCC TTCCGCCGGA 37560 GTGGTGCCCG TGGTGGTGTC GGCTCGTGGG GCCCTGGCGG GTCAGGCCGG CCGGCTGGCC 37620 GCGTTCCTCG AGGCGTCCGA CGAGCCGTTG GTGACCGTCG CCGGGGCGCT GATCTGCGGC 37680 CGGTCCCGGT TCGGCGACCG GGCCGTCGTG GTGGCGGGCA CGCGCGCAGA GGCGACGGCC 37740 GGGCTGGCCG CGCTGGCCCG CGGCGAAAGC GCCGCCGACG TCGTGACCGG CACGGTCGCG 37800 GCCTCGGGCG TGCCGGGCAA GCTCGTGTGG GTGTTCCCGG GCCAGGGTTC GCAGTGGGTG 37860 GGCATGGGCC GGGAGCTCCT CGAAGCCTCG CCGGTGTTCG CCGCGCGGAT CGCGGAGTGC 37920 GCGGCTGCCC TCGAACCGTG GATCGACTGG TCGCTGCTGG ACGTCCTCCG TGGCGAGGGC 37980 GACCTCGACC GCGTCGACGT GGTGCAGCCC GCGAGTTTCG CGGTGATGGT CGGCCTGGCC 38040 GCGGTGTGGT CGTCCGTCGG GGTGGTGCCC GACGCGGTGC TCGGGCACTC GCAGGGGGAG 38100 ATCGCGGCGG CGTGCGTGTC GGGGGCGTTG TCGCTGCAGG ACGCGGCGAA GGTGGTCGCG 38160 TTGCGCAGCC AGGCGATCGC GGCGAAGCTG GCCGGCCGCG GCGGCATGGC CTCGGTCGCG 38220 CTGAGCGAGG AAGACGCGGT CGCGCGGTTG CGGCACTGGG CGGACCGGGT CGAGGTGGCC 38280 GCGGTCAACA GGCCGTCGTC GGTGGTGATC GCCGGCGACG CCGAAGCCCT CGACCAGGCC 38340 CTCGAAGCAC TGACCGGCCA GGACATCCGG GTCCGGCGGG TGGCGGTGGA CTACGCCTCG 38400 CACACCCGGC ACGTCGAAGA CATCCAGGAG CCCCTCGCCG AGGCACTGGC CGGGATCGAG 38460 GCGCACGCGC CGACCCTGCC GTTCTTCTCG ACCCTCACCG GTGACTGGAT TCGCGAAGCG 38520 GGCGTCGTGG ACGGCGGCTA CTGGTACCGG AACCTGCGCA ACCAGGTCGG TTTCGGCCCG 38580 GCGGTGGCCG AGCTGCTCGG CCTCGGCCAC CGGGTGTTCG TCGAGGTCAG CGCGCACCCC 38640 GTGCTCGTCC AGGCGATCAG CGCGATTGCC GACGACACCG ACGCGGTCGT CACCGGCTCG 38700 CTGCGGCGCG AGGAGGGCGG CCTGCGGCGG CTGCTGACGT CGATGGCCGA GCTGTTCGTC 38760 CGCGGAGTCG ACGTGGACTG GGCCACGATG GTGCCGCCAG CGCGGGTCGA TTTGCCGACC 38820 TACGCCTTCG ACCACCAGCA CTACTGGCTG CGGTACGTCG AGACCGCGAC CGACGCGGCC 38880 GGTCCGGTGG TCCGGCTGCC GCAGACGGGC GGCCTGGTCT TCACCACCGA GTGGTCGCTG 38940 AAGTCACAGC CGTGGCTGGC CGAGCACACC CTGGAAGACC TGGTCGTCGT CCCCGGCGCG 39000 GCACTGGTCG AGCTGGCCGT CCGGGCCGGT GACGAGGCCG GGACCCCGGT GCTGGACGAA 39060 CTCGTCATCG AGACGCCCCT GGTCGTGCCG GAACGCGGCG CGATCCGGGT GCAGGTCACG 39120 GTGAGCGGAC CGGACGACGG CACACGGACC CTGGAAGTGC ATTCCCAGCC CGAAGACGCC 39180 ACCGACGAAT GGACCCGGCA CGCCACCGGC ACGCTGTCGG CGACCCCGGA CGAAAGCAGC 39240 GGGTTCGACT TCACGGCCTG GCCGCCCCCG GGCGCCCGGC AGCTCGACGG CGTTCCGGCG 39300 ATCTGGCGGG CCGGCGACGA GATCTTCGCC GAAGTCTCCC TGCCCGACGA TGCGGACGCC 39360 GAGGCATTCG GCATCCACCC CGCGCTCCTG GACGCGGCCC TGCACCCCGC CCTGCCCGGC 39420 GATGACGGTC TGACGCAGCC CATGGAATGG CGTGGCCTGA CGCTGCACGC CGCGGGGGCG 39480 TCGACGCTGC GGGTCCGGTT GGTGCCCGGC GGGTTCCTGG AAGCGGCCGA CGGCGCCGGC 39540 AGCCTGGTCG TCACGGCGAA GGAGGTTGCC CTCCGCCCGG TGACGATCGC GCGGTCGCGC 39600 ACCACCACCC GAGACTCGCT GTTCCAGCTG AACTGGATCG AGCTGCCCGA GAGTGGCGTG 39660 GTGGCCGCGG CAGACGACAC CGAGGTGCTG GAGGTGCCCG CGGGCGATTC CCCGCTGGCG 39720 GCGACCTCCC GAGTCTTGGA GCGGCTCCAG ACCTGGCTGA CCGAGCCCGA GGCGGAACAG 39780 CTGGTCGTCG TGACGCGCGG CGCGGTGCCC GCCGGGGACA CCCCGGTGAC CGACCCGGCC 39840 GCGGCGGCGG TCTGGGGCCT GGTCCGGTCC GCGCAGGCGG AGAACCCGGA CCGGATCGTC 39900 CTGCTCGACA CCGACGGCGA AGTCCCGCTG GGTGCGGTGC TGGCCGGCGG CGAGCCGCAG 39960 GTCGCGGTGC GCGGCACGGC GCTGTACGTC CCGCGCCTGG CCCGCGCCGA CGCGGCCCCG 40020 GTATCCGGTC TACATGGGAC GGTCCTCGTC TCCGGTGCCG GTGTGCTCGG CGAGATCGTG 40080 GCGCGGCACC TGGTCACCCG CCACGGCGTG CGCAAGCTGG TGCTCGCCAG CCGCCGCGGC 40140 CTGGACGCCG ACGGCGCGAA GGACCTCGTC ACCGACCTCA CCGGCGAGGG CGCGGACGTG 40200 TCCGTCGTCG CCTGCGACCT GGCCGATCGG AACCAGGTGG CCGCGCTGCT GGCCGACCAC 40260 CGCCCGGCGA GCGTCATCCA CACGGCGGGC GTCCTCGACG ACGGCGTCAT CGGGACGCTG 40320 ACCCCGGAGC GGCTGGCCAA GGTGTTCGCG CCCAAGGTCG ACGCGGTCCG CCATCTCGAC 40380 GAGCTGACTC GCGACCTCGA CCTCGACGCG TTCGTCGTGT TCTCCTCCGG CTCCGGCGTG 40440 TTCGGTTCGC CGGGGCAGGG CAACTACGCG GCGGCGAACG CGTTCCTGGA CGCGGCGATG 40500 GCGAGCCGCC GCGCGGCGGG TCTTCCTGGT CTCTCGCTGG CGTGGGGCCT GTGGGAACAG 40560 GCCACCGGCA TGACCGCGCA CCTCGGCGGC ACCGACCAGG CCCGGATGAG CCGGGGCGGG 40620 GTGCGGCCGA TCACGGCCGA GGAAGGCATG GCCCTGTTCG ACACGGCACT GGGTGCGCAG 40680 CCCGCGCTGC TCGTGCCGGT CAAGCTCGAC CTGCGGGAGG TGCGGGCCGG CGGGGCCGTG 40740 CCGCACCTGC TGCGCGGGCT GGTCCGGGCC GGGCGGCGGC AGGCCCAAGC CGCGTCCACA 40800 GTGGACAACC AGCTGCTGGG CCGGCTGCCC GGGCTGGGCG CGCCCGAGCA GGAGGCGCTG 40860 CTCGTCGACC TCGTGCGCGG CCAGGTCGCG GCGGTGCTCG GGCACGCCGG GCCGGACGCG 40920 GTCCGCGCCG ACACGGCGTT CAAGGACGCC GGGTTCGACT CGCTCACCTC GGTCGACCTG 40980 CGCAACCGGC TGCGGGAGAG CACCGGGCTG AAGCTGCCCG CCACGCTCGC CTTCGACTAC 41040 CCGACCCCGC TGGTCCTCGC CCGGCACCTG CGTGACGAGC TCGGGGCCGG CGACGACGCG 41100 CTTTCGGTGG TGCACGCGCG GCTCGAAGAC GTCGAGGCGC TGCTCGGCGG GCTGCGCCTC 41160 GACGAATCCA CGAAGACCGG TCTCACCCTC CGGCTGCAGG GCCTGGTCGC CCGGTGCAAC 41220 GGCGTGAACG ACCAGACCGG CGGCGAAACG CTGGCGGACC GGCTCGAGGC CGCGTCCGCC 41280 GACGAAGTCC TCGACTTCAT CGACGAGGAG CTGGGTCTCA CCTGACCCCG GTTCGAGACC 41340 GACGTTCCAG CAACCCTTGT GAGGACCCGA GAATGGCCAC GGACGAGAAA CTCCTCAAAT 41400 ACCTCAAGCG CGTCACGGCG GAGCTGCACA GCCTGCGCAA GCAGGGTGCC CGGCACGCCG 41460 ACGAGCCGCT CGCCGTCGTC GGGATGGCCT GCCGGTTCCC GGGTGGGGTG TCCTCGCCCG 41520 AAGACCTGTG GCAGCTCGTG GCCGGCGGGG TCGACGCCCT TTCGGACTTC CCCGACGACC 41580 GGGGCTGGGA GCTGGACGGC CTGTTCGACC CGGACCCCGA CCACCCCGGG ACGTCGTACA 41640 CCAGCCAGGG CGGCTTCCTG CGTGGCGCCG GGCTGTTCGA CGCGGGCCTG TTCGGCATCT 41700 CGCCGCGCGA GGCCCTCGTC ATGGACCCGC AGCAGCGGGT GCTGCTGGAG ACGTCGTGGG 41760 AGGCCCTCGA AGACGCCGGG GTCGACCCGC TTTCGCTGAA GGGCAGCGAC GTCGGCGTGT 41820 TCTCCGGCGT CTTCACCCAG GGCTACGGCG CCGGGGCGAT CACGCCGGAC CTCGAGGCGT 41880 TCGCGGGCAT CGGGGCGGCG TCGAGCGTGG CGTCGGGCCG GGTGTCCTAC GTCTTCGGGC 41940 TCGAAGGACC GGCGGTCACC ATCGACACCG CGTGTTCGTC GTCGCTGGTG GCCATCCACC 42000 TCGCCGCGCA GGCCCTGCGC GCGGGCGAGT GCTCGATGGC GCTCGCCGGC GGGGCGACGG 42060 TGATGCCGAC GCCCGGCACC TTCGTCGCGT TCTCGCGGCA GCGGGTGCTG GCTGCCGACG 42120 GCCGGTCCAA GGCCTTCTCC TCGACCGCGG ACGGCACCGG CTGGGCCGAG GGCGCCGGGG 42180 TGCTCGTCCT CGAACGGCTT TCGGTCGCGC AGGAGCGCGG CCACCGGATT CTCGCCGTGC 42240 TGCGCGGCAG CGCGGTCAAC CAGGATGGCG CCTCCAACGG CCTGACCGCG CCGAACGGGC 42300 CTTCGCAGCA GCGGGTGATC CGCAAGGCGC TCGCGGGCGC CGGGCTGGTC GCGTCCGATG 42360 TGGACGTCGT GGAGGCGCAC GGCACGGGCA CCGCGCTGGG CGACCCGATC GAAGCGCAGG 42420 CGCTGCTGGC GACCTACGGC CAGGGCCGTG AGCGGCCGCT GTGGCTGGGG TCGGTCAAGT 42480 CGAACTTCGG GCACACGCAG GCGGCCGCCG GGGTCGCGGG CGTGATCAAG ATGGTCCAGG 42540 CCCTGCGGCA CGGCGCCATG CCGCCGACCC TGCACGTGGC CGAGCCGACG CCGGAGGTCG 42600 ACTGGTCGGC CGGTGCGGTG GAACTGCTGA CCGAGCCGCG CGAGTGGCCC GCCGGTGATC 42660 GGCCGCGCCG GGCCGGGGTG TCCGCGTTCG GGATCAGCGG GACGAACGCC CACCTGATCC 42720 TGGAGGAGGC GCCCCCGGCC GACGCGGTCG CGGAAGAACC GGAGTTCAAG GGGCCGGTGC 42780 CGCTGGTCGT CTCGGCGGGC AGCCCCACAT CTTTGGCGGC TCAGGCCGGC CGGCTCGCGG 42840 AGGTCCTGGC GTCCGGTGGT GTGTCCCGGG CCCGGCTGGC GAGCGGGCTG CTGTCGGGCC 42900 GGGCGCTGCT CGGTGACCGC GCGGTCGTGG TCGCGGGAAC GGACGAGGAC GCGGTGGCCG 42960 GGTTGCGTGC GCTGGCCCGC GGGGACCGCG CGCCCGGCGT GCTGACCGGT TCGGCCAAGC 43020 ACGGCAAGGT CGTCTACGTC TTCCCCGGCC AGGGTTCGCA GCGGCTCGGG ATGGGCCGCG 43080 AGCTCTACGA CCGGTACCCG GTGTTCGCGA CGGCGTTCGA CGAGGCTTGC GAGCAGCTGG 43140 ACGTCTGTCT GGCCGGCCGT GCCGGGCACC GCGTGCGGGA CGTCGTGCTC GGCGAAGTGC 43200 CCGCCGAAAC CGGGCTGCTG AACCAGACGG TCTTCACCCA AGCCGGGCTG TTCGCGGTGG 43260 AGAGCGCGCT GTTCCGGCTC GCCGAATCCT GGGGTGTCCG GCCGGACGTG GTGCTCGGCC 43320 ACTCCATCGG GGAGATCACC GCCGCGTATG CCGCGGGCGT CTTCTCGCTG CCGGACGCCG 43380 CCCGGATCGT CGCGGCGCGC GGCCGGCTGA TGCAGGCGCT GGCGCCGGGC GGGGCGATGG 43440 TCGCCGTCGC CGCCTCCGAA GCCGAGGTGG CCGAACTGCT CGGCGACGGC GTGGAACTCG 43500 CCGCCGTCAA CGGCCCTTCG GCGGTAGTCC TTTCCGGGGA CGCGGACGCG GTCGTCGCGG 43560 CCGCCGCCCG CATGCGCGAG CGCGGGCACA AGACCAAGCA GCTCAAGGTT TCGCACGCGT 43620 TCCACTCCGC GCGGATGGCG CCGATGCTGG CGGAGTTCGC CGCCGAGCTG GCCGGCGTGA 43680 CGTGGCGCGA GCCGGAGATC CCGGTGGTCT CCAACGTGAC CGGCCGGTTC GCCGAGCCCG 43740 GCGAACTGAC CGAGCCGGGC TACTGGGCCG AGCACGTGCG GCGGCCGGTG CGGTTCGCCG 43800 AGGGCGTCGC GGCCGCGACG GAGTCCGGCG GCTCGCTGTT CGTGGAGCTC GGGCCGGGGG 43860 CGGCGCTGAC CGCCCTCGTC GAGGAGACGG CCGAGGTCAC CTGCGTCGCG GCCCTGCGGG 43920 ACGACCGCCC GGAGGTCACC GCGCTGATCA CCGCGGTCGC CGAGCTGTTC GTCCGCGGGG 43980 TTGCGGTCGA TTGGCCGGCC CTGCTGCCGC CGGTCACCGG GTTCGTCGAC CTGCCGAAGT 44040 ACGCCTTCGA CCAGCAGCAC TATTGGCTGC AGCCCGCCGC GCAGGCCACG GACGCGGCCT 44100 CGCTCGGGCA GGTCGCGGCC GACCACCCGC TGCTGGGCGC GGTGGTCCGG CTGCCGCAGT 44160 CGGACGGCCT GGTCTTCACC TCGCGGCTGT CATTGAAATC GCACCCGTGG CTGGCCGACC 44220 ACGTCATCGG CGGGGTGGTG CTCGTCGCGG GCACCGGGCT CGTCGAGCTG GCCGTCCGGG 44280 CCGGGGACGA GGCCGGCTGC CCGGTCCTCG AAGAACTCGT CATCGAGGCT CCGCTGGTCG 44340 TCCCCGACCA CGGCGGGGTC CGGATCCAGG TCGTCGTGGG GGCACCGGGG GAGACCGGTT 44400 CGCGCGCGGT CGAGGTGTAC TCCCTGCGCG AGGACGCCGG TGCCGAAGTG TGGGCCCGGC 44460 ACGCCACCGG GTTCCTGGCT GCGACGCCGT CGCAGCACAA GCCGTTCGAC TTCACCGCCT 44520 GGCCGCCGCC CGGCGTCGAG CGCGTCGACG TCGAGGACTT CTACGACGGC CTCGTCGACC 44580 GCGGGTACGC CTACGGGCCG TCGTTCCGGG GCCTGCGGGC GGTGTGGCGG CGCGGCGACG 44640 AAGTGTTCGC CGAGGTCGCC CTGGCCGAGG ACGACCGCGC GGACGCGGCC CGGTTCGGCA 44700 TCCACCCCGG CCTGCTGGAC GCCGCCCTGC ACGCGGGCAT GGCCGGTGCC ACCACCACGG 44760 AAGAGCCCGG CCGGCCGGTG CTGCCGTTCG CCTGGAACGG CCTGGTGCTG CACGCGGCCG 44820 GGGCGTCCGC GCTGCGGGTC CGGCTCGCCC CGAGCGGTCC GGACGCCCTG TCGGTCGAGG 44880 CCGCGGACGA GGCCGGCGGT CTCGTTGTGA CGGCGGACTC GCTGGTCTCC CGGCCGGTGT 44940 CGGCCGAACA GCTGGGCGCG GCGGCGAACC ACGACGCGTT GTTCCGCGTG GAGTGGACCG 45000 AGATTTCCTC GGCTGGAGAC GTΓCCGGCGG ACCACGTCGA AGTGCTCGAA GCCGTCGGCG 45060 AGGATCCCCT GGAACTGACC GGCCGGGTCC TGGAGGCCGT GCAGACCTGG CTCGCCGACG 45120 CAGCCGACGA CGCTCGCCTG GTCGTGGTGA CCCGCGGCGC CGTCCACGAG GTGACTGACC 45180 CGGCCGGTGC CGCGGTGTGG GGCCTGATCC GGGCCGCGCA GGCGGAAAAC CCGGACCGGA 45240 TCGTGCTGCT GGACACCGAC GGTGAAGTGC CGCTAGGCCG GGTGCTGGCC ACCGGCGAGC 45300 CCCAAACAGC CGTCCGAGGC GCCACGCTGT TCGCCCCGCG GCTGGCCCGC GCCGAGGCCG 45360 CGGAGGCACC GGCAGTGACC GGCGGGACGG TCCTGATCTC GGGCGCCGGC TCGCTGGGCG 45420 CGCTCACCGC CCGGCACCTG GTCGCCCGGC ACGGAGTCCG GCGGCTGGTG CTCGTCAGCC 5480 GCCGTGGCCC CGACGCCGAC GGCATGGCCG AACTGACCGC TGAACTCATC GCTCAGGGCG 45540 CCGAGGTCGC CGTAGTCGCT TGCGACCTGG CCGACCGGGA CCAGGTCCGG GTACTGCTGG 45600 CCGAGCACCG CCCGAACGCC GTCGTGCACA CGGCCGGTGT TCTCGACGAC GGCGTCTTCG 45660 AGTCGCTGAC GCGGGAGCGG CTGGCCAAGG TCTTCGCGCC CAAAGTTACT GCTGCCAATC 45720 ACCTCGACGA GCTGACCCGC GAACTGGATC TTCGCGCGTT CGTCGTGTTC TCCTCCGCCT 5780 CCGGGGTCTT CGGCTCCGCC GGGCAGGGCA ACTACGCCGC TGCCAACGCC TACCTGGACG 45840 CCGTGGTCGC CAACCGCCGG GCCGCGGGCC TGCCCGGCAC ATCGCTGGCC TGGGGCCTGT 45900 GGGAACAGAC CGACGGGATG ACCGCGCACC TCGGCGACGC CGACCAGGCG CGGGCGAGTC 45960 GCGGCGGGGT CCTCGCCATC TCACCCGCCG AAGGCATGGA GCTGTTCGAC GCAGCGCCGG 46020 ACGGGCTCGT CGTCCCGGTC AAGCTGGACC TGCGCAAGAC CCGCGCCGGC GGGACGGTGC 46080 CGCACCTGCT GCGCGGCCTG GTCCGCCCGG GACGGCAGCA GGCCCGTCCG GCGTCCACTG 46140 TGGACAACGG ACTGGCCGGG CGACTCGCCG GGCTCGCGCC GGCGGAGCAG GAGGCGCTGC 46200 TGCTCGACGT CGTCCGCACG CAGGTCGCGC TGGTGCTCGG GCACGCCGGG CCGGAGGCCG 46260 TCCGCGCGGA CACGGCGTTC AAGGACACCG GCTTCGACTC GCTGACGTCG GTGGAACTGC 46320 GCAACCGGCT GCGCGAGGCG AGCGGGCTGA AGCTGCCCGC GACGCTCGTC TTCGACTACC 46380 CGACGCCGGT CGCGCTGGCC CGCTACCTGC GTGACGAACT CGGCGACACG GTGGCAACAA 46440 CTCCGGTGGC CACCGCGGCC GCAGCGGACG CCGGCGAGCC GATCGCCATC GTCGGCATGG 46500 CGTGCCGGCT GCCGGGCGGG GTCACCGATC CCGAAGGCCT GTGGCGCCTG GTGCGCGACG 46560 GCCTCGAAGG GCTGTCTCCC TTCCCCGAGG ACCGGGGCTG GGACCTGGAG AACCTGTTCG 46620 ACGACGACCC CGACCGCTCC GGCACGACGT ACACCAGCCG GGGCGGGTTC CTCGACGGCG 46680 CCGGCCTGTT CGACGCGGGC TTCTTCGGGA TTTCGCCGCG CGAGGCGCTG GCCATGGACC 46740 CGCAGCAGCG GCTGCTGCTC GAGGCGGCCT GGGAAGCCCT CGAAGGCACC GGTGTCGACC 46800 CGGGCTCGTT GAAGGGCGCC GACGTCGGGG TGTTCGCCGG GGTGTCCAAC CAGGGCTATG 46860 GGATGGGCGC GGATCCGGCC GAACTGGCGG GGTACGCGAG CACGGCGGGC GCTTCGAGCG 46920 TCGTCTCGGG CCGAGTCTCG TACGTCTTCG GGTTCGAAGG ACCGGCGGTC ACGATCGACA 46980 CGGCTTGCTC GTCGTCGCTG GTGGCGATGC ACCTGGCCGG GCAGGCGCTG CGGCAGGGCG 47040 AGTGCTCGAT GGCCCTGGCC GGTGGCGTCA CGGTGATGGG GACGCCCGGC ACGTTCGTGG 47100 AGTTCGCGAA GCAGCGCGGC CTGGCCGGCG ACGGCCGGTG CAAGGCCTAC GCCGAAGGCG 47160 CGGACGGCAC GGGCTGGGCC GAGGGCGTCG GGGTCGTCGT GCTGGAGCGG CTGTCGGTGG 47220 CGCGCGAGCG CGGGCACCGG GTGCTGGCCG TGCTGCGCGG CAGCGCGGTC AACTCCGACG 47280 GCGCGTCCAA CGGCCTGACC GCCCCCAACG GGCCGTCGCA GCAACGGGTG ATCCGCCGGG 47340 CCCTGGCCGG CGCCGGCCTC GAACCGTCCG ATGTGGACAT CGTGGAAGGG CACGGCACCG 47400 GGACGGCGCT GGGCGACCCG ATCGAGGCGC AGGCCCTGCT GGCCACCTAC GGCAAGGACC 47460 GCGACCCGGA GACGCCGTTG TGGCTGGGGT CGGTGAAGTC GAACTTCGGC CACACGCAGT 47520 CCGCGGCCGG CGTGGCCGGG GTGATCAAGA TGGTGCAGGC GCTGCGCCAC GGCGTCATGC 47580 CGCCCACCCT GCACGTGGAC CGGCCCACCA GCCAGGTCGA CTGGTCCGCG GGGGCCGTCG 47640 AAGTGCTGAC CGAGGCACGG GAGTGGCCGC GGAACGGCCG TCCGCGCCGG GCCGGGGTGT 47700 CCTCGTTCGG GATCAGCGGC ACGAACGCCC ACCTGATCAT CGAAGAAGCA CCGGCCGAGC 47760 CACAGCTTGC CGGACCACCG CCGGACGGCG GTGTGGTGCC GCTGGTCGTC TCGGCTCGCA 47820 GCCCCGGTGC CCTGGCCGGT CAGGCGCGTC GGCTGGCCAC GTTCCTCGGC GACGGGCCCC 47880 TTTCCGACGT CGCCGGTGCG CTGACGAGCC GCGCCCTGTT CGGCGAGCGC GCGGTCGTCG 47940 TGGCGGATTC GGCCGAGGAA GCCCGCGCCG GTCTGGGCGC ACTGGCCCGC GGCGAAGACG 48000 CGCCGGGCCT GGTCCGCGGC CGGGTGCCCG CGTCCGGCCT GCCGGGCAAG CTCGTGTGGG 48060 TGTTCCCCGG GCAGGGGACG CAGTGGGTGG GCATGGGCCG CGAACTCCTC GAAGAGTCTC 48120 CGGTGTTCGC CGAGCGGATC GCCGAGTGTG CGGCCGCGCT GGAGCCGTGG ATCGGCTGGT 48180 CGCTGTTCGA CGTCCTCCGT GGCGACGGTG ACCTCGATCG GGTCGATGTG CTGCAGCCCG 8240 CGTGCTTTGC GGTGATGGTC GGCTTGGCCG CGGTGTGGTC CTCGGCCGGG GTGGTCCCCG 48300 ATGCGGTGCT CGGCCACTCC CAGGGTGAGA TCGCCGCGGC GTGCGTGTCG GGTGCGTTGT 48360 CGCTGGAGGA TGCGGCGAAG GTGGTTGCCC TGCGCAGCCA GGCCATCGCC GCGAAGCTCT 48420 CCGGCCGCGG CGGGATGGCT TCGGTCGCCT TGGGCGAAGC CGATGTGGTG TCGCGGCTGG 48480 CGGACGGGGT CGAGGTGGCT GCCGTCAACG GTCCGGCGTC CGTGGTGATC GCGGGGGATG 48540 CCCAGGCCCT CGACGAAACG CTGGAAGCGC TGTCCGGTGC GGGAATCCGG GCTCGGCGGG 48600 TGGCGGTGGA CTACGCCTCG CACACCCGGC ACGTCGAAGA CATCGAAGAC ACCCTCGCCG 48660 AAGCGCTGGC CGGGATCGAC GCCCGGGCGC CGCTGGTGCC GTTCCTCTCC ACCCTCACCG 48720 GCGAGTGGAT CCGGGACGAG GGCGTCGTGG ACGGCGGCTA CTGGTACCGG AACCTGCGCG 48780 GCCGGGTGCG GTTCGGCCCG GCCGTCGAGG CGCTGCTGGC CCAGGGGCAC GGTGTGTTCG 48840 TCGAGCTCAG CGCCCACCCG GTGCTGGTCC AGCCGATCAC CGAGCTCACC GACGAAACCG 48900 CCGCCGTCGT CACCGGTTCG CTGCGCCGGG ACGACGGTGG CCTGCGCCGG CTGCTGACCT 48960 CGATGGCCGA GCTCTTCGTC CGTGGGGTCG AAGTGGACTG GACGTCGCTG GTGCCGCCGG 49020 CCCGGGCCGA CCTCCCGACG TACGCCTTCG ACCACGAGCA CTACTGGCTC CGCGCCGCGG 49080 ACACCGCTTC CGACGCCGTC TCGCTGGGGC TGGCCGGGGC GGACCACCCG CTGCTCGGCG 49140 CGGTCGTGCA GCTTCCGCAG TCCGACGGCC TGGTCTTCAC TTCCCGGCTC TCCCTGCGCT 49200 CGCACCCCTG GCTGGCCGAC CACGCGGTCC GGGACGTCGT GATCGTCCCC GGCACCGGGC 49260 TGGTCGAGCT GGCCGTGCGG GCCGGTGACG AAGCCGGCTG CCCGGTGCTC GACGAGCTGG 49320 TGATCGAGGC GCCGCTCGTG GTGCCCCGCC GCGGCGGGGT CCGCGTGCAG GTCGCCCTCG 49380 GCGGCCCCGC CGACGACGGT TCGCGCACGG TGGACGTCTT CTCCCTGCGC GAAGACGCGG 49440 ACAGCTGGCT CCGGCACGCC ACGGGCGTGC TGGTCCCGGA GAACCGGCCG CGGGGGACCG 49500 CCGCGTTCGA CTTCGCCGCC TGGCCGCCAC CGGAGGCGAA GCCCGTGGAC CTCACCGGTG 49560 CCTACGACGT GCTCGCGGAC GTCGGGTACG GCTACGGGCC CACGTTCCGG GCCGTGCGGG 49620 CCGTGTGGCG GCGCGGCAGC GGGAACACCA CCGAGACCTT CGCCGAGATC GCCCTGCCCG 49680 AAGACGCCCG CGCGGAAGCC GGCCGGTTCG GCATCCACCC CGCGCTGCTG GACGCGGCCC 49740 TGCACTCGAC GATGGTCAGC GCCGCGGCGG ACACCGAGTC CTACGGCGAC GAAGTGCGGC 49800 TGCCGTTCGC GTGGA^CGGG CTGCGGCTGC ACGCGGCCGG CGCCTCGGTG CTGCGGGTGC 49860 GCGTCGCCAA GCCCGAGCGG GACAGTCTGT CGCTGGAGGC CGTCGACGAG TCCGGCGGCC 49920 TGGTCGTGAC GCTGGATTCC CTGGTCGGGC GCCCGGTGTC GAACGACCAG CTGACGACGG 49980 CGGCGGGGCC GGCGGGCGCC GGCTCGCTGT ACCGCGTGGA CTGGACGCCA TTGTCCTCAG 50040 TGGACACTTC GGGACGGGTG CCGTCCTGGC TTCCGGTCGC CACCGCGGAA GAGGTGGCGA 50100 CGCTGGCCGA CGACGTCCTG ACCGGCGCGA CCGAGGCGCC GGCGGTGGCC GTCATGGAGG 50160 CCGTCGCCGA CGAGGGTTCC GTGCTGGCGC TCACCGTCCG GGTGCTGGAC GTGGTCCAGT 50220 GCTGGCTGGC CGGCGGCGGG CTGGAGGGGA CGAAGCTCGC GATCGTGACC CGCGGCGCGG 50280 TGCCCGCCGG CGACGGCGTG GTGCACGACC CGGCCGCGGC CGCGGTGTGG GGGCTGGTCC 50340 GGGCCGCGCA GGCGGAGAAC CCGGACCGGA TCGTCCTCCT CGACGTCGAG CCGGAAGCCG 50400 ACGTACCGCC GCTGCTGGGT TCGGTGCTCG CCGACGGCGA GCCGCAGGTC GCGGTGCGCG 50460 GAACCACGCT GTCCATCCCC CGCCTCGCCC GCGCCGCCCG GCCCGACCCG GCCGCCGGGT 50520 TCAAGACCCG GGGACCGGTG CTGGTCACCG GCGGGACCGG GTCGCTCGGC GGCCTGGTCG 50580 CCCGGCACCT GGTCGAGCGG CACGGCGTCC GGCAGCTGGT GCTGGCGAGT CGCCGGGGCC 50640 • TGGACGCCGA AGGCGCGAAG GACCTGGTCA CCGACCTCAC CGCACTGGGG GCCGACGTCG 50700 CGGTCGCCGC TTGCGACGTC GCCGACCGGG ACCAGGTGGC GGCCCTGCTG ACCGAGCACC 50760 GGCCGTCCGC CGTGGTGCAC ACGGCCGGCG TCCCGGACGC CGGGGTGATC GGGACGGTGA 50820 CCCCGGACCG GCTGGCCGAG GTGTTCGCGC CCAAGGTCAC CGCGGCCCGG CACCTCGACG 50880 AGCTGACCCG CGACCTGGAC CTCGACAGTT TCGTCGTCTA CTCCTCGGTT TCCGCGGTGT 50940 TCATGGGCGC CGGCAGCGGC AGCTACGCCG CGGCGAACGC GTACCTGGAC GGGCTGATGG 51000 CCCACCGGCG CGCGGCCGGC CTGCCGGGCC AGTCGCTGGC GTGGGGGCTG TGGGACCAGA 51060 CCACCGGCGG CATGGCGGCC GGGACCGACG AGGCCGGCCG GGCCCGGATG ACCCGGCGCG 51120 GCGGCCTGGT CGCGATGAAA CCCGCCGCCG GACTGGACCT CTTCGACGCT GCCATCGGGT 51180 CCGGCGAGCC GCTGCTGGTG CCCGCCCAGC TCGACCTGCG GGGCCTGCGC GCCGAAGCGG 51240 CGGGCGGCAC CGAAGTGCCG CACCTGCTGC GCGGCCTGGT CCGCGCCGGA CGCCAGCAGG 51300 CCCGTGCGGC GTCCACTGTG GAGGAGAACT GGGCCGGCCG GCTGGCCGGG CTCGAGCCGG 51360 CCGAGCGGGG CCAGGTCCTC CTGGAACTGG TGCGCGCCCA GGTGGCAGGG GTCCTGGGCT 51420 ACCGCGCCGC CCACCAGGTC GACCCGGACC AGGGCCTGTT CGAGATCGGG TTCGACTCGC 51480 TCACCGCGAT CGAACTCCGC AACCGGCTGC GCGCCAGGAC CGAACGGAAG ATCTCGCCCG 51540 GTGTCGTCTT CGACCATCCC ACGCCGGCCC TGCTCGCCGC GCACTTGAAC GAGCTGCTCC 51600 GAAAGAAGGT GTGAACGTGT TCGACGTGGA GACCTACCTC CAGCGGATCG GCTGCGGCGG 51660 GGAAA,CCGGC GTGGACCTCG AAACGCTGGC GAAGCTGCAG AAGAGCCACC TGATGGCGAT 51720 CCCGTACAGC AGCCTCGCCT ACGAACTCCG GGACGCGGTG AACGTCGTCG ACCTCGACGA 51780 GGACGACGTC TTCGTCACCA GCATCGCCGA AGGGCAGGGC GGCGCCTGCT ACCACCTGAA 51840 CCGGCTGTTC CACCGGCTCC TGACCGAACT CGGCTACGAC GTCACGCCGC TGGCCGGCAG 51900 CACCGCCGAA GGCCGGGAGA CCTTCGGCAC CGACGTCGAG CACATGTTCA ACCTGGTCAC 51960 CCTGGACGGC GCCGACTGGC TCGTGGACGT CGGCTACCCC GGCCCCACCT ACGTCGAGCC 52020 ACTGGCGGTC TCGCCCGCGG TGCAGACCCA GTACGGGAGC CAGTTCCGGT TGGTGGAACA 52080 GGAAACCGGT TATGCGCTGC AACGCCGGGG TGCGGTCACC CGCTGGAGCG TCGTCTACAC 52140 GTTCACGACG CAACCGCGTC AGTGGAGTGA CTGGAAGGAA CTGGAGGACA ACTTCCGGGC 52200 CCTCGTGGGG GACACCACCC GCACCGACAC GCAGGAAACC CTGTGCGGCC GCGCGTTCGC 52260 GAACGGCCAG GTCTTCCTGC GGCAGCGCCG CTACCTGACG GTCGAGAACG GCCGCGAGCA 52320 GGTGCGCACG ATCACCGACG ACGACGAGTT CCGGGCGCTG GTGTCCCGCG TGCTGTCCGG 52380 CGACCACGGC TGAACTGGCG AAAGGCACGA CGATGACGGA AAAAGCGGGC CTGCTGGCGA 52440 AGTTCGCCGG CCTCTGCAAA ACCGCCTACG AGCACCACTA CATCCCGTAC CTGCACTTCT 52..( 0 TCTACGGCGG CGAGTACCTC CACCACGGCA GCGAGCCGGT GTCCCGGATC GCGGACCTGC 52560 CGTACGTGAC CGTGCCGGAG CCGCGGAAGA AGGCGCCGTG AGGACGACGA TCCCGGTCCG 52620 CCTGGCGGAA CGGTCCTACG ACGTGCTCGT CGGCCCCGGG GTGCGGGCGG CGCTGCCCGA 52680 GGTCGTCCGG CGGCTCGGCG CGAGACGGGC CGTGGTCGTG TCGGCCCGGC CGGCGGACTG 52740 GGTGCCCGGC ACCGGCGTCG AGACCCTGCT GCTCCAGGCG CGCGACGGCG AGCCGACCAA 52800 GCGGCTGTCC ACAGTGGAGG AACTGTGCGG TGAGTTCGCG CGGTTCGGGC TCACCCGGTC 52860 CGACGTCGTG GTCTCCTGCG GCGGCGGCAC GACCACGGAC GTCGTCGGGC TCGCGGCCGC 52920 GCTGTACCAC CGGGGGGTCG CCGTGGTCCA CCTGCCCACG TCCCTGCTCG CCCAGGTCGA 52980 CGCCAGCGTC GGCGGGAAGA CCGCGGTGAA CCTGCCGGCG GGCAAGAACC TCGTCGGGGC 53040 GTACTGGCAG CCCAGCGCGG TGCTGTGCGA CACGGACTAC CTGACGACGC TGCCGCGGCG 53100 GGAGGTGCTG AACGGCCTCG GCGAGATCGC CCGCTGCCAC TTCATCGGCG CGCCGGACCT 53160 GCGGGGGCGC TCGCGCCCGG AGCAGATCGC CGCCAGCGTC ACCCTCAAGG CGGGCATCGT 53220 CGCGCAGGAC GAGCGGGACA CCGGCCCGCG GCACCTGCTC AACTACGGCC ACACGCTGGG 53280 GCACGCGCTG GAGATCGCGA CCGGCTTCGC CCTGCGCCAC GGCGAGGCGG TGGCGATCGG 53340 CACGGTCTTC GCGGGCCGGC TGGCCGGCGC GCTCGGCCGC CTCGACCAGT CCGGTGTGGA 53400 CGAACACCTC GCCGTCGTCC GCCACTACGG CCTGCCCGCC GCGCTGCCCG CGGACGTCGA 53460 CCCGGCGGTG CTCGTCCGGC AGATGTACCG GGACAAGAAG GCGATCACCG GGCTCGCCTT 53520 CGTCCTGGCC GGGCCGCGGG GCGCGGAGCT GGTGAGCGAC GTGCCGGCGC CGGTCGTCAC 53580 CGACGTCCTG GACCGGATGC CCCGCGACAG CCTGGAAAAC CTGGTGGGGA CGACGGAAGC 53640 GGCGGCGCCG TGAAGCGGCA GCCGGACTTC GCGGCCCACG GCCGGGCGGT CGACCGGGTG 53700 CTGGCCGGCC GGCTGAGCGC GGCGCTGGCC CGGCCGGCCG CGCAGCAGCC GGGCTGGCCG 53760 GACGCCGAGC GGGCGGCCGA GGTGAATTC 53789 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4572 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Met Phe Tyr Thr Ser Gly Thr Thr Gly Arg Pro Lys Gly Val Val Ser 1 5 10 15 Thr Gin Arg Asn Cys Leu Trp Ser Val Ala Ser Cys Tyr Val Pro Phe 20 25 30 Pro Gly Leu Ser Asp Gin Asp Arg Val Leu Trp Pro Leu Pro Leu Phe 35 40 45 His Ser Leu Ser His lie Ala Cys Val Leu Ser Ala Thr Val Val Gly 50 55 60 Ala Ser Val Arg lie Ala Asp Gly Ser Ser Ala Asp Asp Val Met Arg 65 70 75 80 Leu lie Glu Ala Glu Ser Ser Thr Phe Leu Ala Gly Val Pro Thr Thr 85 90 95 Tyr His His Leu Val Arg Ala Ala Arg Gin Arg Gly Phe Ser Ala Pro 100 105 110 Ser Leu Arg lie Gly Leu Ala Gly Gly Ala Val Leu Gly Ala Gly Leu 115 120 125 Arg Ser Glu Phe Glu Glu Thr Phe Gly Val Pro Leu lie Asp Ala Tyr 130 135 140 Gly Ser Thr Glu Thr Cys Gly Ala lie Thr Met Asn Pro Pro Asp Gly 145 150 155 160 Ala Arg Val Glu Gly Ser Cys Gly Leu Ala Val Pro Gly Val Asp Val 165 170 175 Arg Val Val Asp Pro Asp Thr Gly Leu Asp Val Pro Ala Gly Glu Glu 180 185 190 Gly Glu Val Trp Val Ser Gly Pro Asn Val Met Leu Gly Tyr His Asn 195 200 205 Ser Pro Glu Ala Thr Ala Ala Ala Met Arg Asp Gly Trp Phe Arg Thr 210 215 220 Gly Asp Leu Ala Arg Arg Asp Asp Ala Gly Tyr Phe Thr lie Cys Gly 225 230 235 240 Arg lie Lys Glu Leu lie lie Arg Gly Gly Ala Asn lie His Pro Gly 245 250 255 Glu Val Glu Ala Val Leu Arg Thr Val Asp Gly Val Ala Asp Ala Ala 260 265 270 Val Gly Gly Val Pro His Asp Thr Leu Gly Glu Val Pro Val Ala Tyr 275 280 285 Val lie Pro Gly Pro Thr Gly Phe Asp Pro Ala Ala Leu lie Glu Lys 290 295 300 Cys Arg Glu Gin Leu Ser Ala Tyr Lys Val Pro Asp Arg lie Leu Glu 305 310 315 320 Val Ala His lie Pro Arg Thr Ala Ser Gly Lys lie Arg Arg Gly Leu 325 330 335 Leu Thr Asp Glu Pro Ala Gin Leu Arg Tyr Ala Ala Thr Glu His Glu 340 345 350 Glu Gin Ser Arg His Ala Asp Glu Ser Val Ala Ala Ala Leu Arg Ala 355 360 365 Arg Leu Ser Gly Leu .Asp Glu Arg Ala Gin Cys Glu Leu Leu Glu Asp 370 375 380 Leu Val Arg Thr Gin Ala Ala Asp Val Leu Gly Gin Pro Val Pro Asp 385 390 395 400 Gly Arg Ala Phe Arg Asp Leu Gly Phe Thr Ser Leu Ala lie Val Glu 405 410 415 Leu Arg Asn Arg Leu Thr Glu His Thr Gly Leu Trp Leu Pro Ala Ser 420 425 430 Ala Val Phe Asp His Pro Thr Pro Ala Ala Leu Ala Ala Arg Val Arg 435 440 445 Ala Glu Leu Leu Gly lie Thr Gin Ala Val Ala Glu Pro Val Val Ala 450 455 460 Ala Asp Pro Gly Glu Pro lie Ala lie Val Gly Met Ala Cys Arg Leu 465 470 475 480 Pro Gly Gly Val Ala Ser Pro Glu Asp Leu Trp Arg Leu Val Ala Glu 485 490 495 Arg Val Asp Ala Val Ser Glu Phe Pro Gly Asp Arg Gly Trp Asp Leu 500 505 510 Asp Ser Leu lie Asp Pro Asp Arg Glu Arg Ala Gly Thr Ser Tyr Val 515 520 525 Gly Gin Gly Gly Phe Leu His Asp Ala Gly Glu Phe Asp Ala Gly Phe 530 535 540 Phe Gly lie Ser Pro Arg Glu Ala Val Ala Met Asp Pro Gin Gin Arg 545 550 555 560 Leu Leu Leu Glu Thr Ser Trp Glu Ala Leu Glu Asn Ala Gly Val Asp 565 570 575 Pro lie Ala Leu Lys Gly Thr Asp Thr Gly Val Phe Ser Gly Leu Met 580 585 590 Gly Gin Gly Tyr Gly Ser Gly Ala Val Ala Pro Glu Leu Glu Gly Phe 595 600 605 Val Thr Thr Gly Val Ala Ser Ser Val Ala Ser Gly Arg Val Ser Tyr 610 615 620 Val Leu Gly Leu Glu Gly Pro Ala Val Thr Val Asp Thr Ala Cys Ser 625 630 635 640 Ser Ser Leu Val Ala Met His Leu Ala Ala Gin Ala Leu Arg Gin Gly 645 650 655 Glu Cys Ser Met Ala Leu Ala Gly Gly Val Thr Val Met Ala Thr Pro 660 665 670 Gly Ser Phe Val Glu Phe Ser Arg Gin Arg Ala Leu Ala Pro Asp Gly 675 680 685 Arg Cys Lys Ala Phe Ala Ala Ala Ala Asp Gly Thr Gly Trp Ser Glu 690 695 700 Gly Val Gly Val Val Val Leu Glu Arg Leu Ser Val Ala Arg Glu Arg 705 710 715 720 Gly His Arg He Leu Ala Val Leu Arg Gly Ser Ala Val Asn Gin Asp 725 730 735 Gly Ala Ser Asn Gly Leu Thr Ma Pro Asn Gly Leu Ser Gin Gin Arg 740 745 750 Val He Arg Arg Ma Leu Ma Ma Ma Gly Leu Ma Pro Ser Asp Val 755 760 765 Asp Val Val Glu Ma His Gly Thr Gly Thr Thr Leu Gly Asp Pro He 770 775 780 Glu Ma Gin Ma Leu Leu Ma Thr Tyr Gly Gin Glu Arg Lys Gin Pro 785 790 795 800 Leu Trp Leu Gly Ser Leu Lys Ser Asn He Gly His Ma Gin Ala Ma 805 810 815 Ma Gly Val Ma Gly Val He Lys Met Val Gin Ma Leu Arg His Glu 820 825 830 Thr Leu Pro Pro Thr Leu His Val Asp Lys Pro Thr Leu Glu Val Asp 835 840 845 Trp Ser Ma Gly Ma He Glu Leu Leu Thr Glu Ma Arg Ma Trp Pro 850 855 860 Arg Asn Gly Arg Pro Arg Arg Ma Gly Val Ser Ser Phe Gly Val Ser 865 870 875 880 Gly Thr Asn Ma His Leu He Leu Glu Glu Ma Pro Ma Glu Glu Pro 885 890 895 Val Ma Ma Pro Glu Leu Pro Val Val Pro Leu Val Val Ser Ma Arg 900 905 910 Ser Thr Glu Ser Leu Ser Gly Gin Ma Glu Arg Leu Ma Ser Leu Leu 915 920 925 Glu Gly Asp Val Ser Leu Thr Glu Val Ma Gly Ma Leu Val Ser Arg 930 935 940 Arg Ma Val Leu Asp Glu Arg Ma Val Val Val Ma Gly Ser Arg Glu 945 950 955 960 Glu Ma Val Thr Gly Leu Arg Ma Leu Asn Thr Ma Gly Ser Gly Thr 965 970 975 Pro Gly Lys Val Val Trp Val Phe Pro Gly Gin Gly Thr Gin Trp Ma 980 985 990 Gly Met Gly Arg Glu Leu Leu Ma Glu Ser Pro Val Phe Ma Glu Arg 995 1000 1005 He Ma Glu Cys Ma Ma Ma Leu Ma Pro Trp He Asp Trp Ser Leu 1010 1015 1020 Val Asp Val Leu Arg Gly Glu Gly Asp Leu Gly Arg Val Asp Val Leu 1025 1030 1035 1040 Gin Pro Ma Cys Phe Ma Val Met Val Gly Leu Ma Ma Val Trp Glu 1045 1050 1055 Ser Val Gly Val Arg Pro Asp Ma Val Val Gly His Ser Gin Gly Glu 1060 1065 1070 He Ma Ma Ma Cys Val Ser Gly Ma Leu Ser Leu Glu Asp Ma Ma 1075 1080 1085 Lys Val Val Ma Leu Arg Ser Gin Ma He Ma Ma Glu Leu Ser Gly 1090 1095 1100 Arg Gly Gly Met Ma Ser Val Ma Leu Gly Glu Asp Asp Val Val Ser 1105 1110 1115 1120 Arg Leu Val Asp Gly Val Glu Val Ma Ma Val Asn Gly Pro Ser Ser 1125 1130 1135 Val Val He Ma Gly Asp Ma His Ma Leu Asp Ma Thr Leu Glu He 1140 1145 1150 Leu Ser Gly Glu Gly He Arg Val Arg Arg Val Ma Val Asp Tyr Ma 1155 1160 1165 Ser His Thr Arg His Val Glu Asp He Arg Asp Thr Leu Ala Glu Thr 1170 1175 1180 Leu Ma Gly He Ser Ma Gin Ma Pro Ma Val Pro Phe Tyr Ser Thr 1185 1190 1195 1200 Val Thr Ser Glu Trp Val Arg Asp Ma Gly Val Leu Asp Gly Gly Tyr 1205 1210 1215 Trp Tyr Arg Asn Leu Arg Asn Gin Val Arg Phe Gly Ma Ala Ma Thr 1220 1225 1230 Ma Leu Leu Glu Gin Gly His Thr Val Phe Val Glu Val Ser Ma His 1235 1240 1245 Pro Val Thr Val Gin Pro Leu Ser Glu Leu Thr Gly Asp Ma He Gly 1250 1255 1260 Thr Leu Arg Arg Glu Asp Gly Gly Leu Arg Arg Leu Leu Ma Ser Met 1265 1270 1275 1280 Gly Glu Leu Phe Val Arg Gly He Asp Val Asp Trp Thr Ma Met Val 1285 1290 1295 Pro Ma Ma Gly Trp Val Asp Leu Pro Thr Tyr Ma Phe Glu His Arg 1300 1305 1310 His Tyr Trp Leu Glu Pro Ma Glu Pro Ma Ser Ma Gly Asp Pro Leu 1315 1320 1325 Leu Gly Thr Val Val Ser Thr Pro Gly Ser Asp Arg Leu Thr Ma Val 1330 1335 1340 Ma Gin Trp Ser Arg Arg Ma Gin Pro Trp Ma Val Asp Gly Leu Val 1345 1350 1355 1360 Pro Asn Ma Ma Leu Val Glu Ma Ma He Arg Leu Gly Asp Leu Ma 1365 1370 1375 Gly Thr Pro Val Val Gly Glu Leu Val Val Asp Ma Pro Val Val Leu 1330 1385 1390 Pro Arg Arg Gly Ser Arg Glu Val Gin Leu He Val Gly Glu Pro Gly 1395 1400 1405 Glu Gin Arg Arg Arg Pro He Glu Val Phe Ser Arg Glu Ma Asp Glu 1410 1415 1420 Pro Trp Thr Arg His Ma His Gly Thr Leu Ma Pro Ma Ma Ma Ma 1425 1430 1435 1440 Val Pro Glu Pro Ma Ma Ma Gly Asp Ma Thr Asp Val Thr Val Ala 1445 1450 1455 Gly Leu Arg Asp Ma Asp Arg Tyr Gly He His Pro Ma Leu Leu Asp 1460 1465 1470 Ma Ma Val Arg Thr Val Val Gly Asp Asp Leu Leu Pro Ser Val Trp 1475 1480 1485 Thr Gly Val Ser Leu Leu Ma Ser Gly Ma Thr Ma Val Thr Val Thr 1490 1495 1500 Pro Thr Ma Thr Gly Leu Arg Leu Thr Asp Pro Ma Gly Gin Pro Val 1505 1510 1515 1520 Leu Thr Val Glu Ser Val Arg Gly Thr Pro Phe Val Ma Glu Gin Gly 1525 1530 1535 Thr Thr Asp Ma Leu Phe Arg Val Asp Trp Pro Glu He Pro Leu Pro 1540 1545 1550 Thr Ma Glu Thr Ma Asp Phe Leu Pro Tyr Glu Ma Thr Ser Ma Glu 1555 1560 1565 Ma Thr Leu Ser Ma Leu Gin Ma Trp Leu Ma Asp Pro Ma Glu Thr 1570 1575 1580 Arg Leu Ma Val Val Thr Gly Asp Cys Thr Glu Pro Gly Ma Ma Ma 1585 1590 1595 1600 He Trp Gly Leu Val Arg Ser Ma Gin Ser Glu His Pro Gly Arg He 1605 1610 1615 Val Leu Ma Asp Leu Asp Asp Pro Ma Val Leu Pro Ma Val Val Ma 1620 1625 1630 Ser Gly Glu Pro Gin Val Arg Val Arg Asn Gly Val Ma Ser Val Pro 1635 1640 1645 Arg Leu Thr Arg Val Thr Pro Arg Gin Asp Ma Arg Pro Leu Asp Pro 1650 1655 1660 Glu Gly Thr Val Leu He Thr Gly Gly Thr Gly Thr Leu Gly Ma Leu 1665 1670 1675 1680 Thr Ma Arg His Leu Val Thr Ma His Gly Val Arg His Leu Val Leu 1685 1690 1695 Val Ser Arg Arg Gly Glu Ma Pro Glu Leu Gin Glu Glu Leu Thr Ma 1700 1705 1710 Leu Gly Ma Ser Val Ma He Ma Ma Cys Asp Val Ma Asp Arg Ma 1715 1720 1725 Gin Leu Glu Ma Val Leu Arg Ma He Pro Ma Glu His Pro Leu Thr 1730 1735 1740 Ma Val He His Thr Ma Gly Val Leu Asp Asp Gly Val Val Thr Glu 1745 1750 1755 1760 Leu Thr Pro Asp Arg Leu Ma Thr Val Arg Arg Pro Lys Val Asp Ma 1765 1770 1775 Ma Arg Leu Leu Asp Glu Leu Thr Arg Glu Ma Asp Leu Ma Ma Phe 1780 1785 1790 Val Leu Phe Ser Ser Ma Ma Gly Val Leu Gly Asn Pro Gly Gin Ma 1795 1800 1805 Gly Tyr Ma Ma Ma Asn Ma Glu Leu Asp Ma Leu Ma Arg Gin Arg 1810 1815 1820 Asn Ser Leu Asp Leu Pro Ma Val Ser He Ma Trp Gly Tyr Trp Ma 1825 1830 1835 1840 Thr Val Ser Gly Met Thr Glu His Leu Gly Asp Ma Asp Leu Arg Arg 1845 1850 1855 Asn Gin Arg He Gly Met Ser Gly Leu Pro Ma Asp Glu Gly Met Ma 1860 1865 1870 Leu Leu Asp Ma Ma He Ma Thr Gly Gly Thr Leu Val Ma Ma Lys 1875 1880 1885 Phe Asp Val Ma Ma Leu Arg Ma Thr Ma Lys Ma Gly Gly Pro Val 1890 1895 1900 Pro Pro Leu Leu Arg Gly Leu Ma Pro Leu Pro Arg Arg Ma Ma Ma 1905 1910 1915 1920 Lys Thr Ma Ser Leu Thr Glu Arg Leu Ma Gly Leu Ma Glu Thr Glu 1925 1930 1935 Gin Ma Ma Ma Leu Leu Asp Leu Val Arg Arg His Ma Ma Glu Val 1940 1945 1950 Leu Gly His Ser Gly Ma Glu Ser Val His Ser Gly Arg Thr Phe Lys 1955 1960 1965 Asp Ma Gly Phe Asp Ser Leu Thr Ma Val Glu Leu Arg Asn Arg Leu 1970 1975 1980 Ma Ma Ma Thr Gly Leu Thr Leu Ser Pro Ma Met He Phe Asp Tyr 1985 1990 1995 2000 Pro Lys Pro Pro Ala Leu Ma Asp His Leu Arg Ma Lys Leu Phe Gly 2005 2010 2015 Ser Ma Ma Asn Arg Pro Ma Glu He Gly Thr Ma Ma Ma Glu Glu 2020 2025 2030 Pro He Ma He Val Ma Met Ma Cys Arg Phe Pro Gly Gly Val His 2035 2040 2045 Ser Pro Glu Asp Leu Trp Arg Leu Val Ma Asp Gly Ma Asp Ma Val 2050 2055 2060 Thr Glu Phe Pro Ma Asp Arg Gly Trp Asp Thr Asp Arg Leu Tyr His 2065 2070 2075 2080 Glu Asp Pro Asp His Glu Gly Thr Thr Tyr Val Arg His Gly Ma Phe 2085 2090 2095 Leu Asp Asp Ala Ma Gly Phe Asp Ma Ma Phe Phe Gly He Ser Pro 2100 2105 2110 Asn Glu Ma Leu Ma Met Asp Pro Gin Gin Arg Leu Leu Leu Glu Thr 2115 2120 2125 Ser Trp Glu Leu Phe Glu Arg Ala Ala He Asp Pro Thr Thr Leu Ma 2130 2135 2140 Gly Gin Asp He Gly Val Phe Ala Gly Val Asn Ser His Asp Tyr Ser 2145 2150 2155 2160 Met Arg Met His Arg Ma Ma Gly Val Glu Gly Phe Arg Leu Thr Gly 2165 2170 2175 Gly Ser Ma Ser Val Leu Ser Gly Arg Val Ma Tyr His Phe Gly Val 2180 2185 2190 Glu Gly Pro Ma Val Thr Val Asp Thr Ma Cys Ser Ser Ser Leu Val 2195 2200 2205 Ala Leu His Met Ma Val Gin Ma Leu Gin Arg Gly Glu Cys Ser Met 2210 2215 2220 Ma Leu Ma Gly Gly Val Met Val Met Gly Thr Val Glu Thr Phe Val 2225 2230 2235 2240 Glu Phe Ser Arg Gin Arg Gly Leu Ma Pro Asp Gly Arg Cys Lys Ma 2245 2250 2255 Phe Ma Asp Gly Ma Asp Gly Thr Gly Trp Ser Glu Gly Val Gly Leu 2260 2265 2270 Leu Leu Val Glu Arg Leu Ser Glu Ma Gin Arg Arg Gly His Gin Val 2275 2280 2285 Leu Ma Val Val Arg Gly Ser Ma Val Asn Ser Asp Gly Ma Ser Asn 2290 2295 2300 Gly Leu Thr Ma Pro Asn Gly Pro Ser Gin Gin Arg Val He Arg Lys 2305 2310 2315 2320 Ma Leu Ma Ma Ma Gly Leu Ser Thr Ser Ajsp Val Asp Ma Val Glu 2325 2330 2335 Ma His Gly Thr Gly Thr Thr Leu Gly Asp Pro He Glu Ma Glu Ma 2340 2345 2350 Leu Leu Ma Thr Tyr Gly Gin Asn Arg Glu Thr Pro Leu Trp Leu Gly 2355 2360 2365 Ser Val Lys Ser Asn Leu Gly His Thr Gin Ma Ma Ma Gly Val Ma 2370 2375 2380 Gly Val He Lys Met Val Met Ma Met Arg His Gly Val Leu Pro Arg 2385 2390 2395 2400 Thr Leu His Val Asp Arg Pro Ser Ser Tyr Val Asp Trp Ser Ma Gly 2405 2410 2415 Ala Val Glu Leu Leu Thr Glu Ma Arg Asp Trp Val Ser Asn Gly His 2420 2425 2430 Pro Arg Arg Ma Gly Val Ser Ser Phe Gly He Gly Gly Thr Asn Ma 2435 2440 2445 His Val Val Leu Glu Glu Val Ma Ma Pro He Thr Thr Pro Gin Pro 2450 2455 2460 Glu Pro Ma Glu Phe Leu Val Pro Val Leu Val Ser Ma Arg Thr Ma 2465 2470 2475 2480 Ma Gly Leu Arg Gly Gin Ma Gly Arg Leu Ma Ma Phe Leu Gly Asp 2485 2490 2495 Arg Thr Asp Val Arg Val Pro Asp Ma Ma Tyr Ma Leu Ma Thr Thr 2500 2505 2510 Arg Ma Gin Leu Asp His Arg Ma Val Val Leu Ma Ser Asp Arg Ma 2515 2520 2525 Gin Leu Cys Ma Asp Leu Ma Ma Phe Gly Ser Gly Val Val Thr Gly 2530 2535 2540 Thr Pro Val Asp Gly Lys Leu Ma Val Leu Phe Thr Gly Gin Gly Ser 2545 2550 2555 2560 Gin Trp Ma Gly Met Gly Arg Glu Leu Ma Glu Thr Phe Pro Val Phe 2565 2570 2575 Arg Asp Ma Phe Glu Ma Ma Cys Glu Ma Val Asp Thr His Leu Arg 2580 2585 2590 Glu Arg Pro Leu Arg Glu Val Val Phe Asp Asp Ser Ma Leu Leu Asp 2595 2600 2605 Gin Thr Met Tyr Thr Gin Gly Ma Leu Phe Ma Val Glu Thr Ma Leu 2610 2615 2620 Phe Arg Leu Phe Glu Ser Trp Gly Val Arg Pro Gly Leu Leu Ma Gly 2625 2630 2635 2640 His Ser He Gly Glu Leu Ma Ma Ma His Val Ser Gly Val Leu Asp 2645 2650 2655 Leu Ma Asp Ma Gly Glu Leu Val Ma Ma Arg Gly Arg Leu Met Gin 2660 2665 2670 Ma Leu Pro Ma Gly Gly Ma Met Val Ma Val Gin Ma Thr Glu Asp 2675 2680 2685 Glu Val Ma Pro Leu Leu Asp Gly Thr Val Cys Val Ma Ma Val Asn 2690 2695 2700 Gly Pro Asp Ser Val Val Leu Ser Gly Thr Glu Ma Ma Val Leu Ma 2705 2710 2715 2720 Val Ma Asp Glu Leu Ma Gly Arg Gly Arg Lys Thr Arg Arg Leu Ma 2725 2730 2735 Val Ser His Ma Phe His Ser Pro Leu Met Glu Pro Met Leu Asp Asp 2740 2745 2750 Phe Arg Ma Val Ma Glu Arg Leu Thr Tyr Arg Ma Gly Ser Leu Pro 2755 2760 2765 Val Val Ser Thr Leu Thr Gly Glu Leu Ma Ma Leu Asp Ser Pro Asp 2770 2775 2780 Tyr Trp Val Gly Gin Val Arg Asn Ma Val Arg Phe Ser Asp Ma Val 2785 2790 2795 2800 Thr Ma Leu Gly Ma Gin Gly Ma Ser Thr Phe Leu Glu Leu Gly Pro 2805 2810 2815 Gly Gly Ma Leu Ma Ala Met Ma Leu Gly Thr Leu Gly Gly Pro Glu 2820 2825 2830 Gin Ser Cys Val Ma Thr Leu Arg Lys Asn Gly Ma Glu Val Pro Asp 2835 2840 2845 Val Leu Thr Ma Leu Ma Glu Leu His Val Arg Gly Val Gly Val Asp 2850 2855 2860 Trp Thr Thr Val Leu Asp Glu Pro Ma Thr Ma Val Gly Thr Val Leu 2865 2870 2875 2880 Pro Thr Tyr Ma Phe Gin His Gin Arg Phe Trp Val Asp Val Asp Glu 2885 2890 2895 Thr Ma Ma Val Ser Val Thr Pro Pro Pro Ma Glu Pro He Val Asp 2900 2905 2910 Arg Pro Val Gin Asp Val Leu Glu Leu Val Arg Glu Ser Ma Ma Val 2915 2920 2925 Val Leu Gly His Arg Asp Ma Gly Ser Phe Asp Leu Asp Arg Ser Phe 2930 2935 2940 Lys Asp His Gly Phe Asp Ser Leu Ser Ma Val Lys Leu Arg Asn Arg ■ 2945 2950 2955 2960 Leu Arg Asp Phe Thr Gly Val Glu Leu Pro Ser Thr Leu He Phe Asp 2965 2970 2975 Tyr Pro Asn Pro Ma Val Leu Ma Asp His Leu Arg Ma Glu Leu Leu 2980 2985 2990 Gly Glu Arg Pro Ma Ma Pro Ma Pro Val Thr Arg Asp Val Ser Asp 2995 3000 3005 Glu Pro He Ma He Val Gly Met Ser Thr Arg Leu Pro Gly Gly Ma 3010 3015 3020 Asp Ser Pro Glu Glu Leu Trp Lys Leu Val Ma Glu Gly Arg Asp Ma 3025 3030 3035 3040 Val Ser Gly Phe Pro Val Asp Arg Gly Trp Asp Leu Asp Gly Leu Tyr 3045 3050 3055 His Pro Asp Pro Ma His Ma Gly Thr Ser Tyr Thr Arg Ser Gly Gly 3060 3065 3070 Phe Leu His Asp Ma Ma Gin Phe Asp Ma Gly Leu Phe Gly He Ser 3075 3080 3085 Pro Arg Glu Ma Leu Ma Met Asp Pro Gin Gin Arg Leu Leu Leu Glu 3090 3095 3100 Thr Ser Trp Glu Ma Leu Glu Arg Ma Gly Val Asp Pro Leu Ser Ma 3105 3110 3115 3120 Arg Gly Ser Asp Val Gly Val Phe Thr Gly He Val His His Asp Tyr 3125 3130 3135 Val Thr Arg Leu Arg Glu Val Pro Glu Asp Val Gin Gly Tyr Thr Met 3140 3145 3150 Thr Gly Thr Ma Ser Ser Val Ma Ser Gly Arg Val Ma Tyr Val Phe 3155 3160 3165 Gly Phe Glu Gly Pro Ma Val Thr Val Asp Thr Ma Cys Ser Ser Ser 3170 3175 3180 Leu Val Ma Met His Leu Ma Ma Gin Ma Leu Arg Gin Gly Glu Cys 3185 3190 3195 3200 Ser Met Ma Leu Ma Gly Gly Ma Thr Val Met Ma Ser Pro Asp Ma 3205 3210 3215 Phe Leu Glu Phe Ser Arg Gin Arg Gly Leu Ser Ma Asp Gly Arg Cys 3220 3225 3230 Lys Ala Tyr Ma Glu Gly Ma Asp Gly Thr Gly Trp Ma Glu Gly Val 3235 3240 3245 Gly Val Val Val Leu Glu Arg Leu Ser Val Ma Arg Glu Arg Gly His 3250 3255 3260 Arg Val Leu Ma Val Leu Arg Gly Ser Ma Val Asn Gin Asp Gly Ma 3265 3270 3275 3280 Ser Asn Gly Leu Thr Ma Pro Asn Gly Pro Ser Gin Gin Arg Val He 3285 3290 3295 Arg Gly Ma Leu Ma Ser Ma Gly Leu Ma Pro Ser Asp Val Asp Val 3300 3305 3310 Val Glu Gly His Gly Thr Gly Thr Ma Leu Gly Asp Pro He Glu Val 3315 3320 3325 Gin Ma Leu Leu Ma Thr Tyr Gly Gin Glu Arg Glu Gin Pro Leu Trp 3330 3335 3340 Leu Gly Ser Leu Lys Ser Asn Leu Gly His Thr Gin Ma Ma Ma Gly 3345 3350 3355 3360 Val Val Gly Val He Lys Met He Met Ma Met Arg His Gly Val Met 3365 3370 3375 Pro Ma Thr Leu His Val .Asp Glu Arg Thr Ser Gin Val Asp Trp Ser 3380 3385 3390 Ma Gly Ala He Glu Val Leu Thr Glu Ma Arg Glu Trp Pro Arg Thr 3395 3400 3405 Gly Arg Pro Arg Arg Ma Gly Val Ser Ser Phe Gly Ma Ser Gly Thr 3410 3415 3420 Asn Ma His Leu He He Glu Glu Gly Pro Ma Glu Glu Ma Val Asp 3425 3430 3435 3440 Glu Glu Val Ma Ser Val Val Pro Leu Val Val Ser Ma Arg Ser Ma 3445 3450 3455 Gly Ser Leu Ma Gly Gin Ma Gly Arg Leu Ma Ma Val Leu Glu Asn 3460 3465 3470 Glu Ser Leu Ma Gly Val Ma Gly Ma Leu Val Ser Gly Arg Ma Thr 3475 3480 3485 Leu Asn Glu Arg Ma Val Val He Ma Gly Ser Arg Asp Glu Ma Gin 3490 3495 3500 Asp Gly Leu Gin Ma Leu Ma Arg Gly Glu Asn Ma Pro Gly Val Val 3505 3510 3515 3520 Thr Gly Thr Ma Gly Lys Pro Gly Lys Val Val Trp Val Phe Pro Gly 3525 3530 3535 Gin Gly Ser Gin Trp Met Gly Met Gly Arg Asp Leu Leu Asp Ser Ser 3540 3545 3550 Pro Val Phe Ma Ma Arg He Lys Glu Cys Ma Ma Ma Leu Glu Gin 3555 3560 3565 Trp Thr Asp Trp Ser Leu Leu Asp Val Leu Arg Gly Asp Ala Asp Leu 3570 3575 3580 Leu Asp Arg Val Asp Val Val Gin Pro Ma Ser Phe Ma Met Met Val 3585 3590 3595 3600 Gly Leu Ma Ma Val Trp Thr Ser Leu Gly Val Thr Pro Asp Ma Val 3605 3610 3615 Leu Gly His Ser Gin Gly Glu He Ma Ma Ala Cys Val Ser Gly Ma 3620 3625 3630 Leu Ser Leu Asp Asp Ala Ma Lys Val Val Ma Leu Arg Ser Gin Ma 3635 3640 3645 He Ala Gly Glu Leu Ma Gly Arg Gly Gly Met Ma Ser Val Ma Leu 3650 3655 3660 Ser Glu Glu Asp Ma Val Ma Arg Leu Thr Pro Trp Ma Asn Arg Val 3665 3670 3675 3680 Glu Val Ala Ma Val Asn Ser Pro Ser Ser Val Val He Ma Gly Asp 3685 3690 3695 Ala Gin Ma Leu Asp Glu Ma Leu Glu Ma Leu Ala Gly Asp Gly Val 3700 3705 3710 Arg Val Arg Arg Val Ma Val Asp Tyr Ma Ser His Thr Arg His Val 3715 3720 3725 Glu Ma He Ma Glu Thr Leu Ma Lys Thr Leu Ma Gly He Asp Ma 3730 3735 3740 Arg Val Pro Ma He Pro Phe Tyr Ser Thr Val Leu Gly Thr Trp He 3745 3750 3755 3760 Glu Gin Ala Val Val Asp Ma Gly Tyr Trp Tyr Arg Asn Leu Arg Gin 3765 3770 3775 Gin Val Arg Phe Gly Pro Ser Val Ma Asp Leu Ala Gly Leu Gly His 3780 37S5 3790 Thr Val Phe Val Glu He Ser Ma His Pro Val Leu Val Gin Pro Leu 3795 3800 3805 Ser Glu He Ser Asp Asp Ma Val Val Thr Gly Ser Leu Arg Arg Asp 3810 3815 3820 Asp Gly Gly Leu Arg Arg Leu Leu Ma Ser Ma Ma Glu Leu Tyr Val 3825 3830 3835 3840 Arg Gly Val Ma Val Asp Trp Thr Ma Ma Val Pro Ma Ma Gly Trp 3845 3850 3855 Val Asp Leu Pro Thr Tyr Ma Phe Asp Arg Arg His Phe Trp Leu His 3860 3865 3870 Glu Ma Glu Thr Ala Glu Ma Ma Glu Gly Met Asp Gly Glu Phe Trp 3875 3880 3885 Thr Ma He Glu Gin Ser Asp Val Asp Ser Leu Ma Glu Leu Leu Glu 3890 3895 3900 Leu Val Pro Glu Gin Arg Gly Ma Leu Ser Thr Val Val Pro Val Leu 3905 3910 3915 3920 Ma Gin Trp Arg Asp Arg Arg Arg Glu Arg Ser Thr Ma Glu Lys Leu 3925 3930 3935 Arg Tyr Gin Val Thr Trp Gin Pro Leu Glu Arg Glu Ma Ma Gly Val 3940 3945 3950 Pro Gly Gly Arg Trp Leu Ma Val Val Pro Ma Gly Thr Thr Asp Ma 3955 3960 3965 Leu Leu Lys Glu Leu Thr Gly Gin Gly Leu Asp He Val Arg Leu Glu 3970 3975 3980 He Glu Glu Ma Ser Arg Ma Gin Leu Ala Glu Gin Leu Arg Asn Val 3985 3990 3995 4000 Leu Ma Glu His Asp Leu Thr Gly Val Leu Ser Leu Leu Ma Leu Asp 4005 4010 4015 Gly Gly Pro Ala Asp Ma Ala Glu He Thr Ma Ser Thr Leu Ma Leu 4020 4025 4030 Val Gin Ma Leu Gly Asp Thr Thr Thr Ser Ma Pro Leu Trp Cys Leu 4035 4040 4045 Thr Ser Gly Ma Val Asn He Gly He Gin Asp Ma Val Thr Ala Pro 4050 4055 4060 Ma Gin Ma Ma Val Trp Gly Leu Gly Arg Ma Val Ma Leu Glu Arg 4065 4070 4075 4080 Leu Asp Arg Trp Gly Gly Leu Val Asp Leu Pro Ma Ma He Asp Ma 4085 4090 4095 Arg Thr Ala Gin Ma Leu Leu Gly Val Leu Asn Gly Ma Ma Gly Glu 4100 4105 4110 Asp Gin Leu Ma Val Arg Arg Ser Gly Val Tyr Arg Arg Arg Leu Val 4115 4120 4125 Arg Lys Pro Val Pro Glu Ser Ma Thr Ser Arg Trp Glu Pro Arg Gly 4130 4135 4140 Thr Val Leu Val Thr Gly Gly Ma Glu Gly Leu Gly Arg His Ala Ser 4145 4150 4155 4160 Val Trp Leu Ma Gin Ser Gly Ala Glu Arg Leu He Val Thr Gly Thr 4165 4170 4175 Asp Gly Val Asp Glu Leu Thr Ma Glu Leu Ma Glu Phe Gly Thr Thr 4180 4185 4190 Val Glu Phe Cys Ma Asp Thr Asp Arg Asp Ma He Ma Gin Leu Val 4195 4200 4205 Ma Asp Ser Glu Val Thr Ma Val Val His Ma Ma Asp He Ma Gin 4210 4215 4220 Thr Ser Ser Val Asp Asp Thr Gly Val Ma Asp Leu Asp Glu Val Phe 4225 4230 4235 4240 Ma Ma Lys Val Thr Thr Ma Val Trp Leu Asp Gin Leu Phe Glu Asp 4245 4250 4255 Thr Pro Leu Asp Ma Phe Val Val Phe Ser Ser He Ma Gly He Trp 4260 4265 4270 Gly Gly Gly Gly Gin Gly Pro Ma Gly Ma Ma Asn Ma Val Leu Asp 4275 4280 4285 Ma Leu Val Glu Trp Arg Arg Ma Arg Gly Leu Lys Ma Thr Ser He 4290 4295 4300 Ma Trp Gly Ma Leu Asp Gin He Gly He Gly Met Asp Glu Ma Ma 4305 4310 4315 4320 Leu Ma Gin Leu Arg Arg Arg Gly Val He Pro Met Ma Pro Pro Leu 4325 4330 4335 Ma Val Thr Ma Met Val Gin Ma Val Ma Gly Asn Glu Lys Ma Val 4340 4345 4350 Ma Val Ma Asp Met Asp Trp Ma Ma Phe He Pro Ma Phe Thr Ser 4355 4360 4365 Val Arg Pro Ser Pro Leu Phe Ala Asp Leu Pro Glu Ala Lys Ma He 4370 4375 4380 Leu Arg Ma Ma Gin Asp Asp Gly Glu Asp Gly Asp Thr Ma Ser Ser 4385 4390 4395 4400 Leu Ma Asp Ser Leu Arg Ala Val Pro Asp Ma Glu Gin Asn Arg He 4405 4410 4415 Leu Leu Lys Leu Val Arg Gly His Ma Ser Thr Val Leu Gly His Ser 4420 4425 4430 Gly Ma Glu Gly He Gly Pro Arg Gin Ma Phe Gin Glu Val Gly Phe 4435 4440 4445 Asp Ser Leu Ma Ma Val Asn Leu Arg Asn Ser Leu His Ma Ma Thr 4450 4455 4460 Gly Leu Arg Leu Pro Ma Thr Leu He Phe Asp Tyr Pro Thr Pro Glu 4465 4470 4475 4480 Ma Leu Val Gly Tyr Leu Arg Val Glu Leu Leu Arg Glu Ma Asp Asp 4485 4490 4495 Gly Leu Asp Gly Arg Glu Asp Asp Leu Arg Arg Val Leu Ma Ma Val 4500 4505 4510 Pro Phe Ma Arg Phe Lys Glu Ma Gly Val Leu Asp Thr Leu Leu Gly 4515 4520 4525 Leu Ma Asp Thr Gly Thr Glu Pro Gly Thr Asp Ma Glu Thr Thr Glu 4530 4535 4540 Ma Ala Pro Ma Ala Asp Asp Ma Glu Leu He Asp Ma Leu Asp He 4545 4550 4555 4560 Ser Gly Leu Val Gin Arg Ma Leu Gly Gin Thr Ser 4565 4570 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5069 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: Met Ma Asn Gin Ser Trp Arg Lys Asn Met Ser Ma Pro Asn Glu Gin 1 5 10 15 He Val Asp Ma Leu Arg Ma Ser Leu Lys Glu Asn Val Arg Leu Gin 20 25 30 Gin Glu Asn Ser Ma Leu Ma Ala Ma Ma Ala Glu Pro Val Ma He 35 40 45 Val Ser Met Ma Cys Arg Tyr Ma Gly Gly He Arg Gly Pro Glu Asp 50 55 60 Phe Trp Arg Val Val Ser Glu Gly Ma Asp Val Tyr Thr Gly Phe Pro 65 70 75 80 Glu Asp Arg Gly Trp Asp Val Glu Gly Leu Tyr His Pro Asp Pro Asp 85 90 95 Asn Pro Gly Thr Thr Tyr Val Arg Glu Gly Ma Phe Leu Gin Asp Ma 100 105 110 Ma Gin Phe Asp Ma Gly Phe Phe Gly He Ser Pro Arg Glu Ma Leu 115 120 125 Ala Met Asp Pro Gin Gin Arg Gin Leu Leu Glu Val Ser Trp Glu Thr 130 135 140 Leu Glu Arg Ma Gly He Asp Pro His Ser Val Arg Gly Ser Asp He 145 150 155 160 Gly Val Tyr Ma Gly Val Val His Gin jf * sp Tyr Ma Pro Asp Leu Ser 165 170 175 Gly Phe Glu Gly Phe Met Ser Leu Glu Arg Ma Leu Gly Thr Ma Gly 180 185 190 Gly Val Ala Ser Gly Arg Val Ala Tyr Thr Leu Gly Leu Glu Gly Pro 195 200 205 Ma Val Thr Val Asp Thr Met Cys Ser Ser Ser Leu Val Ala He His 210 215 220 Leu Ma Ma Gin Ma Leu Arg Arg Gly Glu Cys Ser Met Ma Leu Ma 225 230 235 240 Gly Gly Ser Thr Val Met Ma Thr Pro Gly Gly Phe Val Gly Phe Ma 245 250 255 Arg Gin Arg Ma Leu Ala Phe Asp Gly Arg Cys Lys Ser Tyr Ma Ma 260 265 270 Ma Ma Asp Gly Ser Gly Trp Ma Glu Gly Val Gly Val Leu Leu Leu 275 280 285 Glu Arg Leu Ser Val Ma Arg Glu Arg Gly His Gin Val Leu Ma Val 290 295 300 He Arg Gly Ser Ma Val Asn Gin Asp Gly Ma Ser Asn Gly Leu Thr 305 310 315 320 Ala Pro Asn Gly Pro Ma Gin Gin Arg Val He Arg Lys Ma Leu Ma 325 330 335 Ser Ala Gly Leu Thr Pro Ser Asp Val Asp Thr Val Glu Gly His Gly 340 345 350 Thr Gly Thr Val Leu Gly Asp Pro He Glu Val Gin Ma Leu Leu Ma 355 360 365 Thr Tyr Gly Gin Gly Arg Asp Pro Gin Gin Pro Leu Trp Leu Gly Ser 370 375 380 Val Lys Ser Val Val Gly His Thr Gin Ala Ma Ser Gly Val Ma Gly 385 390 395 400 Val He Lys Met Val Gin Ser Leu Arg His Gly Gin Leu Pro Ma Thr 405 410 415 Gin His Val Asp Ma Pro Thr Pro Gin Val Asp Trp Ser Ma Gly Ma 420 425 430 He Glu Leu Leu Ma Glu Gly Arg Glu Trp Pro Arg Asn Gly His Pro 435 440 445 Arg Arg Gly Gly He Ser Ser Phe Gly Ma Ser Gly Thr Asn Ma His 450 455 460 Met He Leu Glu Glu Ma Pro Glu Asp Glu Pro Val Thr Glu Ma Pro 465 470 475 480 Ma Pro Thr Gly Val Val Pro Leu Val Val Ser Ma Ma Thr Ma Ma 485 490 495 Ser Leu Ma Ma Gin Ma Gly Arg Leu Ala Glu Val Gly Asp Val Ser 500 505 510 Leu Ma Asp Val Ma Gly Thr Leu Val Ser Gly Arg Ma Met Leu Ser 515 520 525 Glu Arg Ma Val Val Val Ma Gly Ser His Glu Glu Ma Val Thr Gly 530 535 540 Leu Arg Ma Leu Ma Arg Gly Glu Ser Ma Pro Gly Leu Leu Ser Gly 545 550 555 560 Arg Gly Ser Gly Val Pro Gly Lys Val Val Trp Val Phe Pro Gly Gin 565 570 575 Gly Thr Gin Trp Ma Gly Met Gly Arg Glu Leu Leu Asp Ser Ser Glu 580 585 590 Val Phe Ala Ma Arg He Ma Glu Cys Glu Thr Ma Leu Gly Arg Trp 595 600 605 Val Asp Trp Ser Leu Thr Asp Val Leu Arg Gly Glu Ma Asp Leu Leu 610 615 620 Asp Arg Val Asp Val Val Gin Pro Ma Ser Phe Ma Val Met Val Gly 625 630 635 640 Leu Ma Ma Val Trp Ma Ser Leu Gly Val Glu Pro Glu Ma Val Val 645 650 655 Gly His Ser Gin Gly Glu He Ma Ma Ma Cys Val Ser Gly Ma Leu 660 665 670 Ser Leu Glu Asp Ma Ala Lys Val Val Ma Leu Arg Ser Gin Ma He 675 680 685 Ala Ma Ser Leu Ma Gly Arg Gly Gly Met Ma Ser Val Ma Leu Ser 690 695 700 Glu Glu Asp Ma Thr Ala Arg Leu Glu Pro Trp Ma Gly Arg Val Glu 705 710 715 720 Val Ma Ma Val Asn Gly Pro Thr Ser Val Val He Ma Gly Asp Ma 725 730 735 Glu Ma Leu A-sp Glu Ma Leu Asp Ma Leu Asp Asp Gin Gly Val Arg 740 745 750 Ile Arg Arg Val Ma Val Asp Tyr Ma Ser His Thr Arg His Val Glu 755 760 765 Ma Ma Arg Asp Ma Leu Ma Glu Met Leu Gly Gly He Arg Ma Gin 770 775 780 Ma Pro Glu Val Pro Phe Tyr Ser Thr Val Thr Gly Gly Trp Val Glu 785 790 795 800 Asp Ma Gly Val Leu Asp Gly Gly Tyr Trp Tyr Arg Asn Leu Arg Arg 805 810 815 Gin Val Arg Phe Gly Pro Ma Val Ma Glu Leu He Glu Gin Gly His 820 825 830 Arg Val Phe Val Glu Val Ser Ma His Pro Val Leu Val Gin Pro He 835 840 845 Asn Glu Leu Val Asp Asp Thr Glu Ma Val Val Thr Gly Thr Leu Arg 850 855 860 Arg Glu Asp Gly Gly Leu Arg Arg Leu Leu Ma Ser Ala Ma Glu Leu 865 870 875 880 Phe Val Arg Gly Val Thr Val Asp Trp Ser Gly Val Leu Pro Pro Ser 885 890 895 Arg Arg Val Glu Leu Pro Thr Tyr Ma Phe Asp His Gin His Tyr Trp 900 905 910 Leu Gin Met Gly Gly Ser Ma Thr Asp Ma Val Ser Leu Gly Leu Ma 915 920 925 Gly Ma Asp His Pro Leu Leu Gly Ma Val Val Pro Leu Pro Gin Ser 930 935 940 JAS P Gly Leu Val Phe Thr Ser Arg Leu Ser Leu Lys Ser His Pro Trp 945 950 955 960 Leu Ma Gly His Ma He Gly Gly Val Val Leu He Pro Gly Thr Val 965 970 975 Tyr Val Asp Leu Ma Leu Arg Ma Gly Asp Glu Leu Gly Phe Gly Val 980 985 990 Leu Glu Glu Leu Val He Glu Ma Pro Leu Val Leu Gly Glu Arg Gly 995 1000 1005 Gly Val Arg Val Gin Val Ma Val Ser Gly Pro Asn Glu Thr Gly Ser 1010 1015 1020 Arg Ma Val Asp Val Phe Ser Met Arg Glu Asp Gly Asp Glu Trp Thr 1025 1030 1035 1040 Arg His Ala Thr Gly Leu Leu Gly Ma Ser Thr Ser Arg Glu Pro Ser 1045 1050 1055 Arg Phe Asp Phe Ma Ma Trp Pro Pro Ala Gly Ma Glu Pro He Asp 1060 1065 1070 Val Glu Asn Phe Tyr Thr Asp Leu Thr Glu Arg Gly Tyr Ma Tyr Ser 1075 1080 1085 Gly Ma Phe Gin Gly Met Arg Ma Val Trp Arg Arg Gly Asp Glu Val 1090 1095 1100 Phe Ma Glu Val Ma Leu Pro Asp Asp His Arg Glu Asp Ma Gly Lys 1105 1110 1115 1120 Phe Gly Leu His Pro Ma Leu Leu Asp Ma Ma Leu His Thr Asn Ma 1125 1130 1135 Phe Ma Asn Pro Asp Asp Asp Arg Ser Val Leu Pro Phe Ma Trp Asn 1140 1145 1150 Gly Leu Val Leu His Ma Val Gly Ala Ser Ma Leu Arg Val Arg Val 1155 1160 1165 Ma Pro Gly Gly Pro Asp Ma Leu Thr Phe Gin Ma Ma Asp Glu Thr 1170 1175 1180 Gly Gly Leu Val Val Thr Met Asp Ser Leu Val Ser Arg Glu Val Ser 1185 1190 1195 1200 Ma Ma Gin Leu Glu Thr Ma Ma Gly Glu Glu Arg Asp Ser Leu Phe 1205 1210 1215 Gin Val Asp Trp He Glu Val Pro Ma Thr Glu Thr Ma Ma Thr Glu 1220 1225 1230 His Ma Glu Val Leu Glu Ma Phe Gly Glu Ma Ma Pro Leu Glu Leu 1235 1240 1245 Thr Ser Arg Val Leu Glu Ma Val Gin Ser Trp Leu Ma Asp Ma Ma 1250 1255 1260 Asp Glu Ma Arg Leu Val Val Val Thr Arg Gly Ma Val Arg Glu Val 1265 1270 1275 1280 Thr Asp Pro Ma Gly Ma Ma Val Trp Gly Leu Val Arg Ala Ma Gin 1285 1290 1295 Ma Glu Asn Pro Gly Arg He He Leu Val Asp Thr Asp Gly Asp Val 1300 1305 1310 Pro Leu Gly Ma Val Leu Ma Ser Gly Glu Pro Gin Leu Ma Val Arg 1315 1320 1325 Gly Asn Ma Phe Ser Val Pro Arg Leu Ma Arg Ma Thr Gly Glu Val 1330 1335 1340 Pro Glu Ma Pro Ma Val Phe Ser Pro Glu Gly Thr Val Leu Leu Thr 1345 1350 1355 1360 Gly Gly Thr Gly Ser Leu Gly Gly Leu Val Ma Lys His Leu Val Ma 1365 1370 1375 Arg His Gly Val Arg Arg Leu Val Leu Ma Ser Arg Arg Gly Val Ma 1380 1385 1390 Ma Glu Asp Leu Val Thr Glu Leu Thr Glu Gin Gly Ma Thr Val Ser 1395 1400 1405 Val Val Ala Cys Asp Val Ser Asp Arg Asp Gin Val Ma Ala Leu Leu 1410 1415 1420 Ma Glu His Arg Pro Thr Gly He Val His Leu Ma Gly Leu Leu Asp 1425 1430 1435 1440 Asp Gly Val He Gly Ma Leu Asn Arg Glu Arg Leu Ma Gly Val Phe 1445 1450 1455 Ma Pro Lys Val Asp Ma Val Gin His Leu Asp Glu Leu Thr Arg Asp 1460 1465 1470 Leu Gly Leu Asp Ma Phe Val Val Phe Ser Ser Ma Ma Ala Leu Met 1475 1480 1485 Gly Ser Ma Gly Gin Gly Asn Tyr Ma Ma Ma Asn Ala Phe Leu Asp 1490 1495 1500 Gly Leu Met Ma Gly Arg Arg Ma Ma Gly Leu Pro Gly Val Ser Leu 1505 1510 1515 1520 Ala Trp Gly Leu Trp Glu Gin Ma Asp Gly Leu Thr Ma Asn Leu Ser 1525 1530 1535 Ma Thr Asp Gin Ma Arg Met Ser Arg Gly Gly Val Leu Pro Met Thr 1540 1545 1550 Pro Ma Glu Ma Leu Asp He Phe Asp He Gly Leu Ma Ma Glu Gin 1555 1560 1565 Ma Leu Leu Val Pro He Lys Leu Asp Leu Arg Thr Leu Arg Gly Gin 1570 1575 1580 Ma Thr Ma Gly Gly Glu Val Pro His Leu Leu Arg Gly Leu Val Arg 1585 1590 1595 1600 Ma Ser Arg Arg Val Thr Arg Thr Ma Ma Ma Ser Gly Gly Gly Gly 1605 1610 1615 Leu Val His Lys Leu Ma Gly Arg Pro Ma Glu Glu Gin Glu Ma Val 1620 1625 1630 Leu Leu Gly He Val Gin Ma Glu Ma Ma Ma Val Leu Gly Phe Asn 1635 1640 1645 Ma Pro Glu Leu Ma Gin Gly Thr Arg Gly Phe Ser Asp Leu Gly Phe 1650 1655 1660 Asp Ser Leu Thr Ma Val Glu Leu Arg Asn Arg Leu Ser Ma Ma Thr 1665 1670 1675 1680 Gly Vai Lys Leu Pro Ma Thr Leu Val Phe Asp Tyr Pro Thr Pro Val 1685 1690 1695 Ma Leu Ma Arg His Leu Arg Glu Glu Leu Gly Glu Thr Val Ma Gly 1700 1705 1710 Ma Pro Ala Thr Pro Val Thr Thr Val Ma Asp Ma Gly Glu Pro He 1715 1720 1725 Ma He Val Gly Met Ma Cys Arg Leu Pro Gly Gly Val Met Ser Pro 1730 1735 1740 Asp Asp Leu Trp Arg Met Val Ma Glu Gly Arg Asp Gly Met Ser Pro 1745 1750 1755 1760 Phe Pro Gly Asp Arg Gly Trp Asp Leu Asp Gly Leu Phe Asp Ser Asp 1765 1770 1775 Pro Glu Arg Pro Gly Thr Ma Tyr He Arg Gin Gly Gly Phe Leu His 1780 1785 1790 Glu Ala Ma Leu Phe Asp Pro Gly Phe Phe Gly He Ser Pro Arg Glu 1795 1800 1805 Ma Leu Ma Met Asp Pro Gin Gin Arg Leu Leu Leu Glu Ma Ser Trp 1810 1815 1820 Glu Ala Leu Glu Arg Ma Gly He Asp Pro Thr Lys Ma Arg Gly Asp 1825 1830 1835 1840 Ma Val Gly Val Phe Ser Gly Val Ser He His Asp Tyr Leu Glu Ser 1845 1850 1855 Leu Ser Asn Met Pro Ma Glu Leu Glu Gly Phe Val Thr Thr Ma Thr 1860 1865 1870 Ma Gly Ser Val Ma Ser Gly Arg Val Ser Tyr Thr Phe Gly Phe Glu 1875 1880 1885 Gly Pro Ala Val Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ma 1890 1895 1900 He His Leu Ma Ala Gin Ala Leu Arg Gin Gly Glu Cys Thr Met Ma 1905 1910 1915 192C Leu Ma Gly Gly Val Ala Val Met Gly Ser Pro He Gly Val He Gly 1925 1930 1935 Met Ser Arg Gin Arg Gly Met Ma Glu Asp Gly Arg Val Lys Ma Phe 1940 1945 1950 Ma Asp Gly Ma Asp Gly Thr Val Leu Ser Glu Gly Val Gly He Val 1955 1960 1965 Val Leu Glu Arg Leu Ser Val Ma Arg Glu Arg Gly His Arg Val Leu 1970 1975 1980 Ma Val Leu Arg Gly Ser Ala Val Asn Gin Asp Gly Ma Ser Asn Gly 1985 1990 1995 2000 Leu Thr Ma Pro Asn Gly Pro Ser Gin Gin Arg Val He Arg Ser Ma 2005 2010 2015 Leu Ma Gly Ma Gly Leu Gin Pro Ser Glu Val Asp Val Val Glu Ma 2020 2025 2030 His Gly Thr Gly Thr Ala Leu Gly Glu Pro He Glu Ma Gin Ma Leu 2035 2040 2045 Leu Ma Thr Tyr Gly Lys Ser Arg Glu Thr Pro Leu Trp Leu Gly Ser 2050 2055 2060 Leu Lys Ser Asn He Gly His Thr Gin Ma Ala Ala Gly Val Ala Ma 2065 2070 2075 2080 Val He Lys Met Val Gin Ma Leu Arg Gin Asp Thr Leu Pro Pro Thr 2085 2090 2095 Leu His Val Gin Glu Pro Thr Lys Gin Val Asp Trp Ser Ma Gly Ma 2100 2105 2110 Val Glu Leu Leu Thr Glu Gly Arg Glu Trp Ala Arg Asn Gly His Pro 2115 2120 2125 Arg Arg Ma Gly Val Ser Ser Phe Gly He Ser Gly Thr Asn Ma His 2130 2135 2140 Leu He Leu Glu Glu Ma Pro Ma Asp Asp Thr Ma Glu Ma Asp Val 2145 2150 2155 2160 Pro Asp Ma Val Val Pro Val Val He Ser Ma Arg Ser Thr Gly Ser 2165 2170 2175 Leu Ma Gly Gin Ma Gly Arg Leu Ma Ma Phe Leu Asp Gly Asp Val 2180 2185 2190 Pro Leu Thr Arg Val Ala Gly Ma Leu Leu Ser Thr Arg Ma Thr Leu 2195 2200 2205 Thr Asp Arg Ma Val Val Val Ma Gly Ser Ma Glu Glu Ma Arg Ala 2210 2215 2220 Gly Leu Thr Ma Leu Ala Arg Gly Glu Ser Ma Ser Gly Leu Val Thr 2225 2230 2235 2240 Gly Thr Ala Gly Met Pro Gly Lys Thr Val Trp Val Phe Pro Gly Gin 2245 2250 2255 Gly Thr Gin Trp Ma Gly Met Gly Arg Glu Leu Leu Glu Ma Ser Pro 2260 2265 2270 Val Phe Ma Glu Arg He Glu Glu Cys Ma Ma Ma Leu Gin Pro Trp 2275 2280 2285 He Asp Trp Ser Leu Leu Asp Val Leu Arg Gly Glu Gly Glu Leu Asp 2290 2295 2300 Arg Val Asp Val Leu Gin Pro Ala Cys Phe Ma Val Met Val Gly Leu 2305 2310 2315 2320 Ma Ma Val Trp Ala Ser Val Gly Val Val Pro Asp Ma Val Leu Gly 2325 2330 2335 His Ser Gin Gly Glu He Ma Ma Ma Cys Val Ser Gly Ma Leu Ser 2340 2345 2350 Leu Glu Asp Ma Ala Lys Val Val Ma Leu Arg Ser Gin Ma He Ma 2355 2360 2365 Ma Glu Leu Ser Gly Arg Gly Gly Met Ma Ser He Gin Leu Ser His 2370 2375 2380 Asp Glu Val Ma Ma Arg Leu Ma Pro Trp Ma Gly Arg Val Glu He 2385 2390 2395 2400 Ma Ma Val Asn Gly Pro Ma Ser Val Val He Ma Gly Asp Ma Glu 2405 2410 2415 Ala Leu Thr Glu Ma Val Glu Val Leu Gly Gly Arg Arg Val Ma Val 2420 2425 2430 Asp Tyr Ala Ser His Thr Arg His Val Glu Asp He Gin Asp Thr Leu 2435 2440 2445 Ma Glu Thr Leu Ma Gly He Asp Ma Gin Ma Pro Val Val Pro Phe 2450 2455 2460 Tyr Ser Thr Val Ma Gly Glu Trp He Thr Asp Ala Gly Val Val Asp 2465 2470 2475 2480 Gly Gly Tyr Trp Tyr Arg Asn Leu Arg Asn Gin Val Gly Phe Gly Pro 2485 2490 2495 Ma Val Ala Glu Leu He Glu Gin Gly His Gly Val Phe Val Glu Val 2500 2505 2510 Ser Ma His Pro Val Leu Val Gin Pro He Ser Glu Leu Thr Asp Ma 2515 2520 2525 Val Val Thr Gly Thr Leu Arg Arg Asp Asp Gly Gly Val Arg Arg Leu 2530 2535 2540 Leu Thr Ser Met Ma Glu Leu Phe Val Arg Gly Val Pro Val Asp Trp 2545 2550 2555 2560 Ala Thr Met Ala Pro Pro Ala Arg Val Glu Leu Pro Thr Tyr Ma Phe 2565 2570 2575 Asp His Gin His Phe Trp Leu Ser Pro Pro Ma Val Ma Asp Ma Pro 2580 2585 2590 Ma Leu Gly Leu Ma Gly Ma Asp His Pro Leu Leu Gly Ala Val Leu 2595 2600 2605 Pro Leu Pro Gin Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Val 2610 2615 2620 Arg Thr Kis Pro Trp Leu Ma Asp Gly Val Pro Ma Ma Ma Leu Val 2625 2630 2635 2640 Glu Leu Ma Val Arg Ma Gly Asp Glu Ma Gly Cys Pro Val Leu Ma 2645 2650 2655 Asp Leu Thr Val Glu Lys Leu Leu Val Leu Pro Glu Ser Gly Gly Leu 2660 2665 2670 Arg Val Gin Val He Val Ser Gly Glu Arg Thr Val Glu Val Tyr Ser 2675 2680 2685 Gin Leu Glu Gly Ma Glu Asp Trp He Arg Asn Ma Thr Gly His Leu 2690 2695 2700 Ser Ma Thr Ala Pro Ma His Glu Ma Phe Asp Phe Thr Ma Trp Pro 2705 2710 2715 2720 Pro Ala Gly Ma Gin Gin Val Asp Gly Leu Trp Arg Arg Gly Asp Glu 2725 2730 2735 He Phe Ma Glu Val Ma Leu Pro Glu Glu Leu Asp Ma Gly Ma Phe 2740 2745 2750 Gly He His Pro Phe Leu Leu Asp Ma Ma Val Gin Pro Val Leu Ma 2755 2760 2765 Asp Asp Glu Gin Pro Ma Glu Trp Arg Ser Leu Val Leu His Ma Ma 2770 2775 2780 Gly Ma Ser Ma Leu Arg Val Arg Leu Val Pro Gly Gly Ma Leu Gin 2785 2790 2795 2800 Ma Ma Asp Glu Thr Gly Gly Leu Val Leu Thr Ma Asp Ser Val Ma 2805 2810 2815 Gly Arg Glu Leu Ser Ma Gly Lys Thr Arg Ma Gly Ser Leu Tyr Arg 2820 2825 2830 Val Asp Trp Thr Glu Val Ser He Ma Asp Ser Ma Val Pro Ma Asn 2835 2840 2845 He Glu Val Val Glu Ma Phe Gly Glu Glu Pro Leu Glu Leu Thr Gly 2850 2855 2860 Arg Val Leu Glu Ma Val Gin Thr Trp Leu Val Thr Ma Ma Asp Asp 2365 2870 2875 2880 Ma Arg Leu Val Val Val Thr Arg Gly Ma Val Arg Glu Val Thr Asp 2885 2890 2895 Pro Ma Gly Ma Ma Val Trp Gly Leu Val Arg Ma Ma Gin Ma Glu 2900 2905 2910 Asn Pro Gly Arg He Phe Leu He Asp Thr Asp Gly Glu He Pro Ma 2915 2920 2925 Leu Thr Gly Asp Glu Pro Glu He Ma Val Arg Gly Gly Lys Phe Phe 2930 2935 2940 Val Pro Arg He Thr Arg Ma Glu Pro Ser Gly Ma Ma Val Phe Arg 2945 2950 2955 2960 Pro Asp Gly Thr Val Leu He Ser Gly Ma Gly Ma Leu Gly Gly Leu 2965 2970 2975 Val Ala Arg Arg Leu Val Glu Arg His Gly Val Arg Lys Leu Val Leu 2980 2985 2990 Ma Ser Arg Arg Gly Arg Asp Ma Asp Gly Val Ma Asp Leu Val Ma 2995 3000 3005 Asp Leu Ma Ma Asp Val Ser Val Val Ma Cys Asp Val Ser Asp Arg 3010 3015 3020 Ma Gin Val Ma Ma Leu Leu Asp Glu His Arg Pro Thr Ma Val Val 3025 3030 3035 3040 His Thr Ma Gly Val He Asp Ma Gly Val He Glu Thr Leu Asp Arg 3045 3050 3055 Asp Arg Leu Ala Thr Val Phe Ala Pro Lys Val Asp Ala Val Arg His 3060 3065 3070 Leu Asp Glu Leu Thr Arg Asp Arg Asp Leu Asp Ma Phe Val Val Tyr 3075 3080 3085 Ser Ser Val Ser Ma Val Phe Met Gly Ma Gly Ser Gly Ser Tyr Ma 3090 3095 3100 Ma Ala Asn Ma Phe Leu Asp Gly Leu Met Ma Asn Arg Arg Ma Ma 3105 3110 3115 3120 Gly Leu Pro Gly Leu Ser Leu Ma Trp Gly Leu Trp Asp Gin Ser Thr 3125 3130 3135 Gly Met Ala Ma Gly Thr Asp Glu Ma Thr Arg Ma Arg Met Ser Arg 3140 3145 3150 Arg Gly Gly Leu Gin He Met Thr Gin Ma Glu Gly Met Asp Leu Phe 3155 3160 3165 Asp Ma Ma Leu Ser Ser Ma Glu Ser Leu Leu Val Pro Ma Lys Leu 3170 3175 3180 Asp Leu Arg Gly Val Arg Ma Asp Ma Ma Ala Gly Gly Val Val Pro 3185 3190 3195 3200 His Met Leu Arg Gly Leu Val Arg Ala Gly Arg Ma Gin Ma Arg Ma 3205 3210 3215 Ma Ser Thr Val Asp Asn Gly Leu Ma Gly Arg Leu Ma Gly Leu Ma 3220 3225 3230 Pro Ma Asp Gin Leu Thr Leu Leu Leu Asp Leu Val Arg Ma Gin Val 3235 3240 3245 Ma Ma Val Leu Gly His Ala Asp Ma Ser Ma Val Arg Val Asp Thr 3250 3255 3260 Ala Phe Lys Asp Ma Gly Phe Asp Ser Leu Thr Ma Val Glu Leu Arg 3265 3270 3275 3280 Asn Arg Met Arg Thr Ma Thr Gly Leu Lys Leu Pro Ma Thr Leu Val 3285 3290 3295 Phe Asp Tyr Pro Asn Pro Gin Ma Leu Ma Arg His Leu Arg Asp Glu 3300 3305 3310 Leu Gly Gly Ma Ma Gin Thr Pro Val Thr Thr Ma Ma Ma Lys Ma 3315 3320 3325 Asp Leu Asp Glu Pro He Ma He Val Gly Met Ma Cys Arg Leu Pro 3330 3335 3340 Gly Gly Val Ala Gly Pro Glu Asp Leu Trp Arg Leu Val Ma Glu Gly 3345 3350 3355 3360 Arg Asp Ma Val Ser Ser Phe Pro Thr Asp Arg Gly Trp Asp Thr Asp 3365 3370 3375 Ser Leu Tyr Asp Pro Asp Pro Ma Arg Pro Gly Lys Thr Tyr Thr Arg 3380 3385 3390 His Gly Gly Phe Leu His Glu Ma Gly Leu Phe Asp Ala Gly Phe Phe 3395 3400 3405 Gly He Ser Pro Arg Glu Ma Val Ma Met Asp Pro Gin Gin Arg Leu 3410 3415 3420 Leu Leu Glu Ma Ser Trp Glu Ma Met Glu Asp Ala Gly Val Asp Pro 3425 3430 3435 3440 Leu Ser Leu Lys Gly Asn Asp Val Gly Val Phe Thr Gly Met Phe Gly 3445 3450 3455 Gin Gly Tyr Val Ma Pro Gly Asp Ser Val Val Thr Pro Glu Leu Glu 3460 3465 3470 Gly Phe Ma Gly Thr Gly Gly Ser Ser Ser Val Ala Ser Gly Arg Val 3475 3480 3485 Ser Tyr Val Phe Gly Phe Glu Gly Pro Ma Val Thr He Asp Ser Ma 3490 3495 3500 Cys Ser Ser Ser Leu Val Ma Met His Leu Ma Ma Gin Ser Leu Arg 3505 3510 3515 3520 Gin Gly Glu Cys Ser Met Ala Leu Ma Gly Gly Ma Thr Val Met Ma 3525 3530 3535 Asn Pre Gly Ala Phe Val Glu Phe Ser Arg Gin Arg Gly Leu Ma Val 3540 3545 3550 Asp Gly Arg Cys Lys Ma Phe Ala Ma Ma Ma Asp Gly Thr Gly Trp 3555 3560 3565 Ma Glu Gly Val Gly Val Val He Leu Glu Arg Leu Ser Val Ma Arg 3570 3575 3580 Glu Arg Gly His Arg He Leu Ma Val Leu Arg Gly Ser Ma Val Asn 3585 3590 3595 3600 Gin Asp Gly Ala Ser Asn Gly Leu Thr Ma Pro Asn Gly Pro Ser Gin 3605 3610 3615 Gin Arg Val He Arg Arg Ma Leu Val Ser Ma Gly Leu Ma Pro Ser 3620 3625 3630 Asp Val Asp Val Val Glu Ma His Gly Thr Gly Thr Thr Leu Gly Asp 3635 3640 3645 Pro He Glu Ma Gin Ma Leu Leu Ma Thr Tyr Gly Lys Asp Arg Glu 3650 3655 3660 Ser Pro Leu Trp Leu Gly Ser Leu Lys Ser Asn He Gly His Ma Gin 3665 3670 3675 3680 Ala Ala Ma Gly Val Ma Gly Val He Lys Met Val Gin Ma Leu Arg 3685 3690 3695 His Glu Val Leu Pro Pro Thr Leu His Val Asp Arg Pro Thr Pro Glu 3700 3705 3710 Val jAsp Trp Ser Ma Gly Ma Val Glu Leu Leu Thr Glu Ma Arg Glu 3715 3720 3725 Trp Pro Arg Asn Gly Arg Pro Arg Arg Ma Gly Val Ser Ma Phe Gly 3730 3735 3740 Val Ser Gly Thr Asn Ma His Leu He Leu Glu Glu Ma Pro Ma Glu 3745 3750 3755 3760 Glu Pro Val Pro Thr Pro Glu Val Pro Leu Val Pro Val Val Val Ser 3765 3770 3775 Ma Arg Ser Arg Ma Ser Leu Ma Gly Gin Ma Gly Arg Leu Ma Gly 3780 3785 3790 Phe Val Ala Gly Asp Ma Ser Leu Ma Gly Val Ma Arg Ma Leu Val 3795 3800 3805 Thr Asn Arg Ma Ma Leu Thr Glu Arg Ma Val Met Val Val Gly Ser 3810 3815 3820 Arg Glu Glu Ma Val Thr Asn Leu Glu Ma Leu Ma Arg Gly Glu Asp 3825 3830 3835 3840 Pro Ma Ala Val Val Thr Gly Arg Ma Gly Ser Pro Gly Lys Leu Val 3845 3850 3855 Trp Val Phe Pro Gly Gin Gly Ser Gin Trp He Gly Met Gly Arg Glu 3860 3865 3870 Leu Leu Asp Ser Ser Pro Val Phe Ala Glu Arg Val Ma Glu Cys Ma 3875 3880 3885 Ma Ma Leu Glu Pro Trp He Asp Trp Ser Leu Leu Asp Val Leu Arg 3890 3895 3900 Gly Glu Ser Asp Leu Leu Asp Arg Val Asp Val Val Gin Pro Ma Ser 3905 3910 3915 3920 Phe Ma Met Met Val Gly Leu Ma Ma Val Trp Gin Ser Val Gly Val 3925 3930 3935 Arg Pro Asp Ma Val Val Gly His Ser Gin Gly Glu He Ma Ma Ma 3940 3945 3950 Cys Val Ser Gly Ma Leu Ser Leu Gin Asp Ma Ma Lys Val Val Ma 3955 3960 3965 Leu Arg Ser Gin Ma He Ma Thr Arg Leu Ala Gly Arg Gly Gly Met 3970 3975 3980 Ma Ser Val 'Ma Leu Ser Glu Glu Asp Ma Thr Ma Trp Leu Ma Pro 3985 3990 3995 4000 Trp Ala Asp Arg Val Gin Val Ma Ma Val Asn Ser Pro Ma Ser Val 4005 4010 4015 Val He Ma Gly Glu Ma Gin Ma Leu Asp Glu Val Val Asp Ma Leu 4020 4025 4030 Ser Gly Gin Glu Val Arg Val Arg Arg Val Ma Val Asp Tyr Gly Ser 4035 4040 4045 His Thr Asn Gin Val Glu Ma He Glu Asp Leu Leu Ma Glu Thr Leu 4050 4055 4060 Ma Gly He Glu Ma Gin Ma Pro Lys Val Pro Phe Tyr Ser Thr Leu 4065 4070 4075 4080 He Gly Asp Trp He Arg Asp Ma Gly He Val Asp Gly Gly Tyr Trp 4085 4090 4095 Tyr Arg Asn Leu Arg Asn Gin Val Gly Phe Gly Pro Ma Val Ma Glu 4100 4105 4110 Leu Val Arg Gin Gly His Gly Val Phe Val Glu Val Ser Ma His Pro 4115 4120 4125 Val Leu Val Gin Pro Leu Ser Glu Leu Ser Asp Asp Ma Val Val Thr 4130 4135 4140 Gly Ser Leu Arg Arg Glu Asp Gly Gly Leu Arg Arg Leu Leu Thr Ser 4145 4150 4155 4160 Met Ma Glu Leu Tyr Val Gin Gly Val Pro Leu Asp Trp Thr Ma Val 4165 4170 4175 Leu Pro Arg Thr Gly Arg Val Asp Leu Pro Lys Tyr Ma Phe Asp His 4180 4185 4190 Arg His Tyr Trp Leu Arg Pro Ma Glu Ser Ma Thr Asp Ma Ma Ser 4195 4200 4205 Leu Gly Gin Ala Ma Ma Asp His Pro Leu Leu Gly Ala Val Val Glu 4210 4215 4220 Leu Pro Gin Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Val Arg 4225 4230 4235 4240 Thr His Pro Trp Leu Ma Asp His Ma Val Gly Gly Val Val He Leu 4245 4250 4255 Pro Gly Ser Gly Leu Ma Glu Leu Ma Val Arg Ma Gly Asp Glu Ma 4260 4265 4270 Gly Cys Thr Ma Leu Asp Glu Leu He He Glu Ma Pro Leu Val Val 4275 4280 4285 Pro Ala Gin Gly Ma Val Arg Val Gin Val Ma Leu Ser Gly Pro Asp 4290 4295 4300 Glu Thr Gly Ser Arg Thr Val Asp Leu Tyr Ser Gin Arg Asp Gly Gly 4305 4310 4315 4320 Ma Gly Thr Trp Thr Arg His Ma Thr Gly Val Leu Ser Thr Ma Pro 4325 4330 4335 Ma Gin Glu Pro Glu Phe Asp Phe His Ma Trp Pro Pro Ma Asp Ma 4340 4345 4350 Glu Arg He Asp Val Glu Thr Phe Tyr Thr Asp Leu Ma Glu Arg Gly 4355 4360 4365 Tyr Gly Tyr Gly Pro Ma Phe Gin Gly Leu Gin Ma Val Trp Arg Arg 4370 4375 4380 Asp Gly Asp Val Phe Ma Glu Val Ma Leu Pro Glu Asp Leu jrg Lys 4385 4390 4395 4400 Asp Ma Gly Arg Phe Gly Val His Pro Ma Leu Leu Asp Ma Ma Leu 4405 4410 4415 Gin Ma Ma Thr Ma Val Gly Gly Asp Glu Pro Gly Gin Pro Val Leu 4420 4425 4430 Ala Phe Ala Trp Asn Gly Leu Val Leu His Ma Ala Gly Ma Ser Ma 4435 4440 4445 Leu Arg Val Arg Leu Ma Pro Ser Gly Pro Asp Thr Leu Ser Val Ma 4450 4455 4460 Ma Ma Asp Glu Thr Gly Gly Leu Val Leu Thr Met Glu Ser Leu Val 4465 4470 4475 4480 Ser Arg Pro Val Ser Ala Glu Gin Leu Gly Ma Ma Ma Asp Ma Gly 4485 4490 4495 His Asp Ala Met Phe Arg Val Asp Trp Thr Glu Leu Pro Ma Val Pro 4500 4505 4510 Arg Ma Glu Leu Pro Pro Trp Val Arg He Asp Thr Ma Asp Asp Val 4515 4520 4525 Ma Ma Leu Ma Glu Lys Ma Asp Ma Pro Pro Val Val Val Trp Glu 4530 4535 4540 Ma Ma Gly Gly Asp Pro Ala Leu Ma Val Ser Ser jrg Val Leu Glu 4545 4550 4555 4560 He Met Gin Ma Trp Leu Ma Ma Pro Ma Phe Glu Glu Ma Arg Leu 4565 4570 4575 Val Val Thr Thr Arg Gly Ma Val Pro Ma Gly Gly Asp His Thr Leu 4580 4585 4590 Thr Asp Pro Ma Ma Ma Ala Val Trp Gly Leu Val Arg Ser Ma Gin 4595 4600 4605 Ma Glu His Pro Asp Arg Val Val Leu Leu Asp Thr Asp Gly Glu Val 4610 4615 4620 Pro Leu Gly Ma Val Leu Ma Ser Gly Glu Pro Gin Leu Ma Val Arg 4625 4630 4635 4640 Gly Thr Thr Phe Phe Val Pro Arg Leu Ma Arg Ma Thr Arg Leu Ser 4645 4650 4655 Asp Ma Pro Pro Ma Phe Asp Pro Asp Gly Thr Val Leu Val Ser Gly 4660 4665 4670 Ala Gly Ser Leu Gly Thr Leu Val Ma Arg His Leu Val Thr Arg His 4675 4680 4685 Gly Val Arg Arg Val Val Leu Ma Ser Arg Gin Gly Arg Asp Ma Glu 4690 4695 4700 Gly Ma Gin Asp Leu He Thr Glu Leu Thr Gly Glu Gly Ma Asp Val 4705 4710 4715 4720 Ser Phe Val Ma Cys Asp Val Ser Asp Arg Asp Gin Val Ma Ma Leu 4725 4730 4735 Leu Ma Gly Leu Pro Asp Leu Thr Gly Val Val His Thr Ma Gly Val 4740 4745 4750 Phe Glu Asp Gly Val He Glu Ma Leu Thr Pro Asp Gin Leu Ma Asn 4755 4760 4765 Val Tyr Ala Ma Lys Val Thr Ma Ala Met His Leu Asp Glu Leu Thr 4770 4775 4780 Arg Asp Arg Asp Leu Gly Ma Phe Val Val Phe Ser Ser Val Ma Gly 4785 4790 4795 4800 Val Met Gly Gly Gly Gly Gin Gly Pro Tyr Ma Ma Ma Asn Ma Phe 4805 4810 4815 Leu Asp Ma Ma Met Ma Ser Arg Gin Ma Ma Gly Leu Pro Gly Leu 4820 4825 4830 Ser Leu Ala Trp Gly Leu Trp Glu Arg Ser Ser Gly Met Ala Ma His 4835 4840 4845 Leu Ser Glu Val Asp His Ma Arg Ala Ser Arg Asn Gly Val Leu Glu 4850 4855 4860 Leu Thr Arg Ma Glu Gly Leu Ala Leu Phe Asp Leu Gly Leu Arg Met 4865 4870 4875 4880 Ma Glu Ser Leu Leu Val Pro He Lys Leu Asp Leu Ma Ma Met Arg 4885 4890 4895 Ma Ser Thr Val Pro Val Leu Phe Arg Gly Leu Val Arg Pro Ser Arg 4900 4905 4910 Thr Gin Ma Arg Thr Ma Ser Thr Val Asp Arg Gly Leu Ma Gly Arg 4915 4920 4925 Leu Ma Gly Leu Pro Val Ma Glu Arg Ma Ala Val Leu Val Asp Leu 4930 4935 4940 Val Arg Gly Gin Val Ala Val Val Leu Gly Tyr Asp Gly Pro Glu Ma 4945 4950 4955 4960 Val Arg Pro Asp Thr Ma Phe Lys Asp Thr Gly Phe Asp Ser Leu Thr 4965 4970 4975 Ser Val Glu Leu Arg Asn Arg Leu Arg Glu Ma Thr Gly Leu Lys Leu 4980 4985 4990 Pro Ma Thr Leu Val Phe Asp Tyr Pro Asn Pro Leu Ala Val Ma Arg 4995 5000 5005 Tyr Leu Gly Ala Arg Leu Val Pro Asp Gly Thr Ma Asn Gly Asn Gly 5010 5015 5020 Asn Gly Asn Gly His Ser Glu Asp Asp Arg Leu Arg His Ma Leu Ma 5025 5030 5035 5040 Ma He Ma Ma Glu Asp Ma Gly Glu Glu Arg Ser He Ma Asp Leu 5045 5050 5055 Gly Val Asp Asp Leu Val Gin Leu Ma Phe Gly Asp Glu 5060 5065 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1721 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Met Ma Cys Arg Leu Pro Gly Gly Val Thr Gly Pro Gly Asp Leu Trp 1 5 10 15 Arg Leu Val Ma Glu Gly Gly Asp Ma Val Ser Gly Phe Pro Thr Asp 20 25 30 Arg Cys Trp Asp Leu Asp Thr Leu Phe Asp Pro Asp Pro Asp His Ma 35 40 45 Gly Thr Ser Tyr Thr Asp Gin Gly Gly Phe Leu His Asp Ala Ala Leu 50 55 60 Phe Asp Pro Gly Phe Phe Gly He Ser Pro Arg Glu Ma Leu Ala Met 65 70 75 80 Asp Pro Gin Gin Arg Leu Leu Leu Glu Ala Ser Trp Glu Ma Leu Glu 85 90 95 Gly Val Gly Leu Asp Pro Ma Ser Leu Gin Gly Thr Asp Val Gly Val 100 105 110 Phe Thr Gly Ma Gly Gly Ser Gly Tyr Gly Gly Gly Leu Thr Gly Pro 115 120 125 Glu Met Gin Ser Phe Ma Gly Thr Gly Leu Ma Ser Ser Val Ma Ser 130 135 140 Gly Arg Val Ser Tyr Val Phe Gly Phe Glu Gly Pro Ma Val Thr He 145 150 155 160 Asp Thr Ma Cys Ser Ser Ser Leu Val Ma Met His Leu Ma Ma Gin 165 170 175 Ma Leu Arg Gin Gly Asp Cys Ser Met Ma Leu Ma Gly Gly Ma Met 180 185 190 Val Met Ser Gly Pro Asp Ser Phe Val Val Phe Ser Arg Gin Arg Gly 195 200 205 Leu Ma Thr Asp Gly Arg Cys Lys Ma Phe Ma Ser Gly Ma Asp Gly 210 215 220 Met Val Leu Ma Glu Gly He Ser Val Val Val Leu Glu Arg Leu Ser 225 230 235 240 Val Ma Arg Glu Arg Gly His Arg Val Leu Ma Val Leu Arg Gly Ser 245 250 255 Ala Val Asn Gin Asp Gly Ma Ser Asn Gly Leu Thr Ma Pro Asn Gly 260 265 270 Pro Ser Gin Gin Arg Val He Arg Ma Ma Leu Ma Asn Ma Gly He 275 280 285 Gly Pro Ser Asp Val Asp Leu Val Glu Ala His Gly Thr Gly Thr Ser 290 295 300 Leu Gly Asp Pro He Glu Ma Gin Ala Leu Leu Ma Thr Tyr Gly Gin 305 310 315 320 Asp Arg Glu Thr Pro Leu Trp Leu Gly Ser Leu Lys Ser Asn He Gly 325 330 335 His Thr Gin Ala Ma Ma Gly Val Ma Ser Val He Lys Val Val Gin 340 345 350 Ma Leu Arg His Gly Val Met Pro Pro Thr Leu His Val Asp Glu Pro 355 360 365 Ser Ser Gin Val Asp Trp Ser Glu Gly Ma Val Glu Leu Leu Thr Gly 370 375 380 Ser Arg Asp Trp Pro Arg Gly Asp Arg Pro Arg Arg Ma Gly Val Ser 385 390 395 400 Ser Phe Gly Val Ser Gly Thr Asn Val His Leu He He Glu Glu Ma 405 410 415 Pro Glu Glu Pro Ma Ma Ma Val Pro Thr Ser Ma Asp Val Val Pro 420 425 430 Leu Val Val Ser Ma Arg Ser Thr Gly Ser Leu Ma Gly Gin Ma Asp 435 440 445 Arg Leu Thr Glu Val Asp Val Pro Leu Gly His Leu Ma Gly Ma Leu 450 455 460 Val Ma Gly Arg Ma Val Leu Glu Glu Arg Ma Val Val Val Ma Gly 465 470 475 480 Ser Ma Glu Glu Ma Arg Ala Gly Leu Gly Ma Leu Ala Arg Gly Glu 485 490 495 Ma Ma Pro Gly Val Val Thr Gly Thr Ma Gly Lys Pro Gly Lys Val 500 505 510 Val Trp Val Phe Pro Gly Gin Gly Thr Gin Trp Val Gly Met Gly Arg 515 520 525 Glu Leu Leu Asp Ma Ser Pro Val Phe Ala Glu Arg He Lys Glu Cys 530 535 540 Ala Ma Ma Leu Asp Gin Trp Thr Asp Trp Ser Leu Leu Asp Val Leu 545 550 555 560 Arg Gly Asp Gly Asp Leu Asp Ser Val Glu Val Leu Gin Pro Ma Cys 565 570 575 Phe Ala Val Met Val Gly Leu Ala Ma Val Trp Glu Ser Ma Gly Val 580 585 590 Arg Pro Asp Ala Val Val Gly His Ser Gin Gly Glu He Ma Ma Ma 595 600 605 Cys Val Ser Gly Ma Leu Thr Leu Asp Asp Ma Ma Lys Val Val Ma 610 615 620 Leu Arg Ser Gin Ma He Ala Ala Arg Leu Ser Gly Arg Gly Gly Met 625 630 635 640 Ala Ser Val Ma Leu Ser Glu Asp Glu Ma Asn Ma Arg Leu Gly Leu 645 650 655 Trp Asp Gly Arg He Glu Val Ma Ma Val Asn Gly Pro Ala Ser Val 660 665 670 Val He Ma Gly Asp Ma Gin Ma Leu Asp Glu Ma Leu Glu Val Leu 675 680 685 Ma Gly Asp Gly Val Arg Val Arg Gin Val Ala Val Asp Tyr Ma Ser 690 695 700 His Thr Arg His Val Glu Asp He Arg Asp Thr Leu Ma Glu Thr Leu 705 710 715 720 Ma Gly He Thr Ala Gin Ma Pro Asp Val Pro Phe Arg Ser Thr Val 725 730 735 Thr Gly Gly Trp Val Arg Asp Ma Asp Val Leu Asp Gly Gly Tyr Trp 740 745 750 Tyr Arg Asn Leu Arg Asn Gin Val Arg Phe Gly Pro Ma Val Ma Glu 755 760 765 Leu Leu Glu Gin Gly His Gly Val Phe Val Glu Val Ser Ala His Pro 770 775 780 Val Leu Val Gin Pro He Ser Glu Leu Thr jAsp Ma Val Val Thr Gly 785 790 795 800 Thr Leu Arg Arg Asp Asp Gly Gly Leu Arg Arg Leu Leu Thr Ser Met 805 810 815 Ma Glu Leu Phe Val Arg Gly Val Arg Val Asp Trp Ma Thr Leu Val 820 825 830 Pro Pre Ma Arg Val Asp Leu Pro Thr Tyr Ma Phe Asp His Gin His 835 840 845 Phe Trp Leu Arg Pro Ma Ma Gin Ala Asp Ma Val Ser Leu Gly Gin 850 855 860 Ma Ala Ala Glu His Pro Leu Leu Gly Ma Val Val Arg Leu Pro Gin 865 870 875 880 Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Leu Arg Thr His Pro 885 890 895 Trp Leu Ma Asp His Thr He Gly Gly Val Val Leu Phe Pro Gly Thr 900 905 910 Gly Leu Val Glu Leu Ma Val Arg Ma Gly Asp Glu Ma Gly Cys Pro 915 920 925 Val Leu Asp Glu Leu Val Thr Glu Ma Pro Leu Val Val Pro Gly Gin 930 935 940 Gly Gly Val Asn Val Gin Val Thr Val Ser Gly Pro Asp Gin Asn Gly 945 950 955 960 Leu Arg Thr Val Asp He His Ser Gin Arg Asp Asp Val Trp Thr Arg 965 970 975 His Ala Thr Gly Thr Val Ser Ma Thr Pro Ma Ser Ser Pro Gly Phe 980 985 990 Asp Phe Thr Ma Trp Pro Pro Pro Asp Gly Gin Arg Val Glu He Gly 995 1000 1005 Asp Phe Tyr Ma Asp Leu Ma Glu Arg Gly Tyr Ma Tyr Gly Pro Leu 1010 1015 1020 Phe Gin Gly Val Arg Ma Val Trp Gin Arg Gly Glu Asp Val Phe Ma 1025 1030 1035 1040 Glu Val Ma Leu Pro Glu Asp Arg Arg Glu Asp Ma Ma Arg Phe Gly 1045 1050 1055 Leu His Pro Ala Leu Leu Asp Ma Ma Leu Gin Thr Gly Thr He Ma 1060 1065 1070 Ma Ala Ma Ser Gly Gin Pro Gly Lys Ser Val Met Pro Phe Ser Trp 1075 1080 1085 Asn Arg Leu Ala Leu His Ma Val Gly Ma Ala Gly Leu Arg Val Arg 1090 1095 1100 Val Ma Pro Gly Gly Pro Asp Ma Leu Thr Val Glu Ma Ma Asp Glu 1105 1110 1115 1120 Thr Gly Ma Pro Val Leu Thr Met Asp Ser Leu He Leu Arg Glu Val 1125 1130 1135 Ma Leu Asp Gin Leu Asp Thr Ma Arg Ma Gly Ser Leu Tyr Arg Val 1140 1145 1150 Asp Trp Thr Pro Leu Pro Thr Val Asp Ser Ma Val Pro Ma Gly Arg 1155 1160 1165 Ma Glu Val Leu Glu Ala Phe Gly Glu Glu Pro Leu Asp Leu Thr Gly 1170 1175 1180 Arg Val Leu Ala Ala Leu Gin Ala Trp Leu Ser Asp Ma Ma Glu Glu 1185 1190 1195 1200 Ma Arg Leu Val Val Val Thr Arg Gly Ma Val Pro Ma Gly Asp Gly 1205 1210 1215 Val Val Ser Asp Pro Ma Gly Ma Ma Val Trp Gly Leu Val Arg Ma 1220 1225 1230 Ma Gin Ma Glu Asn Pro Asp Arg Phe Val Leu Leu Asp Thr Asp Gly 1235 1240 1245 Glu Val Pro Leu Glu Ma Val Leu Ala Thr Gly Glu Pro Gin Leu Ma 1250 1255 1260 Leu Arg Gly Thr Thr Phe Ser Val Pro Arg Leu Ma Arg Val Thr Glu 1265 1270 1275 1280 Pro Ma Glu Ma Pro Leu Thr Phe Arg Pro Asp Gly Thr Val Leu Val 1285 1290 1295 Ser Gly Ma Gly Thr Leu Gly Ala Leu Ala Ma Arg Asp Leu Val Thr 1300 1305 1310 Arg His Gly Val Arg Arg Leu Val Leu Ma Ser Arg Arg Gly Arg Ma 1315 1320 1325 Ma Glu Gly He Asp Asp Leu Val Ma Glu Leu Thr Gly His Gly Ma 1330 1335 1340 Glu Val Thr Val Ma Ma Cys Asp Val Ser Asp Arg Asp Gin Val Ma 1345 1350 1355 1360 Ma Leu Leu Lys Glu His Ma Leu Thr Ma Val Val His Thr Ma Gly 1365 1370 1375 Val Phe Asp Ma Gly Val Thr Gly Ma Leu Thr Arg Glu Arg Leu Ma 1380 1385 1390 Lys Val Phe Ala Pro Lys Val Asp Ala Ma Asn His Leu Asp Glu Leu 1395 1400 1405 Thr Arg Asp Leu Asp Leu Asp Ma Phe He Val Tyr Ser Ser Ma Ser 1410 1415 1420 Ser He Phe Met Gly Ala Gly Ser Gly Gly Tyr Ala Ma Ma Asn Ma 1425 1430 1435 1440 Tyr Leu Asp Gly Leu Met Ala Ma Arg Arg Ma Ma Gly Leu Pro Gly 1445 1450 1455 Leu Ser Leu Ala Trp Gly Pro Trp Glu Gin Leu Thr Gly Met: Ma Asp 1460 1465 1470 Thr He Asp Asp Leu Thr Leu Ala Arg Met Ser Arg Arg Glu Gly Arg 1475 1480 1485 Gly Gly Val Arg Ma Leu Gly Ser Ala Asp Gly Met Glu Leu Phe Asp 1490 1495 1500 Ma Ma Leu Ma Ma Gly Gin Ma Leu Leu Val Pro He Glu Leu Asp 1505 1510 1515 1520 Leu Arg Glu Val Arg Ma Asp Ma Ma Gly Gly Gly Thr Val Pro His 1525 1530 1535 Leu Leu Arg Gly Leu Val Arg Ala Gly Arg Gin Ma Ma Arg Thr Ma 1540 1545 1550 Ala Thr Glu Asp Gly Gly Leu Glu Arg Arg Leu Ma Gly Leu Thr Val 1555 1560 1565 Ma Glu Gin Glu Ala Leu Leu Leu Asp Leu Val Arg Gly Gin Val Ma 1570 1575 1580 Val Val Leu Gly His Ma Asp Ser Ser Gly Val Arg Ma Asp Ma Ma 1585 1590 1595 1600 Phe Lys Asp Ma Gly Phe Asp Ser Leu Thr Ser Val Glu Leu Arg Asn 1605 1610 1615 Arg Leu Arg Glu Thr Thr Gly Leu Lys Leu Pro Ma Thr Leu Val Phe 1620 1625 1630 jAsp His Pro Asn Pro Leu Ma Leu Ala Arg His Leu Arg Ala Glu Leu 1635 1640 1645 Ma Val Asp Glu Ma Ser Pro Ma Asp Ma Val Leu Ma Gly Leu Ma 1650 1655 1660 Gly Leu Glu Ma Ma He Ma Ma Ma Gly Ma Pro Asp Gly Asp Arg 1665 1670 1675 1680 He Thr Ma Arg Leu Arg Glu Leu Leu Lys Ma Ma Glu Ma Ma Glu 1685 1690 1695 Ma Arg Pro Gly Thr Ser Gly Asp Leu Asp Thr Ma Ser Asp Glu Glu 1700 1705 1710 Leu Phe Ma Leu Val Asp Gly Leu Asp 1715 1720 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1688 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: Met Ma Cys Arg Tyr Pro Gly Gly Val Ser Ser Pro Glu Asp Leu Trp 1 5 10 15 Arg Leu Val Ala Glu Gly Thr Asp Ma Val Ser Ma Phe Pro Gly Asp 20 25 30 Arg Gly Trp Asp Val Asp Gly Leu Val Asp Pro Asp Pro Asp Arg Pro 35 40 45 Gly Thr Thr Tyr Thr Asp Gin Gly Gly Phe Leu His Glu Ma Gly Leu 50 55 60 Phe Asp Ma Gly Phe Phe Gly He Ser Pro Arg Glu Ma Val Ma Met 55 70 75 80 Asp Pro Gin Gin Arg Leu Leu Leu Glu Thr Ser Trp Glu Ma He Glu 85 90 95 Arg Thr Gly Thr Asp Pro Leu Ser Leu Lys Gly Ser Asp He Gly Val 100 105 110 Phe Thr Gly Val Ma Ser Met Gly Tyr Gly Ma Gly Gly Gly Val Val 115 120 125 Ala Pro Glu Leu Glu Gly Phe Val Gly Thr Gly Ma Ma Pro Cys He 130 135 140 Ma Ser Gly Arg Val Ser Tyr Val Leu Gly Phe Glu Gly Pro Ma Val 145 150 155 160 Thr Val Asp Thr Gly Cys Ser Ser Ser Leu Val Ma Met His Leu Ma 165 170 175 Ma Gin Ma Leu ,Arg Arg Gly Glu Cys Ser Met Ma Leu Ma Gly Gly 180 185 190 Ma Met Val Met Ma Gin Pro Gly Ser Phe Val Ser Phe Ser Arg Gin 155 200 205 Arg Gly Leu Ma Leu Asp Gly Arg Cys Lys Ma Phe Ser Asp Ser Ma 210 215 220 Asp Gly Met Gly Leu Ma Glu Gly Val Gly Val He Ma Leu Glu Arg 225 230 235 240 Leu Ser Val Ala Arg Glu Arg Gly His Arg Val Leu Ala Val Leu Arg 245 250 255 Gly He Ma Val Asn Gin Asp Gly Ala Ser Asn Gly Leu Thr Ma Pro 260 265 270 Asn Gly Pro Ser Gin Gin Arg Val He Arg Ma Ma Leu Ma Glu Ma 275 280 285 Gly Leu Ser Pro Ser Asp Val Asp Ma Val Glu Gly His Gly Thr Gly 290 295 300 Thr Thr Leu Gly Asp Pro He Glu Ma Gin Ma Leu Leu Ma Thr Tyr 305 310 315 320 Gly Lys Gly Arg Asp Pro Glu Lys Pro Leu Trp Leu Gly Ser Val Lys 325 330 335 Ser Asn Leu Gly His Thr Gin Ma Ala Ma Gly Val Ma Ser Val He 340 345 350 Lys Met Val Gin Ma Leu Arg His Gly Val Leu Pro Pro Thr Leu His 355 360 365 Val Asp Arg Pro Ser Thr Glu Val Asp Trp Ser Ma Gly Ma Val Ser 370 375 380 Leu Leu Thr Glu Ma Arg Glu Trp Pro Arg Glu Gly Arg Pro Arg Arg 385 390 395 400 Ma Gly Val Ser Ser Phe Gly He Ser Gly Thr Asn Ma His Leu He 405 410 415 Leu Glu Glu Ma Pro Glu Glu Glu Pro Pro Val Ma Glu Ma Pro Ser 420 425 430 Ma Gly Val Val Pro Val Val Val Ser Ala Arg Gly Ma Leu Ma Gly 435 440 445 Gin Ala Gly Arg Leu Ma Ma Phe Leu Glu Ma Ser Asp Glu Pro Leu 450 455 460 Val Thr Val Ma Gly Ma Leu He Cys Gly Arg Ser Arg Phe Gly Asp 465 470 475 480 Arg Ma Val Val Val Ma Gly Thr Arg Ma Glu Ma Thr Ma Gly Leu 485 490 495 Ala Ma Leu Ma Arg Gly Glu Ser Ma Ma Asp Val Val Thr Gly Thr 500 505 510 Val Ma Ma Ser Gly Val Pro Gly Lys Leu Val Trp Val Phe Pro Gly 515 520 525 Gin Gly Ser Gin Trp Val Gly Met Gly Arg Glu Leu Leu Glu Ma Ser 530 535 540 Pro Val Phe Ma Ala Arg He Ma Glu Cys Ma Ma Ma Leu Glu Pro 545 550 555 560 Trp He Asp Trp Ser Leu Leu Asp Val Leu Arg Gly Glu Gly Asp Leu 565 570 575 Asp Arg Val Asp Val Val Gin Pro Ma Ser Phe Ala Val Met Val Gly 580 585 590 Leu Ala Ma Val Trp Ser Ser Val Gly Val Val Pro Asp Ma Val Leu 595 600 605 Gly His Ser Gin Gly Glu He Ma Ma Ma Cys Val Ser Gly Ma Leu 610 615 620 Ser Leu Gin Asp Ma Ala Lys Val Val Ala Leu Arg Ser Gin Ma He 625 630 635 640 Ma Ala Lys Leu Ma Gly Arg Gly Gly Met Ma Ser Val Ma Leu Ser 645 650 655 Glu Glu Asp Ma Val Ma Arg Leu Arg His Trp Ma Asp Arg Val Glu 660 665 670 Val Ala Ala Val Asn Ser Pro Ser Ser Val Val He Ma Gly Asp Ma 675 680 685 Glu Ma Leu Asp Gin Ma Leu Glu Ma Leu Thr Gly Gin Asp He Arg 690 695 700 Val Arg Arg Val Ma Val Asp Tyr Ma Ser His Thr Arg His Val Glu 705 710 715 720 Asp He Gin Glu Pro Leu Ma Glu Ma Leu Ma Gly He Glu Ma His 725 730 735 Ma Pre Thr Leu Pro Phe Phe Ser Thr Leu Thr Gly Asp Trp He Arg 740 745 750 Glu Ma Gly Val Val Asp Gly Gly Tyr Trp Tyr Arg Asn Leu Arg Asn 755 760 765 Gin Val Gly Phe Gly Pro Ma Val Ma Glu Leu Leu Gly Leu Gly His 770 775 780 Arg Val Phe Val Glu Val Ser Ala His Pro Val Leu Val Gin Ala He 785 790 795 800 Ser Ma He Ma Asp Asp Thr Asp Ma Val Val Thr Gly Ser Leu Arg 805 810 815 Arg Glu Glu Gly Gly Leu Arg Arg Leu Leu Thr Ser Met Ma Glu Leu 820 825 830 Phe Val Arg Gly Val Asp Val Asp Trp Ma Thr Met Val Pro Pro Ma 835 840 845 Arg Val Asp Leu Pro Thr Tyr Ma Phe Asp His Gin His Tyr Trp Leu 850 855 860 Arg Tyr Val Glu Thr Ma Thr Asp Ma Ma Gly Pro Val Val Arg Leu 865 870 875 880 Pro Gin Thr Gly Gly Leu Val Phe Thr Thr Glu Trp Ser Leu Lys Ser 885 890 895 Gln Pro Trp Leu Ma Glu His Thr Leu Glu Asp Leu Val Val Val Pro 900 905 910 Gly Ma Ma Leu Val Glu Leu Ma Val Arg Ma Gly Asp Glu Ma Gly 915 920 925 Thr Pro Val Leu Asp Glu Leu Val He Glu Thr Pro Leu Val Val Pro 930 935 940 Glu Arg Gly Ma He Arg Val Gin Val Thr Val Ser Gly Pro Asp Asp 945 950 955 960 Gly Thr Arg Thr Leu Glu Val His Ser Gin Pro Glu Asp Ma Thr Asp 965 970 975 Glu Trp Thr Arg His Ma Thr Gly Thr Leu Ser Ma Thr Pro Asp Glu 980 985 990 Ser Ser Gly Phe Asp Phe Thr Ma Trp Pro Pro Pro Gly Ma Arg Gin 995 1000 1005 Leu Asp Gly Val Pro Ma He Trp Arg Ma Gly Asp Glu He Phe Ma 1010 1015 1020 Glu Val Ser Leu Pro Asp Asp Ma Asp Ma Glu Ma Phe Gly He His 1025 1030 1035 1040 Pro Ma Leu Leu Asp Ma Ala Leu His Pro Ma Leu Pro Gly Asp Asp 1045 1050 1055 Gly Leu Thr Gin Pro Met Glu Trp Arg Gly Leu Thr Leu His Ma Ma 1060 1065 1070 Gly Ala Ser Thr Leu Arg Val Arg Leu Val Pro Gly Gly Phe Leu Glu 1075 1080 1085 Ma Ma Asp Gly Ala Gly Ser Leu Val Val Thr Ma Lys Glu Val Ma 1090 1095 1100 Leu Arg Pro Val Thr He Ma Arg Ser Arg Thr Thr Thr Arg Asp Ser 1105 1110 1115 1120 Leu Phe Gin Leu Asn Trp He Glu Leu Pro Glu Ser Gly Val Val Ma 1125 1130 1135 Ma Ma Asp Asp Thr Glu Val Leu Glu Val Pro Ma Gly Asp Ser Pro 1140 1145 1150 Leu Ala Ma Thr Ser Arg Val Leu Glu Arg Leu Gin Thr Trp Leu Thr 1155 1160 1165 Glu Pro Glu Ala Glu Gin Leu Val Val Val Thr Arg Gly Ma Val Pro 1170 1175 1180 Ma Gly Asp Thr Pro Val Thr Asp Pro Ala Ma Ala Ma Val Trp Gly 1185 1190 1195 1200 Leu Val Arg Ser Ma Gin Ma Glu Asn Pro Asp Arg He Val Leu Leu 1205 1210 1215 Asp Thr Asp Gly Glu Val Pro Leu Gly Ma Val Leu Ma Gly Gly Glu 1220 1225 1230 Pro Gin Val Ma Val Arg Gly Thr Ala Leu Tyr Val Pro Arg Leu Ma 1235 1240 1245 Arg Ma Asp Ma Ma Pro Val Ser Gly Leu His Gly Thr Val Leu Val 1250 1255 1260 Ser Gly Ma Gly Val Leu Gly Glu He Val Ma Arg His Leu Val Thr 1265 1270 1275 1280 Arg His Gly Val Arg Lys Leu Val Leu Ma Ser Arg Arg Gly Leu Asp 1285 1290 1295 Ma Asp Gly Ma Lys Asp Leu Val Thr Asp Leu Thr Gly Glu Gly Ma 1300 1305 1310 Asp Val Ser Val Val Ma Cys Asp Leu Ma Asp Arg Asn Gin Val Ma 1315 1320 1325 Ma Leu Leu Ma Asp His Arg Pro Ma Ser Val He His Thr Ma Gly 1330 1335 1340 Val Leu Asp Asp Gly Val He Gly Thr Leu Thr Pro Glu Arg Leu Ma 1345 1350 1355 1360 Lys Val Phe Ala Pro Lys Val Asp Ma Val Arg His Leu Asp Glu Leu 1365 1370 1375 Thr Arg Asp Leu Asp Leu Asp Ala Phe Val Val Phe Ser Ser Gly Ser 1380 1385 1390 Gly Val Phe Gly Ser Pro Gly Gin Gly Asn Tyr Ma Ma Ma Asn Ma 1395 1400 1405 Phe Leu Asp Ala Ma Met Ma Ser Arg Arg Ma Ma Gly Leu Pro Gly 1410 1415 1420 Leu Ser Leu Ma Trp Gly Leu Trp Glu Gin Ma Thr Gly Met Thr Ma 1425 1430 1435 1440 His Leu Gly Gly Thr jsp Gin Ma Arg Met Ser Arg Gly Gly Val Arg 1445 1450 1455 Pro He Thr Ma Glu Glu Gly Met Ma Leu Phe Asp Thr Ma Leu Gly 1460 1465 1470 Ma Gin Pro Ma Leu Leu Val Pro Val Lys Leu Asp Leu Arg Glu Val 1475 1480 1485 Arg Ma Gly Gly Ma Val Pro His Leu Leu Arg Gly Leu Val Arg Ma 1490 1495 1500 Gly Arg Arg Gin Ma Gin Ma Ma Ser Thr Val Asp Asn Gin Leu Leu 1505 1510 1515 1520 Gly Arg Leu Ma Gly Leu Gly Ma Pro Glu Gin Glu Ma Leu Leu Val 1525 1530 1535 Asp Leu Val Arg Gly Gin Val Ma Ma Val Leu Gly His Ma Gly Pro 1540 1545 1550 Asp Ma Val Arg Ma Asp Thr Ma Phe Lys Asp Ala Gly Phe Asp Ser 1555 1560 1565 Leu Thr Ser Val Asp Leu Arg Asn Arg Leu Arg Glu Ser Thr Gly Leu 1570 1575 1580 Lys Leu Pro Ma Thr Leu Ala Phe Asp Tyr Pro Thr Pro Leu Val Leu 1585 1590 1595 1600 Ma Arg His Leu Arg Asp Glu Leu Gly Ma Gly Asp Asp Ma Leu Ser 1605 1610 1615 Val Val His Ma Arg Leu Glu Asp Val Glu Ma Leu Leu Gly Gly Leu 1620 1625 1630 Arg Leu Asp Glu Ser Thr Lys Thr Gly Leu Thr Leu Arg Leu Gin Gly 1635 1640 1645 Leu Val Ma Arg Cys Asn Gly Val Asn Asp Gin Thr Gly Gly Glu Thr 1650 1655 1660 Leu Ma Asp Arg Leu Glu Ma Ma Ser Ma Asp Glu Val Leu Asp Phe 1665 1670 1675 1680 Ile Asp Glu Glu Leu Gly Leu Thr 1685 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3413 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Met Ala Thr Asp Glu Lys Leu Leu Lys Tyr Leu Lys Arg Val Thr Ma 1 5 10 15 Glu Leu His Ser Leu Arg Lys Gin Gly Ma Arg His Ma Asp Glu Pro 20 25 30 Leu Ala Val Val Gly Met Ma Cys Arg Phe Pro Gly Gly Val Ser Ser 35 40 45 Pro Glu Asp Leu Trp Gin Leu Val Ala Gly Gly Val Asp Ma Leu Ser 50 55 50 Asp Phe Pro Asp Asp Arg Gly Trp Glu Leu Asp Gly Leu Phe Asp Pro 65 70 75 80 Asp Pro Asp His Pro Gly Thr Ser Tyr Thr Ser Gin Gly Gly Phe Leu 85 90 95 Arg Gly Ma Gly Leu Phe Asp Ma Gly Leu Phe Gly He Ser Pro Arg 100 105 110 Glu Ma Leu Val Met Asp Pro Gin Gin Arg Val Leu Leu Glu Thr Ser 115 120 125 Trp Glu Ala Leu Glu Asp Ala Gly Val Asp Pro Leu Ser Leu Lys Gly 130 135 140 Ser Asp Val Gly Val Phe Ser Gly Val Phe Thr Gin Gly Tyr Gly Ma 145 150 155 160 Gly Ma He Thr Pro Asp Leu Glu Ma Phe Ma Gly He Gly Ma Ma 165 170 175 Ser Ser Val Ma Ser Gly Arg Val Ser Tyr Val Phe Gly Leu Glu Gly 180 185 190 Pro Ala Vai Thr He Asp Thr Ma Cys Ser Ser Ser Leu Val Ma He 195 200 205 His Leu Ma Ma Gin Ma Leu Arg Ma Gly Glu Cys Ser Met Ma Leu 210 215 220 Ma Gly Gly Ala Thr Val Met Pro Thr Pro Gly Thr Phe Val Ma Phe 225 230 235 240 Ser Arg Gin Arg Val Leu Ala Ala Asp Gly Arg Ser Lys Ala Phe Ser 245 250 255 Ser Thr Ala Asp Gly Thr Gly Trp Ma Glu Gly Ma Gly Val Leu Val 260 265 270 Leu Glu Arg Leu Ser Val Ala Gin Glu Arg Gly His Arg He Leu Ma 275 280 285 Val Leu Arg Gly Ser Ala Val Asn Gin Asp Gly Ma Ser Asn Gly Leu 290 295 300 Thr Ma Pro Asn Gly Pro Ser Gin Gin Arg Val He Arg Lys Ma Leu 305 310 315 320 Ma Gly Ma Gly Leu Val Ma Ser .Asp Val Asp Val Val Glu Ma His 325 330 335 Gly Thr Gly Thr Ma Leu Gly Asp Pro He Glu Ma Gin Ma Leu Leu 340 345 350 Ma Thr Tyr Gly Gin Gly Arg Glu Arg Pro Leu Trp Leu Gly Ser Val 355 360 365 Lys Ser Asn Phe Gly His Thr Gin Ma Ma Ma Gly Val Ma Gly Val 370 375 380 He Lys Met Val Gin Ma Leu Arg His Gly Ma Met Pro Pro Thr Leu 385 390 395 400 His Val Ma Glu Pro Thr Pro Glu Val jAsp Trp Ser Ma Gly Ma Val 405 410 415 Glu Leu Leu Thr Glu Pro Arg Glu Trp Pro Ma Gly Asp Arg Pro Arg 420 425 430 Arg Ma Gly Val Ser Ala Phe Gly He Ser Gly Thr Asn Ma His Leu 435 440 445 He Leu Glu Glu Ma Pro Pro Ma Asp Ma Val Ala Glu Glu Pro Glu 450 455 460 Phe Lys Gly Pro Val Pro Leu Val Val Ser Ma Gly Ser Pro Thr Ser 465 470 475 480 Leu Ma Ma Gin Ma Gly Arg Leu Ma Glu Val Leu Ma Ser Gly Gly 485 490 495 Val Ser Arg Ma Arg Leu Ma Ser Gly Leu Leu Ser Gly Arg Ma Leu 500 505 510 Leu Gly Asp Arg Ma Val Val Val Ma Gly Thr Asp Glu Asp Ma Val 515 520 525 Ma Gly Leu Arg Ma Leu Ma Arg Gly Asp Arg Ma Pro Gly Val Leu 530 535 540 Thr Gly Ser Ma Lys His Gly Lys Val Val Tyr Val Phe Pro Gly Gin 545 550 555 560 Gly Ser Gin Arg Leu Gly Met Gly Arg Glu Leu Tyr Asp Arg Tyr Pro 565 570 575 Val Phe Ma Thr Ma Phe Asp Glu Ma Cys Glu Gin Leu Asp Val Cys 580 585 590 Leu Ma Gly Arg Ma Gly His Arg Val Arg Asp Val Val Leu Gly Glu 595 600 605 Val Pro Ma Glu Thr Gly Leu Leu Asn Gin Thr Val Phe Thr Gin Ma 610 615 620 Gly Leu Phe Ma Val Glu Ser Ma Leu Phe Arg Leu Ala Glu Ser Trp 625 630 635 640 Gly Val Arg Pro Asp Val Val Leu Gly His Ser He Gly Glu He Thr 645 650 655 Ma Ma Tyr Ma Ma Gly Val Phe Ser Leu Pro Asp Ma Ma Arg He 660 665 670 Val Ma Ma Arg Gly Arg Leu Met Gin Ma Leu Ma Pro Gly Gly Ma 675 680 685 Met Val Ma Val Ma Ma Ser Glu Ma Glu Val Ma Glu Leu Leu Gly 690 695 700 Asp Gly Val Glu Leu Ma Ma Val Asn Gly Pro Ser Ma Val Val Leu 705 710 715 720 Ser Gly Asp Ma Asp Ma Val Val Ma Ma Ma Ma Arg Met Arg Glu 725 730 735 Arg Gly His Lys Thr Lys Gin Leu Lys Val Ser His Ma Phe His Ser 740 745 750 Ma Arg Met Ma Pro Mer Leu Ala Glu Phe Ma Ma Glu Leu Ma Gly 755 760 765 Val Thr Trp Arg Glu Pro Glu He Pro Val Val Ser Asn Val Thr Gly 770 775 780 Arg Phe Ma Glu Pro Gly Glu Leu Thr Glu Pro Gly Tyr Trp Ala Glu 785 790 795 800 His Val Arg Arg Pro Val Arg Phe Ma Glu Gly Val Ma Ma Ma Thr 805 810 815 Glu Ser Gly Gly Ser Leu Phe Val Glu Leu Gly Pro Gly Ma Ma Leu 820 825 830 Thr Ma Leu Val Glu Glu Thr Ma Glu Val Thr Cys Val Ma Ma Leu 835 840 845 Arg Asp Asp Arg Pro Glu Val Thr Ma Leu He Thr Ma Val Ma Glu 850 855 860 Leu Phe Val Arg Gly Val Ala Val Asp Trp Pro Ma Leu Leu Pro Pro 865 870 875 880 Val Thr Gly Phe Val Asp Leu Pro Lys Tyr Ma Phe Asp Gin Gin His 885 890 895 Tyr Trp Leu Gin Pro Ala Ma Gin Ma Thr Asp Ma Ma Ser Leu Gly 900 905 910 Gin Val Ala Ma Asp His Pro Leu Leu Gly Ma Val Val Arg Leu Pro 915 920 925 Gin Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Leu Lys Ser His 930 935 940 Pro Trp Leu Ma Asp His Val He Gly Gly Val Val Leu Val Ma Gly 945 950 955 960 Thr Gly Leu Val Glu Leu Ma Val Arg Ma Gly Asp Glu Ma Gly Cys 965 970 975 Pro Val Leu Glu Glu Leu Val He Glu Ma Pro Leu Val Val Pro Asp 980 985 990 His Gly Gly Val Arg He Gin Val Val Val Gly Ma Pro Gly Glu Thr S95 1000 1005 Gly Ser Arg Ma Val Glu Val Tyr Ser Leu Arg Glu Asp Ma Gly Ma 1010 1015 1020 Glu Val Trp Ala Arg His Ala Thr Gly Phe Leu Ma Ma Thr Pro Ser 1025 1030 1035 1040 Gin His Lys Pro Phe Asp Phe Thr Ma Trp Pro Pro Pro Gly Val Glu 1045 1050 1055 Arg Val Asp Val Glu Asp Phe Tyr Asp Gly Leu Val Asp Arg Gly Tyr 1060 1065 1070 Ma Tyr Gly Pro Ser Phe Arg Gly Leu Arg Ma Val Trp Arg Arg Gly 1075 1080 1085 Asp Glu Val Phe Ma Glu Val Ma Leu Ma Glu Asp Asp Arg Ma Asp 1090 1095 1100 Ma Ma Arg Phe Gly He His Pro Gly Leu Leu Asp Ma Ma Leu His 1105 1110 1115 1120 Ma Gly Met Ma Gly Ma Thr Thr Thr Glu Glu Pro Gly Arg Pro Val 1125 1130 1135 Leu Pro Phe Ma Trp Asn Gly Leu Val Leu His Ala Ma Gly Ma Ser 1140 1145 1150 Ma Leu Arg Val Arg Leu Ma Pro Ser Gly Pro Asp Ma Leu Ser Val 1155 1160 1165 Glu Ma Ma Asp Glu Ma Gly Gly Leu Val Val Thr Ma Asp Ser Leu 1170 1175 1180 Val Ser Arg Pro Val Ser Ala Glu Gin Leu Gly Ma Ma Ma Asn His 1185 1190 1195 1200 Asp Ala Leu Phe Arg Val Glu Trp Thr Glu He Ser Ser Ma Gly Asp 1205 1210 1215 Val Pro Ma Asp His Val Glu Val Leu Glu Ma Val Gly Glu Asp Pro 1220 1225 1230 Leu Glu Leu Thr Gly Arg Val Leu Glu Ma Val Gin Thr Trp Leu Ma 1235 1240 1245 Asp Ma Ma Asp Asp Ma Arg Leu Val Val Val Thr Arg Gly Ma Val 1250 1255 1260 His Glu Val Thr Asp Pro Ma Gly Ala Ma Val Trp Gly Leu He Arg 1265 1270 1275 1280 Ma Ma Gin Ma Glu Asn Pro Asp Arg He Val Leu Leu Asp Thr Asp 1285 1290 1295 Gly Glu Val Pro Leu Gly Arg Val Leu Ala Thr Gly Glu Pro Gin Thr 1300 1305 1310 Ma Val Arg Gly Ma Thr Leu Phe Ma Pro Arg Leu Ma Arg Ma Glu 1315 1320 1325 Ma Ma Glu Ala Pro Ala Val Thr Gly Gly Thr Val Leu He Ser Gly 1330 1335 1340 Ma Gly Ser Leu Gly Ma Leu Thr Ma Arg His Leu Val Ma Arg His 1345 1350 1355 1360 Gly Val Arg Arg Leu Val Leu Val Ser Arg Arg Gly Pro Asp Ma Asp 1365 1370 1375 Gly Met Ma Glu Leu Thr Ma Glu Leu He Ma Gin Gly Ma Glu Val 1380 1385 1390 Ma Val Val Ma Cys Asp Leu Ma Asp Arg Asp Gin Val Arg Val Leu 1395 1400 1405 Leu Ma Glu His Arg Pro Asn Ma Val Val His Thr Ma Gly Val Leu 1410 1415 1420 Asp Asp Gly Val Phe Glu Ser Leu Thr Arg Glu Arg Leu Ma Lys Val 1425 1430 1435 1440 Phe Ma Pro Lys Val Thr Ma Ma Asn His Leu Asp Glu Leu Thr Arg 1445 1450 1455 Glu Leu Asp Leu Arg Ma Phe Val Val Phe Ser Ser Ma Ser Gly Val 1460 1465 1470 Phe Gly Ser Ma Gly Gin Gly Asn Tyr Ma Ma Ma Asn Ma Tyr Leu 1475 1480 1485 Asp Ma Val Val Ma Asn Arg Arg Ma Ma Gly Leu Pro Gly Thr Ser 1490 1495 1500 Leu Ma Trp Gly Leu Trp Glu Gin Thr Asp Gly Met Thr Ma His Leu 1505 1510 1515 1520 Gly A-sp Ma Asp Gin Ma Arg Ma Ser Arg Gly Gly Val Leu Ma He 1525 1530 1535 Ser Pro Ma Glu Gly Met Glu Leu Phe Asp Ma Ma Pro Asp Gly Leu 1540 1545 1550 Val Val Pro Val Lys Leu Asp Leu Arg Lys Thr Arg Ma Gly Giy Thr 1555 1560 1565 Val Pro His Leu Leu Arg Gly Leu Val Arg Pro Gly Arg Gin Gin Ma 1570 1575 1580 Arg Pro Ma Ser Thr Val Asp Asn Gly Leu Ma Gly Arg Leu Ma Gly 1585 1590 1595 1600 Leu Ma Pro Ma Glu Gin Glu Ala Leu Leu Leu Asp Val Val Arg Thr 1605 1610 1615 Gin Val Ala Leu Val Leu Gly His Ma Gly Pro Glu Ma Val Arg Ma 1620 1625 1630 Asp Thr Ma Phe Lys Asp Thr Gly Phe Asp Ser Leu Thr Ser Val Glu 1635 1640 1645 Leu Arg Asn Arg Leu Arg Glu Ma Ser Gly Leu Lys Leu Pro Ma Thr 1650 1655 1660 Leu Val Phe Asp Tyr Pro Thr Pro Val Ma Leu Ma Arg Tyr Leu Arg 1665 1670 1675 1680 Asp Glu Leu Gly Asp Thr Val Ma Thr Thr Pro Val Ma Thr Ma Ma 1685 1690 1695 Ma Ma Asp Ma Gly Glu Pro He Ma He Val Gly Met Ma Cys Arg 1700 1705 1710 Leu Pro Gly Gly Val Thr Asp Pro Glu Gly Leu Trp Arg Leu Val Arg 1715 1720 1725 Asp Gly Leu Glu Gly Leu Ser Pro Phe Pro Glu Asp Arg Gly Trp Asp 1730 1735 1740 Leu Glu Asn Leu Phe Asp Asp Asp Pro Asp Arg Ser Gly Thr Thr Tyr 1745 1750 1755 1760 Thr Ser Arg Gly Gly Phe Leu Asp Gly Ma Gly Leu Phe Asp Ma Gly 1765 1770 1775 Phe Phe Gly He Ser Pro Arg Glu Ma Leu Ala Met Asp Pro Gin Gin 1780 1785 1790 Arg Leu Leu Leu Glu Ma Ma Trp Glu Ala Leu Glu Gly Thr Gly Val 1795 1800 1805 Asp Pro Gly Ser Leu Lys Gly Ma Asp Val Gly Val Phe Ma Gly Val 1810 1815 1820 Ser Asn Gin Gly Tyr Gly Met Gly Ma Asp Pro Ma Glu Leu Ma Gly 1825 1830 1835 1840 Tyr Ma Ser Thr Ma Gly Ma Ser Ser Val Val Ser Gly Arg Val Ser 1845 1850 1855 Tyr Val Phe Gly Phe Glu Gly Pro Ma Val Thr He Asp Thr Ma Cys 1860 1865 1870 Ser Ser Ser Leu Val Ala Mer His Leu Ma Gly Gin Ma Leu Arg Gin 1875 1880 1885 Gly Glu Cys Ser Met Ma Leu Ma Gly Gly Val Thr Val Met Gly Thr 1890 1895 1900 Pro Gly Thr Phe Val Glu Phe Ma Lys Gin Arg Gly Leu Ma Gly Asp 1905 1910 1915 1920 Gly Arg Cys Lys Ma Tyr Ma Glu Gly Ma Asp Gly Thr Gly Trp Ma 1925 1930 1935 Glu Gly Val Gly Val Val Val Leu Glu Arg Leu Ser Val Ma Arg Glu 1940 1945 1950 Arg Gly His Arg Val Leu Ma Val Leu Arg Gly Ser Ma Val Asn Ser 1955 1960 1965 Asp Gly Ma Ser Asn Gly Leu Thr Ma Pro Asn Gly Pro Ser Gin Gin 1970 1975 1980 Arg Val He Arg Arg Ma Leu Ma Gly Ma Gly Leu Glu Pro Ser Asp 1985 1990 1995 2000 Val Asp He Val Glu Gly His Gly Thr Gly Thr Ma Leu Gly Asp Pro 2005 2010 2015 He Glu Ma Gin Ma Leu Leu Ma Thr Tyr Gly Lys Asp Arg Asp Pro 2020 2025 2030 Glu Thr Pro Leu Trp Leu Gly Ser Val Lys Ser Asn Phe Gly His Thr 2035 2040 2045 Gin Ser Ma Ma Gly Val Ma Gly Val He Lys Met Val Gin Ma Leu 2050 2055 2060 Arg His Gly Val Met Pro Pro Thr Leu His Val Asp Arg Pro Thr Ser 2065 2070 2075 2080 Gin Val Asp Trp Ser Ma Gly Ma Val Glu Val Leu Thr Glu Ma Arg 2085 2090 2095 Glu Trp Pro Arg Asn Gly Arg Pro Arg Arg Ma Gly Val Ser Ser Phe 2100 2105 2110 Gly He Ser Gly Thr Asn Ma His Leu He He Glu Glu Ala Pro Ma 2115 2120 2125 Glu Pro Gin Leu Ma Gly Pro Pro Pro Asp Gly Gly Val Val Pro Leu 2130 2135 2140 Val Val Ser Ala Arg Ser Pro Gly Ala Leu Ma Gly Gin Ala Arg Arg 2145 2150 2155 2160 Leu Ma Thr Phe Leu Gly Asp Gly Pro Leu Ser Asp Val Ma Gly Ma 2165 2170 2175 Leu Thr Ser Arg Ma Leu Phe Gly Glu Arg Ma Val Val Val Ma Asp 2180 2185 2190 Ser Ma Glu Glu Ma Arg Ma Gly Leu Gly Ala Leu Ma Arg Gly Glu 2195 2200 2205 Asp Ma Pro Gly Leu Val Arg Gly Arg Val Pro Ma Ser Gly Leu Pro 2210 2215 2220 Gly Lys Leu Val Trp Val Phe Pro Gly Gin Gly Thr Gin Trp Val Gly 2225 2230 2235 2240 Met Gly Arg Glu Leu Leu Glu Glu Ser Pro Val Phe Ma Glu Arg He 2245 2250 2255 Ma Glu Cys Ma Ma Ma Leu Glu Pro Trp He Gly Trp Ser Leu Phe 2260 2265 2270 Asp Val Leu Arg Gly Asp Gly Asp Leu Asp Arg Val Asp Val Leu Gin 2275 2280 2285 Pro Ma Cys Phe Ma Val Met Val Gly Leu Ma Ma Val Trp Ser Ser 2290 2295 2300 Ma Gly Val Val Pro Asp Ala Val Leu Gly His Ser Gin Gly Glu He 2305 2310 2315 2320 Ma Ma Ma Cys Val Ser Gly Ma Leu Ser Leu Glu Asp Ma Ma Lys 2325 2330 2335 Val Val Ma Leu Arg Ser Gin Ma He Ma Ala Lys Leu Ser Gly Arg 2340 2345 2350 Gly Gly Met Ma Ser Val Ma Leu Gly Glu Ala Asp Val Val Ser Arg 2355 2360 2365 Leu Ala Asp Gly Val Glu Val Ma Ala Val Asn Gly Pro Ala Ser Val 2370 2375 2380 Val He Ma Gly Asp Ma Gin Ala Leu Asp Glu Thr Leu Glu Ma Leu 2385 2390 2395 2400 Ser Gly Ma Gly He Arg Ala Arg Arg Val Ma Val Asp Tyr Ma Ser 2405 2410 2415 His Thr Arg His Val Glu Asp He Glu Asp Thr Leu Ma Glu Ma Leu 2420 2425 2430 Ma Gly He Asp Ma Arg Ma Pro Leu Val Pro Phe Leu Ser Thr Leu 2435 2440 2445 Thr Gly Glu Trp He Arg Asp Glu Gly Val Val Asp Gly Gly Tyr Trp 2450 2455 2460 Tyr Arg Asn Leu Arg Gly Arg Val Arg Phe Gly Pro Ma Val Glu Ma 2465 2470 2475 2480 Leu Leu Ma Gin Gly His Gly Val Phe Val Glu Leu Ser Ma His Pro 2485 2490 2495 Val Leu Val Gin Pro He Thr Glu Leu Thr Asp Glu Thr Ma Ma Val 2500 2505 2510 Val Thr Gly Ser Leu Arg Arg Asp Asp Gly Gly Leu Arg Arg Leu Leu 2515 2520 2525 Thr Ser Met Ma Glu Leu Phe Val Arg Gly Val Glu Val Asp Trp Thr 2530 2535 2540 Ser Leu Val Pro Pro Ma Arg Ma Asp Leu Pro Thr Tyr Ma Phe Asp 2545 2550 2555 2560 His Glu His Tyr Trp Leu Arg Ma Ma Asp Thr Ma Ser Asp Ma Val 2565 2570 2575 Ser Leu Gly Leu Ma Gly Ma Asp His Pro Leu Leu Gly Ma Val Val 2580 2585 2590 Gin Leu Pro Gin Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Leu 2595 2600 2605 Arg Ser His Pro Trp Leu Ma Asp His Ala Val Arg Asp Val Val He 2610 2615 2620 Val Pro Gly Thr Gly Leu Val Glu Leu Ma Val Arg Ma Gly Asp Glu 2625 2630 2635 2640 Ma Gly Cys Pro Val Leu Asp Glu Leu Val He Glu Ma Pro Leu Val 2645 2650 2655 Val Pro Arg Arg Gly Gly Val Arg Val Gin Val Ma Leu Gly Gly Pro 2660 2665 2670 Ma Asp Asp Gly Ser Arg Thr Val Asp Val Phe Ser Leu Arg Glu Asp 2675 2680 2685 Ma Asp Ser Trp Leu Arg His Ma Thr Gly Val Leu Val Pro Glu Asn 2690 2695 2700 Arg Pro Arg Gly Thr Ma Ala Phe Asp Phe Ma Ma Trp Pro Pro Pro 2705 2710 2715 2720 Glu Ma Lys Pro Val Asp Leu Thr Gly Ma Tyr Asp Val Leu Ma Asp 2725 2730 2735 Val Gly Tyr Gly Tyr Gly Pro Thr Phe Arg Ma Val Arg Ma Val Trp 2740 2745 2750 Arg Arg Gly Ser Gly Asn Thr Thr Glu Thr Phe Ala Glu He Ma Leu 2755 2760 2765 Pro Glu Asp Ma Arg Ma Glu Ma Gly Arg Phe Gly He His Pro Ma 2770 2775 2780 Leu Leu Asp Ala Ala Leu His Ser Thr Met Val Ser Ma Ma Ma Asp 2785 2790 2795 2800 Thr Glu Ser Tyr Gly Asp Glu Val Arg Leu Pro Phe Ma Trp Asn Gly 2805 2810 2815 Leu Arg Leu His Ma Ma Gly Ala Ser Val Leu Arg Val Arg Val Ma 2820 2825 2830 Lys Pro Glu Arg Asp Ser Leu Ser Leu Glu Ma Val Asp Glu Ser Gly 2835 2840 2845 Gly Leu Val Val Thr Leu Asp Ser Leu Val Gly Arg Pro Val Ser Asn 2850 2855 2860 Asp Gin Leu Thr Thr Ma Ma Gly Pro Ma Gly Ma Gly Ser Leu Tyr 2865 2870 2875 2880 Arg Val Asp Trp Thr Pro Leu Ser Ser Val Asp Thr Ser Gly Arg Val 2885 2890 2895 Pro Ser Trp Leu Pro Val Ma Thr Ma Glu Glu Val Ma Thr Leu Ma 2900 2905 2910 Asp Asp Val Leu Thr Gly Ma Thr Glu Ma Pro Ma Val Ma Val Met 2915 2920 2925 Glu Ma Val Ala Asp Glu Gly Ser Val Leu Ma Leu Thr Val Arg Val 2930 2935 2940 Leu Asp Val Val Gin Cys Trp Leu Ma Gly Gly Gly Leu Glu Gly Thr 2945 2950 2955 2960 Lys Leu Ma He Val Thr Arg Gly Ala Val Pro Ma Gly Asp Gly Val 2965 2970 2975 Val His Asp Pro Ma Ma Ma Ma Val Trp Gly Leu Val Arg Ma Ma 2980 2985 2990 Gin Ma Glu Asn Pro Asp Arg He Val Leu Leu Asp Val Glu Pro Glu 2995 3000 3005 Ma Asp Val Pro Pro Leu Leu Gly Ser Val Leu Ma Asp Gly Glu Pro 3010 3015 3020 Gin Val Ma Val Arg Gly Thr Thr Leu Ser He Pro Arg Leu Ma Arg 3025 3030 3035 3040 Ala Ma Arg Pro Asp Pro Ma Ma Gly Phe Lys Thr Arg Gly Pro Val 3045 3050 3055 Leu Val Thr Gly Gly Thr Gly Ser Leu Gly Gly Leu Val Ma Arg His 3060 3065 3070 Leu Val Glu Arg His Gly Val Arg Gin Leu Val Leu Ma Ser Arg Arg 3075 3080 3085 Gly Leu Asp Ma Glu Gly Ma Lys Asp Leu Val Thr Asp Leu Thr Ma 3090 3095 3100 Leu Gly Ala Asp Val Ma Val Ma Ma Cys Asp Val Ma Asp Arg Asp 3105 3110 3115 3120 Gin Val Ma Ma Leu Leu Thr Glu His Arg Pro Ser Ma Val Val His 3125 3130 3135 Thr Ala Gly Val Pro Asp Ma Gly Val He Gly Thr Val Thr Pro Asp 3140 3145 3150 Arg Leu Ma Glu Val Phe Ma Pro Lys Val Thr Ma Ma Arg His Leu 3155 3160 3165 Asp Glu Leu Thr Arg Asp Leu Asp Leu Asp Ser Phe Val Val Tyr Ser 3170 3175 3180 Ser Val Ser Ma Val Phe Met Gly Ma Gly Ser Gly Ser Tyr Ma Ma 3185 3190 3195 3200 Ma Asn Ala Tyr Leu Asp Gly Leu Met Ma His Arg Arg Ma Ma Gly 3205 3210 3215 Leu Pro Gly Gin Ser Leu Ma Trp Gly Leu Trp Asp Gin Thr Thr Gly 3220 3225 3230 Gly Met Ala Ala Gly Thr Asp Glu Ma Gly Arg Ma Arg Met Thr Arg 3235 3240 3245 Arg Gly Gly Leu Val Ma Met Lys Pro Ma Ma Gly Leu Asp Leu Phe 3250 3255 3260 Asp Ma Ma He Gly Ser Gly Glu Pro Leu Leu Val Pro Ma Gin Leu 3265 3270 3275 3280 Asp Leu Arg Gly Leu Arg Ma Glu Ma Ma Gly Gly Thr Glu Val Pro 3285 3290 3295 His Leu Leu Arg Gly Leu Val Arg Ma Gly Arg Gin Gin Ma Arg Ma 3300 3305 3310 Ma Ser Thr Val Glu Glu Asn Trp Ma Gly Arg Leu Ma Gly Leu Glu 3315 3320 3325 Pro Ma Glu Arg Gly Gin Val Leu Leu Glu Leu Val Arg Ma Gin Val 3330 3335 3340 Ma Gly Val Leu Gly Tyr Arg Ma Ala His Gin Val Asp Pro Asp Gin 3345 3350 3355 3360 Gly Leu Phe Glu He Gly Phe Asp Ser Leu Thr Ma He Glu Leu Arg 3365 3370 3375 Asn Arg Leu Arg Ma Arg Thr Glu Arg Lys He Ser Pro Gly Val Val 3380 3385 3390 Phe Asp His Pro Thr Pro Ala Leu Leu Ma Ala His Leu Asn Glu Leu 3395 3400 3405 Leu Arg Lys Lys Val 3410 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 226 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: Met Ma He Pro Tyr Ser Ser Leu Ma Tyr Glu Leu Arg Asp Ma Val 1 5 10 15 Asn Val Val Asp Leu Asp Glu Asp Asp Val Phe Val Thr Ser He Ma 20 25 30 Glu Gly Gin Gly Gly Ma Cys Tyr His Leu Asn Arg Leu Phe His Arg 35 40 45 Leu Leu Thr Glu Leu Gly Tyr Asp Val Thr Pro Leu Ma Gly Ser Thr 50 55 60 Ma Glu Gly Arg Glu Thr Phe Gly Thr Asp Val Glu His Met Phe Asn 65 70 75 80 Leu Val Thr Leu Asp Gly Ma Asp Trp Leu Val Asp Val Gly Tyr Pro 85 90 95 Gly Pro Thr Tyr Val Glu Pro Leu Ma Val Ser Pro Ma Val Gin Thr 100 105 110 Gin Tyr Gly Ser Gin Phe Arg Leu Val Glu Gin Glu Thr Gly Tyr Ma 115 120 125 Leu Gin Arg Arg Gly Ala Val Thr Arg Trp Ser Val Val Tyr Thr Phe 130 135 140 Thr Thr Gin Pro Arg Gin Trp Ser Asp Trp Lys Glu Leu Glu Asp Asn 145 150 155 160 Phe Arg Ma Leu Val Gly Asp Thr Thr Arg Thr Asp Thr Gin Glu Thr 165 170 175 Leu Cys Gly Arg Ma Phe Ma Asn Gly Gin Val Phe Leu Arg Gin Arg 180 185 190 Arg Tyr Leu Thr Val Glu Asn Gly Arg Glu Gin Val Arg Thr He Thr 195 200 205 Asp Asp Asp Glu Phe Arg Ma Leu Val Ser Arg Val Leu Ser Gly Asp 210 215 220 His Gly 225 - 190 - Ciba-Geigy AG CH-4002 Basel RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the boπom of this page I IDENTIFICATION OF THE MICROORGANISM Identification reference given bv the DEPOSITOR Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY pRi7 - 3 DSM 11114 II SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOM1C DESIGNATION The microorganism identified under I above was accompanied by (X ) a scientific description (X ) a proposed taxonomic designation (Mark with a cross where applicable) III RECEIPT AND ACCEPTANCE This International Depositan' Authority accepts the microorganism identified under I. above, which was received by it on 1 9 9 6 - 0 8 - 1 0 (Date of the original deposit) 1 IV. RECEIPT OF REQUEST FOR CONVERSION The microorganism identified under 1 above was received by this International Depositary Authority on (date of original deposit) and a request to convert the oπginal deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion) V. INTERNATIONAL DEPOSITARY AUTHORITY Name DSM2-DEUTSCHE SAMMLUNG VON Sιgnature(s) of person(s) having the power to represent the IKROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authorized ofTιcial(s) Address Mascheroder Weg lb D-38124 Braunschweig ^ tΛ 'ώ Date 1996 - 08 -14 1 Where Rule 6.4 (d) applies, such date is the dale on which the status of international depositary authority was acquired Form DSMZ-BP/ (sole page) 0196 Ciba-Geigy AG CH-4002 Basel VIABILITY STATEMENT issued pursuant to Rule 10 2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page I DEPOSITOR II IDENTIFICATION OΓ TI IE MICROORGANISM Name Ciba - Geigy AG Accession number given bv the INTERNATIONAL DEPOSITARY AUTHORITY Address CH - 4 002 Basel DSM 11114 Date of the deposit or the transfer' 1996 - 08 - 10 III VIABILITY STATEMENT The viability of the microorganism identified under II above was tested on 1 9 9 6 - 08 - 12 On that date, the said microorganism was (X)' viable ( )' no longer viable IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED' V. INTERNATIONAL DEPOSITARY AUTHORITY Name DSMZ-DEUTSCHE SAMMLUNO VON Sιgnature(s) of person(s) having the power to represent the MIKROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authorized officιal(s) Address Mascheroder Weg lb D-38124 Braunschweig LS. rO Date. 1996 - 08 - 14 Indicate the date of oπginal deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer) In the cases referred to in Rule 10 2(a) (ii) and (ni), refer to the most recent viability test Mark with a cross the applicable box Fill in if the information has been requested and if the results of the test were negative Form DSMZ-BP/9 (sole page) 0196 Novartis AG CH-4002 Basel RECEIPT IN THE CASE OF AN DEPOSIT issued pursuant to Rule 7 1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page IDENTIFICATION OF THE MICROORGANISM Identification reference given by ihe DEPOSITOR Accession number given by Ihe INTERNATIONAL DEPOSITARY AUTHORITY pRi44 - 2 DSM 11655 II SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION The microorganism identified under 1. above was accompanied by (X ) a scientific description (X ) a proposed taxonomic designation (Mark with a cross where applicable) III. RECEIPT AND ACCEPTANCE This International Depositary Authority accepts the microorganism identified under I above, which was received by ii on 1 997 - 0 7 - 14 (Date of the original deposit)' IV. RECEIPT OF REQUEST FOR CONVERSION The microorganism identified under 1 above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date ol receipt of request for conversion). V INTERNATIONAL DEPOSITARY AUTHORITY Name DSMZ-DEUTSCHE SAMMLUNG VON Sιgnature(s) of person(s) having the power to represent the MIKROORGANISMEN UND ZELLKULTUREN GmbH Intemalional Depositary Authority or of authorized ofTιcιal(s) Address Mascheroder Weg lb D-3812 Braunschweig Date 1997 - 07 - 15 Where Rule 64 (d) applies, such date is the date on which the status of international depositary authority was acquired Form DSMZ-BP/4 (sole page) 0196 Novartis AG CH-4002 Basel VIABILITY STATEMENT issued pursuant to Rule 102 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page 1 DEPOSITOR II IDENTIFICATION OF THE MICROORGANISM Name Novart i s AG Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY Address CH - 4 0 02 Base l DSM 11655 Date of the deposit or ihe transfer' 1997 - 07 - 14 III VIABILITY STATEMENT The viability of the microorganism identified under II above was tested on 19 97 - 07 - 14 ' On that date, the said microorganism was (X)' viable ( )' no longer viable IV CONDITIONS UNDER WHICH THE TEST HAS BEEN PERFORMED' V INTERNATIONAL DEPOSITARY AUTHORITY Name DSMZ-DEUTSCHE SAMMLUNG VON Sιgnature(s) of person(s) having the power to represent the MIKROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authorized officιal(s) Address Mascheroder Weg lb D-38124 Braunschweig Date 1997 - 07 - 15 1 Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer) 2 In the cases referred to in Rule 102(a) (n) and (in), refer to the most recent viability lest Mark with a cross the applicable box ' Fill in if the information has been requested and if the results of the test were negative Form DSMZ-BP 9 (sole page) 0196 Novartis AG CH-4002 Basel RECEIPT IN THE CASE OF AN DEPOSIT issued pursuant to Rule 7 1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bonom of this page I IDENTIFICATION OF THE MICROORGANISM Identification reference given bv ihe DEPOSITOR Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY pNE95 DSM 11656 II SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION The microorganism identified under I above was accompanied by (X ) a scientific description (X ) a proposed taxonomic designation (Mark with a cross where applicable) III RECEIPT AND This International Depositary Authonrv accepts the microorganism identified under 1 above, which was received by it on 1 9 97 - 0 7 - 14 (Date of the original deposit)' IV. RECEIPT OF REQUEST FOR CONVERSION The microorganism identified under 1 above was received bv this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion) V. INTERNATIONAL DEPOSITARY AUTHORITY Name DSMZ-DEUTSCHE SAMMLUNG VON Sιgnature(s) of person(s) having the power to represent the MJKROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authorized offιcιal(s) Address Mascheroder Weg lb D-38124 Braunschweig LS, Date 1997 - 07 - 15 1 Where Rule 64 (d) applies, such date is the date on which the status of international depositary authority was acquired Form DSMZ-BPM (sole page) 0196 Novartis AG CH-4002 Basel VIABILITY STATEMENT issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page I DEPOSITOR 11 IDENTIFICATION OF THE MICROORGANISM Name Novart i s AG Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY Address CH - 4 0 02 Basel DSM 1 16 56 Date of the deposit or the transfer' 1997 - 07 - 14 III VIABILITY STATEMENT The viability of the microorganism identified under II above was tested on 1997 - 07 - 14 ' On that date, the said microorganism was (X)' viable ( ) ! no longer viable IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED' V. INTERNATIONAL DEPOSITARY AUTHORITY Name DSMZ-DEUTSCHE SAMMLUNG VON Sιgnature(s) of person(s) having the power to represent the MI ROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authorized official(s) Address Maschcrodcr Weg lb D-38124 Braunschweig LS. Date. 1997 - 07 - 15 ' indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer). 2 In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test ' Mark with a cross the applicable box ' Fill in if the information has been requested and if ihe results of the test were negative Form DSMZ-BP 9 (sole page) 0196 Novartis AG CH-4002 Basel RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7 1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bonom of this page I IDENTIFICATION OF THE MICROORGANISM Identification reference given b\ the DEPOSITOR Accession number given by the INTERNATIONAL DFPOSITARY AUTHORITY pNE112 DSM 11657 I! SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION The microorganism identified under 1 above was accompanied by (X ) a scientific description (X ) a proposed taxonomic designation (Mark with a cross where applicable) III RECEIPT AND ACCEPTANCE This International Depositary Authority accepts the microorganism identified under I above, which was received by it on 1997 - 0 7 - 14 (Date of the original deposit)' IV RECEIPT OF REQUEST FOR CONVERSION The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion) V INTERNATIONAL DEPOSITARY AUTHORITY Name DSMZ-DEUTSCHE SJWΛMLUNG VON Sιgnature(s) of person(s) having the power to represent the MIKROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authorized officιal(s) Address Mascheroder Weg lb D-38124 Braunschweig Date 1997 - 07 - 15 Where Rule 64 (d) applies, such date is the dale on which the status of international depositary auϋioπty was acquired Form DSMZ-BP/4 (sole page) 0196 Novartis AG CH-4002 Basel VIABILITY STATEMENT issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page I DEPOSITOR II. IDENTIFICATION OF THE MICROORGANISM Name Novar 1 s AG Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY Address CH- 4002 Basel DSM 11657 Date of the deposit or the transfer' 1997 - 07 - 14 III. VIABILITY STATEMENT The viability of the microorganism identified under II above was tested on 1997 - 07 - 1 On that date, Ihe said microorganism was (X)' viable ( )' no longer viable IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED' V. INTERNATIONAL DEPOSITARY AUTHORITY Name: DSMZ-DEUTSCHE SAMMLUNG VON Sιgnature(s) of pcrson(s) having the power to represent the UND ZELLKULTUREN GmbH international Depositary Authority or of authorized official(s) Address: Mascheroder Weg lb D-38I2 Braunschweig LS, Date. 1997 - 07 - 15 Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer). In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test Mark with a cross the applicable box Fill in if the information has been requested and if the results of the test were negative Form DSMZ-BP/9 (sole page) 0196

Claims: What is claimed is: 1 . A DNA fragment from the genome of Amycolatopsis mediterranei which comprises a DNA region which is involved directly or indirectly in the gene cluster responsible for rifamycin synthesis, including the adjacent DNA regions to the right and left which, by reason of their function in connection with rifamycin biosynthesis, qualify as constituent of this rifamycin gene cluster; and functional fragments, derivatives or constituents thereof. 2. A DNA fragment according to claim 1 , which is directly or indirectly involved in the gene cluster responsible for rifamycin synthesis. 3. A DNA fragment according to claim 1 , which comprises sequence portions which code for a polyketide synthase or an enzymatically active domain thereof. 4. A DNA fragment according to claim 1 , which comprises SEQ ID NO 1 or SEQ ID NO 3 or at least 15 consecutive nucleotides therefrom. 5. A DNA fragment according to claim 1 , wherein said fragment comprises one or more of the partial nucleotide sequences depicted in SEQ ID NOS 1 and/or 3, or functional fragments Thereof, and all other DNA sequences in ihe vicinity of this sequence which can, by reason of homologies which are present, be regarded as structural or functional equivalents and are therefore able to hybridize with this sequence. 6. A DNA fragment according to claim 1 , wherein said fragment comprises a nucleotide sequence selected from the group consisting of ORF A, B, C, D, E and F or functional fragments thereof, or encodes one or more of the proteins or polypeptides, or functional derivatives thereof, depicted in SEQ ID NOS 4 to 9. 7. A method for identifying, isolating and cloning a DNA fragment according to claim 1. 8. A method according to claim 7, which comprises the following steps: setting up of a genomic gene bank, screening of this gene bank with the assistance of the DNA sequences according to the invention, and • isolation of the clones identified as positive. 9. The use of a DNA fragment according to claim 1 in the production of ansamycins or precursors thereof; including those in which the aliphatic bridge is connected only at one end to the aromatic nucleus. 10. The use of a DNA fragment according to claim 1 in the production of rifamycin, rifamycin analogues or precursors thereof. 1 1 . The use of a DNA fragment according to ciaim 1 for inactivating or modifying genes of ansamycin biosynthesis. 12. The use of a DNA fragment according to claim 1 for inactivating or modifying genes of rifamycin biosynthesis, or the biosynthesis of rifamycin analogues. 13. The use of a DNA fragment according to claim 1 for constructing mutated actinomycetes strains from which the natural rifamycin or ansamycin biosynthesis gene cluster in the chromosome has been partly or completely deleted. 14. The use of DNA fragments according to claim 1 for assembling a library of polyketide synthases. 15. The use of the poiyketide synthases according to claim 14 for assembling a library of polyketides. 16. A polyketide synthase from Amycolatopsis mediterranei which is directly or indirectly involved in rifamycin synthesis; and functional constituents or domains thereof. 17. The use of the polyketide synthase according to claim 1 6 for synthesizing ansamycins. 18. The use of polyketide synthases according to claim 14 for synthesizing a library of ansamycins. 19. A hybrid vector comprising a DNA fragment according to claim 1. 20. A hybrid vector comprising an expression vector comprising a DNA fragment according to claim 1. 21. A host organism comprising a hybrid vector according to claim 19. 22. A hybridization probe comprising a DNA fragment according to claim 1. 23. The use of the hybridization probe according to claim 22 for identifying DNA fragments involved in the biosynthesis of ansamycins.

Inventors: ENGEL NATHALIE, SCHUPP THOMAS, TOUPET CHRISTIANE, ENGEL, NATHALIE, SCHUPP, THOMAS, TOUPET, CHRISTIANE
Applicants: CIBA GEIGY AG, ENGEL NATHALIE, SCHUPP THOMAS, TOUPET CHRISTIANE, ENGEL, NATHALIE, NOVARTIS AG, SCHUPP, THOMAS, TOUPET, CHRISTIANE
Application year: 1997
Main classification: C12N15
IPC codes: C12N1, C12N9, C12N15, C12P17, C12Q1